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Abstract 
 
RA is a destructive and chronic autoimmune inflammatory disease. The inflammation of 
the synovium is associated with the local invasion of inflammatory cells across blood 
vessel endothelial cells (ECs), increases in synovial fluid volume and local pannus 
invasion of the connective tissues and bone. Synovial ECs in RA are involved in a wide 
range of processes, and chemokines are known mediators of inflammatory cell invasion 
into the tissue. Chemokines at the ECs of lymph vessels play a further role in attracting the 
infiltrates out of the tissue.  
This study used immunofluorescence to investigate the presentation of a number 
chemokines in RA tissue ECs, and also the presentation of CCL7, CCL14, CCL16 and 
CCL22 in lymphatic ECs. A number of chemokines were newly identified in synovial ECs, 
and continued investigation showed a marked dysregulation in blood vessel and lymphatic 
vessel chemokine presentation, including CCL7. In vitro studies showed that the 
chemokines also preferentially generated microvilli which may facilitate transendothelial 
migration in vivo. Mononuclear cells expressed the receptors for the chemokines and  
transmigration analysis showed CCL7 (among others) to significantly chemoattract 
monocytes. This suggests that dysregulation of chemokines may have a functional role in 
RA pathology. Furthermore, the analysis of these chemokines in matched synovial fluid 
(DF) and serum indicates that EC chemokines may be inflammatory markers in arthritic 
diseases.   
Overall, this study has shown that the EC interface between the influx and efflux of 
inflammatory cells in the RA synovium may offer currently unexplored therapeutic 
opportunities.  
  
 
xv 
Published abstracts 
 
 
Lisa Rump-Goodrich, Derek Mattey, Jim Middleton. (2012). An assessment of CC 
chemokines present on the microvasculature of synovial tissue in patients with rheumatoid 
arthritis. Rheumatology. 51 (suppl 3): iii140-iii184 
 
Lisa Rump-Goodrich, Derek Mattey, Oksana Kehoe, Alison Cartwright, Jim Middleton. 
(2013). Differential Generation of CC Chemokines at Microvascular Endothelial Cells of 
Blood and Lymphatic Vessels Under Inflammatory Conditions. Rheumatology. 52 (suppl 
1): i135-i172 
 
Lisa Rump-Goodrich, Ayman Askari, Derek Mattey, Jim Middleton (2014). Dysregulation 
of CC Chemokines at Microvascular Endothelial Cells of Blood and Lymphatic Vessels 
Under Inflammatory Conditions. Arthritis & Rheumatology. Special Issue: ACR/ARHP 
Annual Meeting Abstract Supplement. 66, Issue S10, pages S1–S140 
 
 
AG Kay , S Parida , A Stefan , L Rump , J Middleton , O Kehoe. (2015). Assessment of 
aggrecanase- and MMP-driven cartilage degradation following MSC treatment for 
Rheumatoid Arthritis. European Cells and Materials. Vol 29. Supp 3:70 
 
 
xvi 
 
Abbreviations  
ACR   American College of Rheumatology 
ACPA   Anti-citrullinated peptide antibodies 
AKA   Anti-keratin antibodies 
ANOVA  Analysis of variance 
APC    Antigen presenting cell 
BSA   Bovine serum albumin 
CaCl2   Calcium chloride 
CCL   C-C motif ligand 
CCR   C-C motif receptor 
CI   Confidence interval 
CRP   C-reactive protein 
DAF   Decay accelerating factor 
DAPI   4’, 6-diamidino-2-phenylindole 
DARC   Duffy antigen receptor complex 
DC   dendritic cell 
DLEC   Dermal Lymphatic Endothelial Cell 
DMEM-F12  Dublecco’s modified eagle medium: nutrient mixture –F12 
EBM-mv  Endothelial  basal medium (microvascular bullitKit) 
EC   Endothelial cell 
ECM   Extracellular matrix 
EDTA   Ethylene diamine tetra acetate 
EGF   Epidermal growth factor 
ELISA   Enzyme-Linked Immunosorbent Assay 
EM     Endothelial cell microvilli like protrusions 
ESR   Erythrocyte-sedimentary rate 
 
 
xvii 
ET   Endothelin 
EULAR  European league against Rheumatism 
FACs   Fluorescence activated cell sorter 
FGF   Fibroblast growth factor 
F   Filter 
FSC   Forward scatter (forward angle light scatter) 
GAGs   Glycosaminoglycan 
GC   Germinal centre 
GlyCAM  Glycosylated cell adhesion molecule  
GTA   Glutaraldehyde 
HBMECs      Human bone marrow endothelial cells 
HDLECs       Human dermal lymphatic endothelial cells 
HEVs   high endothelial venules 
HIF   Hypoxia inducible factor 
ICAM   Intra cellular adhesion molecule 
IFN-   Interferon-gamma 
Ig   Immunoglobulin 
IL   Interleukin 
iNOS   Inducibel nitrous oxide   
IPA   Isopentane alcohol 
IQR   Inter-quartile range 
IVIg   Intravenous immunoglobulin 
JAM   Junctional adhesion molecule 
L    Lymphocytes 
LEC   Lymphatic endothelial cell 
LF   Lymphoid follicle 
 
 
xviii 
LFA-1   Lymphocyte function antigen 
LM                Lymphocyte microvilli like protrusions 
LYVE-1  Lymphatic vessel endothelial HA receptor-1 
MA   Macrophage 
MCV   Mutated citrullinated vimentin 
MHC   Major- histocompatibility complex 
MMP   Matrix metalloproteinase 
MO   Monocyte 
mRNA   micro ribonucleic acid 
NO   Nitrous oxide 
NK   Natural killer cell 
OA   Osteoarthritis 
OR   Odds ratio 
P    Pseudopodia 
PAF   Platelet activating factor 
PBMC    Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCs   Pannocytes 
PE   Phycoetherine 
PECAM-1  Platelet endothelial cell adhesion molecule-1 
RA    Rheumatoid arthritis 
RF   Rheumatoid Factor 
RNA   Ribonucleic acid 
ROS   reactive oxygen species 
RPMI   Roswell Park memorial institute (medium) 
SD   standard deviation 
SE   Standard error 
 
 
xix 
SF   Synovial fluid 
TEM   Transmission electron microscopy 
TGF   Transforming growth factor 
T H-GFAAS Transverse Heated-Graphite Furnace Atomic Absorption   
Spectrometry 
THGA   Transverse heated graphite atomiser 
TM   Transmembrane 
TLR   Toll like receptor 
TNF-   Tumour necrosis factor-alpha 
tPO   Tissue oxygen pressure 
VCAM-1  Vascular cell adhesion molecule-1 
VEGF   vascular endothelial growth factor 
VWF   von-Willebrand factor 
 
 
 
Chapter 1 
 
 1 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 2 
1. Rheumatoid Arthritis (RA) 
1.1 What is RA? 
RA is a destructive and chronic autoimmune inflammatory disease. Typically the 
peripheral joints are affected with the most visible manifestation of joint destruction being 
at the diarthrodial joints of the feet and hands.  The destruction of the bone and cartilage is 
predominantly due to the release of proteinases acting against the connective tissues which 
are generated at the invasive face of the synovium (Gravallese, 2002), termed the pannus, 
and occurs at periarticular and subchondral bone as well as the cartilage and bone margins 
(Goldring, 2003) (see figure 1.1).  The inflammation of the synovium associated with the 
local invasion of inflammatory cells leads to increases in synovial fluid and local pannus 
invasion of the connective tissues and bone thus playing a lead role in RA pathology.  
  
 
 
Figure 1.1 Diagram of the normal and rheumatoid joint synovium.  Major cell types 
and processes involved in RA synovial inflammation are also shown. (Taken and adapted 
from Strand et al, 2007). 
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As seen in figure 1.1 the rheumatoid synovium is marked by severe inflammation leading 
to hyperplasia. This is associated with the generation of redundant folds and villi in the 
tissue of the synovial lining and extensive angiogenesis with massive increases in cellular 
infiltrates such as B and T-cells, macrophages and dendritic cells (among others), with the 
degree/type of cellular infiltration differing between disease stages and patients.  
Innate immune responses such as dendritic cell (DC) activation are believed to be one of 
the primary events in RA (Smolen et al., 2007). These antigen presenting cells (APCs) 
present antigens to T-cells. This T-cell activation promotes increases in pro-inflammatory 
chemokine and cytokine generation leading to a ‘feedback loop for additional T-cell, B-
cell and macrophage interactions (Smolen and Steiner, 2003; Smolen et al., 2007). 
Antigens are also presented by the B-cells, which also generate a range of cytokines (e.g. 
IL-6) and autoantibodies such as rheumatoid factor (RF) and anti-citrullinated peptides 
(anti-CCP). The autoantibodies can stimulate the generation of cytokines such as TNF- 
(Smolen et al., 2007). The synovial membrane also produces a range of inflammatory 
cytokines and matrix-metalloproteinases (MMPs) from activated fibroblast-like 
synoviocytes (FLS) which in turn facilitate the damage to bone and cartilage as the disease 
progresses (Smolen et al., 2007) (figure 1.1).    
In later stage RA the process of synovial inflammation is essentially the same as in early 
RA with differences in mediators/infiltrates, for example, being largely accounted for by 
differences such as medication and disease activity in different patients (Tak, 2001). 
However, differences have been noticed between early RA and late RA such as increased 
expression of Duffy antigen in early RA (disease duration 7 months) followed by 
decreased Duffy expression at disease duration of 9 years, and further decreases at 18 years 
disease duration. This indicated that Duffy was expressed preferentially by the newly 
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formed angiogenic vessels (Gardner et al., 2006) and was primarily active in early, diffuse 
leukocyte transmigration.  
The development of lymphoid like structures in the RA synovium, known as lymphoid 
follicles  (LFs), is dependent on the organisation of the B and T-cell infiltrate (reviewed by 
Humby et al., 2007). Regions of LFs can become more organised and resemble secondary 
lymphoid organs (SLOs). These organised structures can facilitate disease exacerbating 
immune responses such as antibody production by their role in directing B/T-cell responses 
and so have been referred to as both ectopic lymphoid-like structures (ELSs) and tertiary 
lymphoid organs (TLOs) (Aloisi and Pujol-Borrell, 2006; Neyt et al., 2012).  In RA 50% 
of cases show diffuse infiltration and 50% show the LFs. Of the cases where LF 
development has occurred only 50% of these have germinal centres (GCs). These GC LFs 
manifest as organised arrangements of T and B-cells within the synovium and therefore 
occur in ~20-40% of RA cases (Loetscher and Moser, 2002; Aloisi and Pujol-Borrell, 
2006; Manzo et al., 2010). The lack of LFs in greater numbers of RA sufferers raised the 
possibility that they were not of great importance in disease progression and pathogenesis; 
which was built upon by Thurlings et al., (2008) who showed that disease phenotype is not 
correlated to the development of lymphoid follicles and that their development may well 
be based on an individuals response to cytokine regulation (reviewed by Edwards and 
Leandro, 2008). However, the importance of LF development in RA remains contentious 
as Cañete et al., (2009) showed that RA patients with ELS were more likely to be non-
responsive to anti-TNF therapy. Furthermore an RA synovial B-cell subset can generate 
pro-inflammatory cytokines such as TNF-, IL-6 and  RANKL (Yeo et al., 2012). 
It is still currently unknown if LFs/ELS are representative of persistent inflammation or are 
characteristic of individual pathological subsets present from very early RA (Pitzalis et al., 
2014). 
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The aetiology of RA had been quite elusive, however a range of risk factors has been 
identified (see table 1.1). In addition to the data in table 1.1 there is a huge range of genetic 
loci associated with RA susceptibility which are comprehensively listed/ by Yarwood et 
al., (2014). The National Institute for Health and Care Excellence (NICE) states that there 
are ~400,000 RA sufferers in the UK with 5.1 people per 10,000 being diagnosed per year 
(1.5 men: 3.6 women). The diagnosis peaks in the over 70s population but develops in all 
age groups to some extent.  
It is widely known that the rate of disease progression varies between sufferers and that the 
age of disease onset also shows a marked variation. It is accepted that whilst RA sufferers’ 
immediate relatives appear to have a greater chance of developing the disease, an interplay 
of both genetic and environmental factors are more likely to be causal in its development 
(Hajalilou et al., 2012).  A range of arthropathies manifests with similar symptoms in the 
early stages and in order to better aid diagnosis the American College of Rheumatology 
(ACR) revised the criteria to be met for a diagnosis or RA in 1988 (Arnett et al., 1988) and 
further revisions were done by the ACR, and the European League Against Rheumatism 
(EULAR) revised the criteria to be met for a diagnosis of RA (Aletaha et al., 2010) (table 
1.2). A score of 6/10 is needed for classification of a patient as having definite RA. 
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Table 1.1 Risk factors and markers associated with RA. 
Risk Factor 
Sex 
3:1 females to males develop RA. Factors include (among others), 
hormonal change during pregnancy and/or menstruation and oral 
contraceptive use. (Oliver and Silman, 2009a). 
Age Usually between 40-50 years of age.  
Environmental 
Diet; Lean mass of arms and legs (LMAL), total body fat mass (BFM) 
or truncal fat distribution (TFD) indicated that Low LMAL, high BFM 
and high TFD are present in early RA patients. (Book et al, 2009). 
Caffeine; Implicated in some RA studies but vindicated in others 
(Oliver and Silman, 2009b) 
Smoking; Time spent smoking and the amount smoked correlates to 
increased RA risk (Oliver and Silman, 2009b) 
Traffic pollution; Evidence from Hart et al., (2009) and  A recent 
review by Essouma and Noubiap , (2015) suggests that increased 
exposure to traffic pollution increases the risk of RA.                                         
Infectious agents; The lead viral candidate is Epstein Barr Virus 
(EBV), the genome of which has been found in the human synovial 
membrane. Also seen to be cross-reactivity between EBV proteins and 
human proteins (Toussirot and Roudier, 2008). Other pathogens are also 
being found to have a role in RA development such as Chikungunya 
virus (Becker and Winthrop, 2010). Bacterial infection may also be 
causal. Most recently the Proteus bacteria, active as an upper urinary 
tract infection, have been implicated (Ebringer and Rashid, 2009). 
Geographical 
Worldwide distribution. Populations in the UK and certain American 
Indians have greatly increased risk of RA than many other European 
and American peoples. Between 25-50 per 100,000 in any given 
population (reviewed by Uhlig and Kevin, 2005) 
Genetic risk factors 
(reviewed by Goronzy et al., 2009) 
Familial 
Sporadic but may affect several generations. Recently incidence of RA 
in families has been indicated to correlate with increased risk of other 
autoimmune diseases within the same family (Hemminki et al., 2009) 
HLA- DRB1 
 HLA-DRB1 encoding the shared epitope is the strongest risk factor of 
the HLA type susceptibilities. PAD14_94 have been associated with the 
European population and PAD14 polymorphisms in general associated 
with Asian populations. (Lee et al.,2007) 
PTPN22 
Protein tyrosine phosphatase (PTPN22) has been shown to exert 
regulatory action on both B and T-cells in RA  (Oliver and Silman, 
2009b; reviewed by Imboden, 2009: Messemaker et al.; 2015) 
Other Genes CTLA4 (Messemaker et al; 2015), MHC2A and FCRL3 (Oliver and 
Silman, 2009b). WNT5A (Rauner et al., 2012) 
Markers 
Autoantibodies 
Rheumatoid Factor (RF); Autoantibodies reactive to the Fc portion of 
IgG, used as a diagnostic tool. 
ACPA; Anti-citrullinated peptide antibodies (also known as anti-
citrullinated cyclic antibodies, anti-CCP) react with proteins where 
citrulline has replaced arginine, used as a diagnostic tool.  
AKA; Anti keratin antibodies (an ACPA subtype). Identified among 
other subtypes (reviewed by Song and Kang, 2009). 
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Table 1.2 The 2010 revised criteria for RA classification 
Revised ACR/EULAR criteria of RA classification 
Joint involvement 
1 large joint                                                                                                
2-10 large joints                                                                                        
1-3 small joints (with or without involvement of large joints)                        
4-10 small joints (with or without involvement of large joints)               
>10 joints (at least 1 small joint)                                                         
 
Serology 
Negative RF and negative ACPA                                         
Low-positive RF or low-positive ACPA                              
High-positive RF or high-positive ACPA                            
 
Acute-phase reactants (at least 1 test result required)  
Normal CRP and normal ESR  
Abnormal CRP or abnormal ESR 
 
 Duration of symptoms 
<6 weeks  
6 weeks  
 
0 
1 
2
3 
5 
 
 
0 
2 
3 
 
 
0 
1 
 
 
0 
1 
Table adapted from Aletaha et al., (2010). 
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1.2 Autoimmunity 
RA is the most common autoimmune joint disease (reviewed by El-Jawhari et al., 2014).  
The immune system distinguishes the many cellular components of the human body 
(known as ‘self’) from the cells or components of invading organisms (non-self). The 
harmful ‘non-self’ should generate an immune response while ‘self’ should not. If the 
immune system does not recognize self-cells (or their constituents) and mounts an immune 
response, the result is autoimmune disease leading to self-cell damage/death (figure 1.2).  
 
 
Fig 1.2 Overview of antibody mediated autoimmunity. (image adapted from 
http://stemcells.nih.gov/info/scireport/pages/chapter6.aspx) 
 
In RA, autoimmunity is due to the generation of ‘autoantibodies’ such as rheumatoid factor 
(RF) and anti-citrullinated antibodies (table 1.1). The presence of a number of these 
autoantibodies is used as a diagnostic tool.  
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In cell mediated autoimmune responses T-cells complex with self-antigens such as mutated 
citrullinated vimentin, (MCV) and activate other immune cells via the generation of 
soluble factors. Activated macrophages then ‘attack’ the synovial tissue and produce 
chemical messengers (cytokines) leading to the uncontrolled growth of synovial cells into 
the joint tissue, creating the pannus. Here they damage the cartilage and bone, and T-cells 
and macrophages interact further promoting the inflammation (figure 1.3A).   
The inflammatory process begins with the entry of neutrophils, monocytes and 
macrophages. Local tissue damage is followed by ‘neo-autoantigen’ release, antigen 
priming, T-cell activation then autoantibody generation by B-cells and rheumatoid factor 
(RF) release. Neutrophils take up immune complexes and bind complement C5a, the 
neutrophils then generate inflammatory chemokines and cytokines.  Joint infiltration starts 
with neutrophils expressing CD137 and its receptor, 4-1BB ligand (Mitter, 2004).  
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Figure 1.3.  Autoimmunity in rheumatoid arthritis. (A) An overview of antibody-
mediated immunity in RA.  (B) An overview of cell-mediated autoimmunity in RA. Neutrophil 
(N), monocyte (M), dentritic cell (DC) (figure 1.3A adapted from  
http://www.chemgapedia.de/vsengine/vlu/vsc/en/ch/25/orgentec/autoimmun.vlu/Page/vsc/
en/ch/25/orgentec/autoimmun_ra_en.vscml.html © Orgentec Diagnostika; figure1.3B 
adapted from Mitter, 2004) 
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1.3 Cells involved in RA 
1.3.1 Macrophages (see table 1.3)
Macrophages have long been known to be key factors in RA involved not only in 
inflammation initiation and perpetuation but also angiogenesis, matrix degradation and 
leukocyte adhesion/migration in RA. As well as expressing a range of chemokine 
receptors, adhesion molecules and surface antigens, they secrete a range of  cytokines (a 
number of which increase macrophage activation, Drexler et al., 2008), chemokines, 
growth factors, proteases and further mediators (Szekanecz and Koch, 2007). These are 
shown in tables 1.4 and 1.5).
 
Table 1.3    Macrophage  function and potential role in RA  (Drexler et al., 2008; Kinne 
et al., 2007) 
 
Macrophage function Potential role in RA 
 
Cytokine and protease production Activation and tissue destruction 
Complement activation 
Activated complement recognition. Promotion of 
phagocytosis and Monocyte activation 
Particulate antigen phagocytosis 
Antigen presentation and CD4+/CD8+ T cell 
activation (relevance to RA initiation/perpetuation) 
Antigen processing/presentation 
Important cognate functions upon antigen 
recognition via MHC-II molecule presentation. 
Chemotaxis and Angiogenesis 
Positive feedback between monocyte derived 
cytokines and chemotactic factors (i.e. IL-8 and 
MCP-1) 
Lipid metabolism Pro-inflammatory activity of PGE2 and PGI2 
Intracellular pathogen/apoptotic 
cell clearance 
Induction of monocyte derived cytokines by 
Bacterial toxins 
Persistence of intracellular obligate/facultative 
pathogens with arthritogenic potential.   
Wound healing 
Phagocytosis of matrix debris and endogenous IL-1 
production. 
Immune complex clearance 
RF clearance. Further monocytes activation. 
Complement opsonisation of complexes. 
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Macrophages differentiate from monocytes and are present in large numbers in the 
cartilage-pannus junction and the inflamed synovium. Intimal macrophages are the 
minority cell type in the normal internal layer, but in the diseased state the population can 
rise to 80%. Conceivably, the macrophages are continuously replaced from monocytes in 
the circulation (Bartholome et al., 2004), however Thurlings et al., (2009) obtained results 
indicating that while monocyte migration into the inflamed synovium is continuous the 
macrophage replacement rate is markedly slower. This may be partly due to the cytokine 
imbalance which occurs in RA joints, bone marrow and peripheral blood (Kinne et al., 
2007). As well as expressing a range of chemokines, cytokines (a number of which 
increase macrophage activation, Drexler et al., 2008), chemokine receptors, adhesion 
molecules and surface antigens, they secrete a range of  cytokines, chemokines, growth 
factors, proteases and further mediators (tables 1.4 and 1.5) (reviewed by Szekanecz and 
Koch, 2007).It has also been shown that anti-citrullinated protein autoantibody (ACPA) 
containing immune complexes can induce the generation of TNF-α secretion by synovial 
fluid-derived macrophages from RA patients which would further exacerbate the 
pathophysiology of RA (Laurent et al., 2011).
1.3.2 Synovial fibroblasts 
In normal tissue synovial fibroblasts provide the cavity of the joint and the adjacent 
cartilage with lubricating molecules (such as hyaluronic acid) and nutritive plasma proteins 
as well as the production of matrix components required for matrix remodelling. In RA 
tissue, together with macrophages, synovial fibroblasts are the most prolific cell type in the 
hyperplasic synovial intimal layer. Thus, they are a driving force behind RA joint 
degradation via generation of matrix-degrading molecules and inflammatory cytokines 
(Muller-Ladner et al., 2007). Pretzel et al., (2009) have also demonstrated the degree to 
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which synovial fibroblasts degrade the cartilage matrix via cartilage homeostasis disruption 
by suppressing anabolic matrix synthesis and by producing pro-inflammatory cytokines 
and catabolic enzymes.   
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Table 1.4    Molecules expressed and/or released by macrophages (data adapted from 
Szekanecz and Koch, 2007) 
Macrophage Molecule Ligand/function 
Selectins L-selectin Sialylated carbohydrates, GLyCAM-1 
Integrins 
 
4β1 (VLA-4) Fibronectin, VCAM-1 
5β1 (VLA-5) Fibronectin 
Lβ2 (LFA-1, 
CD11a,CD18) 
ICAM-1, ICAM-2, ICAM-3 
Mβ2 (Mac-1, 
CD11b,CD18) 
ICAM-1, iC3b, fibrinogen 
Xβ2 (CD11c,CD18) iC3b, fibrinogen 
Vβ3  Various ECM components 
Vβ5 Fibronectin, vitronectin 
Immunoglobulin 
superfamily 
 
ICAM-1 (CD54) Lβ2, Mβ2, cd43 
ICAM-2 (CD102) Lβ2 
ICAM-3 (CD50) Lβ2 
VCAM-1 (CD106) 4β1, 4β7 
PECAM-1 (CD31) vβ3 
LFA-3 (CD58) CD2 
Chemokine 
receptors 
 
CXCR1 CXCL8, CXCL6 
CXCR2 
CXCL1, CXCL2, CXCL3,CXCL5, CXCL6, 
CXCL7, CXCL8 
CXCR4 CXCL12 
CXCR5  CXCL13 
CCR1 
CCL3, CCL5, CCL7, CCL14, CCL15, CCL16, 
CCL22 
CCR2 CCL2, CCL7, CCL8, CCL13 
CCR5  CCL3, CCL4, CCL5, CCL8, CCL14 
CCR7 CCL19, CCL21 
CCR8 CCL1, CCL4, CCL17 
XCR1 XCL1  
CX3CR1 CX3CL1 
ECM - extracellular matrix; GlyCAM -  glycosylated cell adhesion molecule; ICAM - intercellular 
cell adhesion molecule; LFA - lymphocyte function associated antigen; PECAM - 
platelet/endothelial cell adhesion molecule; VCAM - vascular cell adhesion molecule; VLA -  very 
late antigen; BCA - B-cell-activating chemokine; CXCL, CXL, CX3CL and CCL -  chemokines’; 
CXCR, CXR , CX3CR and CCR -  chemokine receptors; IL – interleukin. 
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Table 1.5    Molecules secreted by macrophages (data adapted from Szekanecz and 
Koch, 2007 and references therein) 
Secretory product Function 
Chemokines 
CXCL1, CXCL5, 
CXCL7, CXCL8 
Chemotactic for neutrophils, promote 
angiogenesis 
CXCL9, CXCL10 Possibly pro-inflammatory, are antiangiogenic 
CXCL16 Monocyte recruitment 
CCL2, CCL3, CCL5 Monocyte chemoattractants  
CCL18 Homeostatic, T-cell chemoattractant 
CX3CL1 
Chemoattractant for monocytes and 
lymphocytes 
Cytokines 
IL-1, TNF- 
Pro-inflammatory, induces macrophage 
interleukin and chemokine secretion 
IL-6, Oncostatoin-M 
Cytokine release and monocyte effector 
function 
IL-10 Pro-inflammatory 
IL-12, IL-15, IL-18 
Th1 polarisation, IL-18 induces CCL2 
secretion by macrophages 
B-lymphocyte-
stimulator protein 
Proliferation inducer 
Lymphotoxin- 
Induces adhesion molecule changes on  ECs to 
allow phagocytes to bind to them. Previously 
known as TNF-β 
GM-CSF 
Constitutively produced, major role in myeloid 
precursor proliferation and differentiation 
MIF 
Macrophage cytokine release and 
angiogenesis. Secretion of TNF-, IL-1, IL-6, 
CXCL8 and MMP production 
Growth factors 
PDGF-C, PGDF-D  -D isoform increased MMP-1 production 
VEGFR-1 
Implicated in the activation of macrophages 
and angiogenesis 
Proteinases 
MMP-1, MMP-2, 
MMP-9 
ECM degradation, tissue destruction 
Cathepsin G  Monocyte chemotactic mediated by SF 
TIMP-1, TIMP-4 MMP antagonisers 
GM-CSF - granulocyte–monocyte colony-stimulating factor; PDGF - platelet derived 
growth factor; VEGFR, vascular endothelial growth factor receptor;  TIMP - tissue 
inhibitors of MMPs; IL – interleukin; MMP – matrix-metalloproteinases; MIF – macrophage 
inhibatory factor; CXCL, CXL, CX3CL and CCL -  chemokines’; CXCR, CXR , CX3CR and 
CCR -  chemokine receptors; TNF – tumour necrosis factor 
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1.3.3 Dendritic cells (DCs)  
In normal conditions DCs  are essential regulators of both the acquired and innate immune 
systems where they stimulate naive T-cell proliferation and act as accessory cells in the 
generation of primary antibody responses as well as being enhancers of natural killer (NK) 
T-cells and NK cell cytotoxicity (Lutzky et al., 2007).                                                   
In RA DCs play a range of roles (reviewed by Lutzky et al., 2007); 
1. Priming MHC-restricted autoimmune responses in lymphoid organs.   
2. Helping to perpetuate the disease by processing and presenting antigens locally 
following infiltration into synovial fluid and tissue. This initiation and perpetuation of RA 
by DC is by self tolerance abolition followed by the generation of lymphocytes, which are 
self-reactive (Lebre and Tak, 2009).      
3. Drive the generation of ectopic lymphoid tissue (presumably also in the synovium). 
4. Together with macrophages and synoviocytes they produce inflammatory mediators of 
the innate immune system.       
5. Recent evidence suggests that DCs are contributors to atherosclerosis, an RA 
complication. A range of DC subsets have been characterised.  
1.3.4 Neutrophils 
Neutrophils are the most abundant and shortest lived leukocyte with a life span of around 
24-48 hours in a normal individual before their apoptosis and death. It is the 
inhibition/suppression in the levels of neutrophil apoptosis which may lead to severe 
inflammatory conditions such as RA. Neutrophil apoptosis has been shown to be 
suppressed in RA synovial fluid from as little as <3 month disease duration (Raza et al., 
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2006), and the reduction of neutrophil recruitment is a source of potential therapeutic 
avenues as they may be key factors in RA pathogenesis in a number of ways, including the 
secretion of MMP-8 and MMP-9 (Murphy and Nagase, 2008) as well as secreting granule 
enzymes (such as cathepsin G, and proteinase 3) which activate cytokines. They also play a 
role in the functional regulation of immune cells via the secretion of chemokines such as 
CCL2, CCL4, CCL20 and CXCL10 and cytokines such as IL-1, IL1-β and TGF- β 
(reviewed by Wright, Moots and Edwards, 2014).  Furthermore neutrophils have been 
shown to produce neutrophil extracellular traps (NETs) which destroy extracellular 
bacteria and have been indicated as a source of autoantigens in autoimmune disease 
sufferers (reviewed by Wright, Moots and Edwards, 2014). A range of therapies which 
affect neutrophils are used to successfully control RA symptoms. Non-steroidal anti-
inflammatory drugs (NSAIDs, which inhibit the production of reactive oxygen species, 
ROS, and reduce neutrophil adherance), corticosteroids (decrease IL-8 neutrophil 
production) and disease modifying anti-rheumatic drugs (DMARDS, which includes the 
reduction of migration and ROS production of neutrophils) (reviewed by Wright, Moots 
and Edwards, 2014). The high expression levels of adhesion molecules on neutrophils 
allow rapid binding to activated endothelial cells (see section 1.3.10) (Tsubaki et al., 
2005). A range of synovial components have been identified as essential for neutrophil 
survival, including GM-CSF, type 1 IFN, and more recently  lactoferrin, an iron binding 
protein of the transferrin family (Wong et al., 2009). 
1.3.5 B-cells 
B cells form a minority of the infiltrates in RA tissue, accumulating in the germinal centers 
of lymphoid follicles present in ~20% of RA cases (Loetscher and Moser, 2002). Plasma 
cells differentiate from mature B-cells upon their stimulation by toll like receptors (TLRs) 
or antigen encounters and can generate autoantibodies such as rheumatoid factor (see table 
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1.1) which is used as a diagnostic tool for the development of RA. Antigen activated B-
cells can also assist in the differentiation of effector T-cells and thus the production of 
proinflammatory cytokines involved in the destruction of cartilage and bone (Mauri and 
Ehrenstein, 2007) as well as the generation of degrading enzymes and cytokines. Despite 
the low representation of B-cells in RA the role they play in disease pathogenesis has been 
highlighted by the amelioration of symptoms due to B-cell depletion in a range of studies 
(reviewed by Nakken et al., 2011) including anti CD20 (rituximab) administration (Mauri 
and Ehrenstein, 2007) which has been successfully used for a number of years 
1.3.6 T-cells (reviewed by Imboden, 2009) 
T-cells heavily infiltrate the RA synovium. They can be separated into CD4+ and CD8+, 
with CD4+ T-cells being dominant in RA synovial infiltrates. Activated/memory T-cells 
are found in the inflamed RA joint. The naive T-cells are activated via antigens presented 
by HLA molecules of APCs, such as dendritic cells and macrophages. The APC to T-cell 
contact is augmented and T-cell signalling increased with co-stimulation by CD28. CD28 
is expressed on T-cells ligated with CD80/86 on APCs.  Cytotoxic T lymphocyte-
associated antigen (CTLA) T-cells also binds to CD80/86 on APCs and acts as an ‘off’ 
switch for the immune system. Thus its presence causes a down-regulation of T-cell 
signalling (Malmström et al., 2005). A study involving immunising mice with the CTLA4–
Ig showed that it prevented collagen-induced arthritis; and if administered after disease 
onset ameliorated the symptoms (Webb, Walmsley and  Feldmann, 1996) 
A range of genes in RA have shown to be linked to T-cells such as PTPN22 (protein 
tyrosine phosphatase non-receptor type 22), which codes Lyp, a tyrosine phosphatase 
which regulates T-cell receptor signal transduction (Lundy et al., 2007) and  MHC class II 
DR4/DR1.  
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    T-cells can accumulate in the synovium in one of 3 patterns:     
1. Diffuse infiltrates throughout the tissue.     
2. Clustered with B-cells in follicle organisation with germinal centres.    
3. Clustered with B-cells in follicle organisation without germinal centres. 
1.3.7 Pannocytes (PCs) 
PCs were identified at sites of cartilage damage in RA. They share some  phenotypic and 
functional features seen in both fibroblast-like synoviocytes (FLS) and articular 
chondrocytes;  such as mRNA for inducible nitric oxide synthase (iNOS) and collagenase 
for both PCs and chondrocytes, and the mRNA for the collagen type-1 gene. However, 
despite having mRNA for inducible nitric oxide synthase PCs  do not generate NO 
constitutively or when stimulated by cytokines. PCs can also be distinguished 
morphologically as they have a rhomboid morphology which distinguishes them from 
articular chondrocytes and FLS (which are spherical and bipolar respectively). 
Furthermore they exhibit bright VCAM staining compared to chondrocytes and FLS 
(Zvaifler et al., 1997).  Results obtained by Longato et al., (2005) support the reasoning 
that PCs are part of the primitive embryonic connective tissue-forming cell group and 
exclude the theory that PCs originate from fibroblasts or monocyte-macrophages.  
1.3.8 Chondrocytes 
Chondrocytes exclusively form the cell population in human articular cartilage which 
covers the long bone articulating surfaces. Collagen types II, IX , and XI form part of the 
interterritorial cartilage matrix which provides the required tensile strength.  The other 
major component is aggrecan, a large aggregating proteoglycan, which provides the 
cartilage matrix with compressive resistance (reviewed by Otero and Goldring, 2007). 
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Where there is no vascular supply for nutrient/metabolite transfer chondrocytes rely on 
diffusion both from subchondral bone and the articular surface.  
Proteinases such as cathepsin B, L and D and metalloproteinases such as MMP-10 and 
MMP-3 (which activate procollagenases), are generated by chondrocytes. This range of 
cellular responses to inflammation shows that chondrocytes may not only be involved in 
cartilage matrix destruction in response to synovium generated proinflammatory cytokines, 
but could also be a source of proinflammatory cytokines/proteins themselves (reviewed by 
Otero and Goldring, 2007). This was backed up recently by results obtained by Jeong et 
al., (2009), who showed that in the mouse RA animal model, Pin-1 (a peptidyl prolyl 
isomerase) and cyclo-oxygenase-2 (COX-2) were over expressed in ankle cartilage, and 
that cultures of primary human chondrocytes had increased basal expression of the 
proinflammatory proteins COX-2, TNF-alpha, and IL-1beta.  
 
1.3.9 Osteoclasts (Schett, 2007) 
Osteoclasts are essential for bone remodelling throughout life as the primary bone 
resorbing cells, enabling bone shaping in early life, adulthood bone remodelling and old 
age bone loss. In RA monocytes/macrophages differentiate into osteoclasts via signals 
from activated T-cells and FLS. These express RANKL (receptor activator of nuclear 
factor ҡB ligand) and so ‘drive osteoclast formation’. Activated T-cells which express IL-
17 (Th17 cells) as well as RANKL also support the formation of osteoclasts whereby 
RANKL binds the monocyte surface receptor RANK leading to their osteoclastogenesis. 
RANKL and macrophage colony stimulating factor are key factors in osteoclast 
differentiation with RANKL expression being regulated by TNF-α, IL-1, IL-6 and IL-17 
which are abundant in the synovial membrane (reviewed by Schett, 2007). 
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1.3.10 Endothelial cells (ECs) 
Synovial ECs in RA are involved in a wide range of processes such as angiogenesis, 
leukocyte trafficking from the circulation and presentation/expression of a range of 
mediators and effectors involved in disease pathology. These include cytokines IL-1, TNF-
α and IL-15; chemokines, CXCL8, CCL2, CCL21, CXCL5, CXCL12, CCL3 and CCL19;  
chemokine receptors, CXCR3 and CXCR4; proteinases, MMP-1, MMP-3, MMP-9, MMP-
13, cathepsin B and L; adhesion molecules, E-selectin, P-selectin, ICAM-1, ICAM-2 and 
PECAM-1 and angiogenesis regulators, VEGF and TGF-β1 among others (Middleton et al., 
2004). EC phenotypes are characterised as activated, angiogenic, apoptotic and leaky and 
play a major role in the pathophysiology of RA in several ways (Middleton et al., 2004); 
(table 1.6) 
1. Subintimal blood vessel ECs allow leukocyte migration into the synovium and 
synovial fluid. To do this ECs become activated, expressing adhesion molecules 
such as E-selectin and ICAM-1 which facilitate leukocyte adhesion to the ECs 
(reviewed by Middleton et al., 2004)  
2. EC permeability increases leading to extravasation of plasma, formation of 
oedema and joint swelling. The vascular permeability is primarily induced by 
vasoactive agents such as NO (among other ROS), histamine and bradykinin 
(Szekanecz and Koch, 2004; Szekanecz and Koch, 2005) 
3. The proliferation of ECs in angiogenesis allows nutrition and oxygen 
requirements of the expanding pannus and synovial tissue to be met. 
4. Expression of cytokines/chemokines and their receptors involved in 
proliferation, angiogenesis and bone and tissue degeneration. 
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5. Release of inflammatory mediators from vascular ECs such as TGF-β, 
endothelial cell-derived growth factor, and colony stimulating factor 
(Szekanecz and Koch, 2008) 
It should be noted that the regulation of angiogenesis involves phases of apoptosis since 
vascular remodeling is an ongoing process. Therefore, a range of apoptosis related genes 
are also active during angiogenesis,  such as TNF-α, HIF-1, Smo,  and αvβ3 (Firestein, 
1999; Middleton et al., 2003; Semerano et al.,2011; Zhu et al., 2015)  
In the human synovium venular endothelial changes occur very early in RA. These   
include morphological changes with the ECs developing a cuboidal appearance and gaps 
appearing between ECs (Middleton et al, 2004).  
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Table 1.6    Some characteristics of  activated, angiogenic, apoptotic and leaky 
endothelial  cells  (data adapted from  Firestein, 1999; Middleton et al., 2003; Middleton 
et al., 2003 and references therein; Semerano et al.,2011; Zhu et al., 2015) 
Cell Phenotype 
Activated Angiogenic Apoptotic Leaky 
Increased adhesion 
molecule expression 
(ICAM, Selectins, 
MECA-79 etc.) 
Expression of cell-
cycle-associated 
antigens (PCNA and 
Ki67), the αvβ3 
integrin (associated 
with vascular 
proliferation) and 
VEGF stimulates EC 
proliferation 
Decreased 
adhesion molecule 
expression. 
Increased ROS 
Reduced expression 
of tight junction 
proteins  
Increased pro-
inflammatory/cytokine 
chemokine 
presentation and 
expression 
Increased pro-
angiogenic 
chemokine 
expression and 
upregulation of Ets-1 
expression 
Increased ROS. 
Increased oxidative 
stress. The Shh 
signalling pathway 
is involved in  
endothelial cell 
apoptosis in a Smo 
dependent manner 
VEGF generates 
vascular 
permeability 
Cuboidal appearance.  
MECA-79 binding on 
HEVs 
‘Flat’ (normal) 
appearance. The 
influx of EC 
progenitors leads to 
capillary sprouting 
which can be 
observed 
Cell blebbing, 
shrinkage, nuclear 
fragmentation, 
chromatin 
condensation And 
DNA 
fragmentation 
‘Gaps’ between 
cells observed 
αVβ3 integrin is 
expressed by 
endothelial cells and 
considered a marker 
for activation 
αVβ3 is also a 
marker for 
angiogenesis.  
The angiopoietins 
and their receptors 
Tie-1 and Tie-2 play 
a key role in the 
development of the 
vasculature 
The HIF-1 gene is 
associated with  
apoptosis (as are 
changes in NO 
levels and ‘stress 
genes’ and 
angiopoietins 
among others) 
however these 
genes are also 
involved in 
angiogenesis 
Reductions in 
junction protein 
expression are 
considered markers 
for ‘leaky’ ECs 
 
PCNA - Proliferating Cell Nuclear Antigen; MECA-79 - monoclonal antibody  to 
carbohydrate epitope expressed on HEVs; VEGF - vascular endothelial growth factor; HIF 
- Hypoxia inducible factor; HEV - high endothelial venules;  Ets-1 - an angiogenesis 
regulator; Smo - Smoothed protein; Shh - sonic hedgehog; ROS -  reactive oxygen species. 
ICAM – intra cellular adhesion molecule; NO – nitrous oxide; EC – endothelial cell; DNA 
– deoxyribo nucleic acid. 
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1.3.11 Cell populations in acidic environments. 
Little data are available on the pH in vivo in the rheumatoid joint tissue. This is partly due 
to it constantly changing in response to environmental cues, and  the difficulty of 
measuring it in vivo. Much of the data available refer to cultured cell types  in artificially 
induced pH environments; evidence shows the hypoxic joint to be acidic to various degrees 
in nature. Various studies exist showing differential gene expression and thus functional 
differences in reduced pH (Andersson et al., 1999; Lardner, 2001; Murata et al., 2009; 
Dong et al., 2013).  
 Under inflammatory conditions hypoxia stimulates lactate production due to anaerobic 
glycolysis, which leads to the extracellular acidification (Lardner, 2001). pH has been 
established at around pH 5.2-7.1 in a number of disease states, including RA SF (Farr., 
1985) and as between 7.27 and 7.30 in the pannus tissue from antigen induced rat models, 
while being lower at 5.66-6.91 in joint intracellular fluid (Andersson et al., 1999).  
A range of both pro- and anti-inflammatory responses are modulated by acidic 
environments (reviewed my Okajima, 2013).  Macrophages from mice have been shown to 
have inhibited TNF-α and IL-6 expression (Mogi et al., 2009) and increased IL-10 
secretion at between pH 6.2-7.3. Low extracellular pH has also been shown to stimulate 
macrophage phagocytosis (reviewed by Okajima, 2013). Neutrophils at  pH6.8 showed 
inhibited O
2- 
 production (Murata, et al., 2009) and ECs have been shown to stimulate the 
adhesion of monocytes and increase VCAM-1 and ICAM-1 expression (Chen et al., 2011). 
Increases in the expression of a number of genes involved with inflammation such as those 
for chemokines, cytokines, adhesion molecules, and COX-2 have also been observed in 
human ECs (Dong et al., 2013).  
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1.4 Angiogenesis in RA (reviewed by Szekanecz and Koch, 2008; Szekanecz et al., 2009; 
Szekanecz et al., 2010; Szekanecz, Besenyei, Szentpétery, and Koch, 2010). 
 
Due to the thickening of tissue in RA, the nutrient and oxygen requirements from the 
circulating blood for the synovium increase. Angiogenesis is the development of new 
blood vessels from existing vessels and is mediated by a range of both soluble and cell 
surface bound factors. The mediators activate the vascular ECs, which release MMPs to 
breakdown the extracellular matrix (ECM) and basement membrane allowing ECs to 
migrate out. From here ‘capillary sprouts’ form from single ECs which develop into 
capillary loops as the lumen forms and finally into new capillaries upon basal membrane 
formation. The increased vascularisation present in some RA is also a contributing factor 
in the increased infiltration of leukocytes which occurs across the synovial blood vessels. 
Microparticles (MPs) (small membrane-bound vesicles released by cells undergoing 
activation or apoptosis) have been indicated as involved in processes ranging from 
transcellular communication to molecular trafficking as evidenced by their presence on 
biologically active molecules such as DNA, adhesion molecules and cytokines. 
Furthermore, they may be involved in angiogenesis in RA due to their induction of 
chemokines such as CCL5 and cytokines such as TNF-α  (reviewed by Dye, Ullal and 
Pisetsky, 2013).  
The ELR motif divides CXC chemokines onto ELR
+
 (angiogenic) and ELR
-
 (angiostatic). 
It consists of the residues glutamate-leucine-arginine residues and is found near the N-
terminus of pro-angiogenic chemokines such as CXCL1, CXCL5, CXCL7 and CXCL8 
(Haringman et al., 2004; Koch, 2005; Charo and Ransohoff, 2006; Bonecchi et al., 2009).  
The ELR motif is involved in binding to receptor CXCR2 on ECs. This results in 
stimulating EC division and migration which are major components of angiogenesis 
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(reviewed by Keeley et al., 2008). ELR
+
 CXC chemokines can bind and activate 
neutrophils. The angiogenic properties of ELR
+
 CXC chemokines, such as CXCL8 and 
CXCL5 have been stated to be a result of their induction of endothelial cell migration 
which is not seen in the ELR
- 
CXC chemokines such as CXCL4 (Strieter et al., 1995). The 
migration of ECs allows for the development of new vessels within the synovium. 
 
1.5. Structure of the synovium  
The ultrastructure of the synovium was first described by Key (1932) where, based on the 
subintimal structure, it was divided into 3 major types; areolar, adipose and fibrous (see 
figure 1.4). The most highly specialised is areolar (see figure 1.5) which, whilst very rarely 
having villi, often has folds which upon stretching disappear.  
Within the synovium there are two major layers; the intimal (or lining) layer and the sub-
intimal (or sub-lining) layer. The intimal layer is marked by a fine fibrillar structure which 
contains a low number of collagen type I fibres which become denser in the sub-intima. 
The intimal layer of the areolar type is 1-2 cells thick with capillaries lying below or 
between these cells in the compact zone. Barland et al., (1962) described the intimal layer 
as containing two distinct cell types; fibroblast-like and macrophage-like cells. The 
electron microscopy techniques have been superseded by the advent of cytochemical 
analysis, which has identified the presence of intimal fibroblasts via identification of 
specific mRNAs and gene products. 
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Figure 1.4 Diagrammatic representations of the major synovium types. (Edwards, 
1998).   
 
 
Figure 1.5 Diagrammatic representation of areolar synovium. (Edwards, 1998) 
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These intimal fibroblasts show a high degree of uridine diphospho-glucose dehydrogenase 
(UDPGD) enzyme activity (Wilkinson et al., 1992; Pitsillides, 2003) and display high 
expression of a range of adhesion molecules such as vascular cell adhesion molecule-1 
(VCAM-1), (Morales-Ducret et al., 1992; Smith et al., 2003) and  intercellular adhesion 
molecule (ICAM). Decay accelerating factor (DAF) has also been identified in synovial 
intimal fibroblasts (Hamman et al., 1999). Edwards (1998) has also shown that intimal 
fibroblasts are capable of interacting with immune response elements as well as showing 
specialisation in matrix component synthesis and synthesis of synovial fluid.  
The subintimal layer is where the accumulation of infiltrating cells (including leukocytes) 
occurs. Mast cells and associated associated venules and arterioles, some of which are in 
association with nerve fibers, are also seen. The presence of neutrophils within the joint 
space is also seen in RA. (Edwards, 1998) 
Adipose synovium occurs within villi as ‘fat pads’. Whist the intimal layer usually has a 
collagen containing layer separating it from the adipocytes it can also lay directly upon 
them with the lower tissue layers consisting of fat cells. Fibrous synovium consists of 
dense fibres, such as those found in tendon/ligament and carries a non-continuous layer of 
cells.  
 
1.6. Function of the synovium  
The synovium has several major functions: 
 
1.6.1 Cartilage lubrication  
Synovial fluid (SF) is generated by the synovium and is of major importance in lubrication. 
Jay et al., (2007) identified lubricin as being responsible for the elastic behaviour of SF 
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and its ability to safely dissipate the ‘strain energy’ generated by motion, making it not 
only a distinct requirement for ‘boundary lubrication’ but also  chondrocyte protection. 
Lubricin is a glycosylated protein produced by the gene proteoglycan 4 (PRG4), also 
known as ‘superficial zone protein’ (SZP) which is expressed by synoviocytes and 
chondrocytes and in the superficial zone but not by deeper chondrocytes. Lubricin has also 
been suggested to bind polymorphonuclear granulocytes (PMN) which are recruited to the 
synovial tissue during inflammation and so ‘may play a role in PMN mediated 
inflammation’ (Jin et al., 2012). Cartilage does not self-repair so damage due to everyday 
exertion must be minimised and it is the lubricin containing SF which helps to fulfil this 
requirement and maintain joint longevity (Rhee et al., 2005). Gene defects on PRG4 have 
been shown to be involved in several joint defects, including the autosomal recessive 
disease camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) (Marcelino et 
al., 1999).  
 
1.6.2 Tissue surface maintenance 
A non-adherent synovial surface is a requirement for continued movement. Hyaluronan is 
generated by intimal fibroblasts and is considered of importance in adhesion prevention 
(Edwards et al., 2003).  Scarring and fibrin formation at the synovium surface can damage 
synovial function, the intimal fibroblast products plasminogen activator and decay 
accelerating factor (DAF) are thought to inhibit this. Hyaluronan is a major constituent of 
the SF which must be retained within the joint to ensure correct surface maintenance. Yu et 
al., (2005) ascertained that at the surface of the synovium the osmotic pressure of a 
hyaluronan concentration polarisation layer leads to ‘outflow buffering’ and thus gives a 
mechanism which retains the synovial fluid in a joint cavity under pressure. The intimal 
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matrix also aids in synovial fluid retention by being of a specific porosity to prevent 
fluid/hyaluronan loss whilst readily allowing the exchange of other substances. 
 
1.6.3 Chondrocyte nutrition 
It would be expected that the blood vessels within the synovium would provide the most 
direct route for nutrients and oxygen to reach the cartilage via the SF. This is a source of 
controversy as the required evidence to support this is not present as the vessels are not 
structurally adapted to this function (Edwards et al., 2003). Indirect routes such as the 
subchondral bone have also been considered as a route for nutrient delivery, but were 
initially discounted as a route of major importance as the subchondral plate is complete in 
adults and thus would prevent this function. However, Malinin and Ouellette, (2000) 
ascertained using cartilage autografts in primates that disrupting the contact between 
vascularised subchondral bone and cartilage resulted in cartilage degeneration. This is 
supported by work carried out by Amin et al., (2009) whose experiments on in vitro bovine 
tissue showed that removal of subchondral bone led to marked increases in chondrocyte 
death and that the presence of subchondral bone within the tissue culture medium appeared 
to protect superficial zone chondrocytes from death. This suggests that the subchondral 
bone provides mediators essential for chondrocyte and thus articular cartilage survival.  
 
1.6.4 Synovial fluid composition and volume control 
SF components are primarily secreted by cells of the synovium. SF is a plasma dialysate 
with hyaluronan as an added component as well as collagenases, proteinases and lubricin. 
A wide range of binding proteins, structural proteins, degenerative enzymes, lubricating 
molecules and signalling molecules have been identified as altered in differentially altered 
in diseases such as RA, OA, and in response to injury (reviewed by Hui et al., 2012). The 
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SF glutamate concentration has also been shown to which increase in arthritis with the 
glutamate receptors having recently been tied to inflammation and identified as a potential 
therapeutic target (Bonnet et al., 2013). Decreases in synovial fluid lubricin are seen to be 
associated with increases in inflammatory cytokines (Elsaid et al., 2008), as seen in RA 
sufferers. Lubricin is a hyaluronan binding protein important in dissipating the energy 
generated by the strain of everyday wear and tear from normal motion thus acting as a 
‘chondroprotective’ factor distinct from its role in joint lubrication (Jay et al., 2007). 
 In RA there is a marked increase in the volume of SF as the disease progresses which 
contributes to the swelling of the joint. Elevated cytokine levels in RA SF are also 
observed (reviewed by Szekanecz and Koch; 2010). SF from early RA patients has been 
shown to have a differing composition from later stage RA whereby the cytokine and 
MMP profiles between the two shows marked differences. The levels of cytokines in 
patients with early RA has been shown to include increased T-cell related cytokines (Raza 
et al., 2005) such as IL-2, IL-4, IL-13 and IL-17 as well as EGF, bFGF, IL-1 and IL15. In 
established RA IL-2, IL-4, IL-13, IL-15, EGF, bFGF were seen to decrease. A range of 
other cytokines and chemokines including CCL3, CCL4, CCL11, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) 
showed no significant differences between early and late RA  (Raza et al., 2005). MMP-1 
and MMP-3 are both increased in early RA with MMP-8 and MMP-9 increasing as RA 
progresses (Yoshihara et al., 2000)  
 
1.7. Leukocyte infiltration into the synovium 
Inflammation under normal (non-RA) conditions is a protective mechanism in response to 
injury and/or tissue damage whereby leukocytes travel to the site of injury to remove 
infectious agents and facilitate tissue repair. The transendothelial migration of leukocytes 
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is also a major feature in chronic inflammation in RA as it is the method by which 
leukocytes from the post capillary venules cross from the circulating blood to the site of 
‘injury’. This migration across ECs and the basement membrane into the synovial tissue 
and SF is mediated via a range of processes, including chemokines.  
 
1.7.1 Chemokines and transendothelial migration (TEM) 
1.7.1.1 Chemoattraction and Integrin activation 
The unidirectional movement of a cell from a region of low to high ligand concentration 
along a chemical gradient is ‘chemoattraction’. Platelet-activating factor (PAF) and 
leucotreine-B4 (LTB4) are examples of ‘classic’ chemoattractants. PAF is a mediator of 
inflammation, and a potent monocyte chemoattractant.   
While selectins mediate the leukocyte capture at the ECs (McEver, 2002) selectin bonds 
alone cannot arrest rolling leukocytes. This process relies almost exclusively on  
chemokine mediated integrin activation on leukocyte surfaces (Zarbock et al., 2007). Firm 
adhesion is regulated by the integrins and their EC ligands, including the α4 integrins, 
VLA-4 (α4β1) and α4β7 and the β2 integrins, LFA-1 (αLβ2) and MAC-1 (αMβ2) (reviewed by 
Alon and Schulman, 2011). As the leukocytes come into contact with the EC the leukocyte 
G-protein coupled receptors (GPCRs) are ‘triggered’ by heterotrimeric G-proteins, 
activated by the EC surface immobilised chemokines (Alon and Ley, 2008).  The 
chemokine receptor signal causes the α and β subunits of the integrin heterodimer to shift 
from the inactive to the active formation (Tadokoro et al., 2003). Chemokine activated 
VLA-4 molecules rearrange to form dispersed microclusters around their VCAM-1 EC 
ligand and LFA-1 and VLA-1 become mobilised to the leading and trailing edges of 
lymphocytes in the absence of the ligand (Woolfe et al., 2007). Chemokine activated 
ICAM-1/ LFA-1 microclusters are localised to the lymphocyte where it makes contact with 
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the EC and appear to facilitate the shear-resistant crawling of lymphocytes on ECs 
(Schulman et al., 2009). A series of studies have shown this cascade of events as occurring 
rapidly, allowing the abrupt arrest of leukocytes to the ECs  (Campbell et al., 1998; Shamri 
et al., 2005)  
 
1.7.1.2 Activation  
For leukocytes to effectively extravasate they must first firmly adhere to the venule ECs.  
For many years it was believed that soluble chemoattractants were responsible for 
leukocyte-EC adhesion (Middleton et al., 1997 and references therein; Middleton et al., 
2002). However, it was recognised that due to blood flow the chemoattractant gradient 
could not be maintained at the EC-blood interface. This led to the suggestion that 
chemokines were bound to the EC surface (Middleton et al., 1997 and references therein; 
Middleton et al., 2002) from where they effectively enabled leukocyte activation and 
transmigration from circulating blood.  Middleton et al., (1997) showed using CXCL8 (IL-
8) injections into rabbit skin that the chemokine was not only internalised abluminally into 
caveolae by postcapillary and small vein ECs but was also transcytosed and presented on 
the EC luminal surface, predominantly in association with EC microvilli. Mediators 
involved in this process include glycosaminoglycans (GAGs) and the Duffy antigen 
receptor complex (DARC) (reviewed by Middleton et al., 2002; Pruenster et al., 2009) 
which are discussed further below. It is likely that chemokines generated from within the 
ECs themselves are presented in the same fashion but without transcytosis occurring 
(figure 1.6) (Middleton et al., 2002). 
The chemokines are immobilised and presented on EC microvilli (figure 1.6) by GAGs 
which exhibit electrostatic interactions with the largely basic chemokines. However the 
interaction is not entirely electrostatic, as best shown by the fact that acidic chemokines 
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such as CCL3 and CCL4 also bind GAGs (Kuschert et al., 1999). Electrostatic chemokine-
GAG interactions are selective with chemokine immobilisation occurring via the 
chemokine C-terminus α-helix for some chemokines (i.e CXCL8), and at sites distinct 
from the C-terminus for chemokines such as CCL5. The heparin binding motifs XBBXBX, 
XBBBXXBX and BBXB, where B is a basic amino acid residue, are common for a 
number of proteins, as exemplified by chemokines such as CCL5 and CCL3 having the 
BBXB motif.  Binding occurs between the chemokine and carbohydrate structures (e.g 
sulphate groups) of GAGs such as heparan sulphate and chondroitin sulphate are found 
(reviewed by Middleton et al., 2002). 
DARC was first described on the surface of erythrocytes and was later found on 
postcapillary venule ECs where it was shown to bind both CC and CXC chemokines 
(Nibbs et al., 2003; Neote et al., 1993; Gardener et al., 2004). Further studies indicated that 
DARC mediates chemokine-EC interactions (Middleton et al., 1997; Rot, 2005) and 
Pruenster et al., (2009) has shown that DARC mediates chemokine transcytosis, increasing 
leukocyte transmigration across DARC expressing venules. 
As well as the chemokines and chemokine receptors, adhesion molecules such as the 
selectins, integrins and VCAM are present at the EC surface. Each of these can be 
localised on microvilli projections of the ECs (figure 1.6), and a range of work indicating 
the importance of microvilli localised adhesion molecule distribution in leukocyte 
migration has been carried out (reviewed by Middleton et al., 2002).   
As well as microvilli providing a greater surface area allowing the presentation of more 
chemokines and receptors, they have been seen to elongate in response to specific 
molecules such as ICAM-1. This was observed by Oh et al., (2007) where ICAM was seen 
to regulate de novo microvilli elongation allowing its clustering at the most apical region of 
the EC.  
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Figure 1.6 Subcellular events in the endothelium during chemokine-directed 
leukocyte extravasation. (A) Noninflamed tissue. (B) Inflamed tissue. Release of chemokines 
from extravascular cells in the tissue occurs (→), and there is wrinkling of the endothelial cell 
surface. Chemokines are taken up at the abluminal surface of the endothelium and transcytosed in 
caveolae. This process involves binding to glycosaminoglycans (GAGs) and/or the Duffy receptor. 
At the luminal surface, chemokines are released and bound preferentially on the tips of projections. 
These mediators may also be produced and released directly by endothelial cells, in which case 
they are also bound at the luminal surface but not transcytosed (       ). (C) Chemokines bound at 
the luminal endothelial cell surface build up in concentration. They do this sufficiently to bind to 
and activate the signaling receptors on the leukocyte cell surface, leading to activation of integrins 
and firm attachment. (D) Leukocyte migration occurs either transcellularly through a pore in the 
endothelial cell or through the intercellular junction, following a chemokine gradient bound to 
GAGs and/or the Duffy receptor. The cell then enters the basement membrane and continues 
migration along a chemokine gradient that is soluble or immobilized to the extracellular. (Figure 
taken from Middleton et al., 2002).  
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1.7.1.3 Leukocyte capture and rolling.      
Site specific inflammation starts with the capture and rolling of leukocytes along ECs of 
the post capillary venule walls. The capture and rolling are mediated by type-1 
transmembrane glycoproteins (Barreiro and Sanchez-Madrid, 2009) which are members of 
the selectin family. The most important of these here are: L-selectin (CD62L), expressed 
on the leukocyte outer membrane, P-selectin, (CD62P), expressed on ECs and platelet 
surface and E-selectin (CD62E), expressed on activated EC surface and specifically up-
regulated on synovial ECs under inflammatory conditions. These interact with 
carbohydrate structures on P-selectin glycoprotein ligand-1 (PSGL1) and other 
glycosylated ligands. PGSL1 binding to L-selectin ‘nucleates leukocyte-leukocyte 
interactions by which leukocyte derived fragments and adherent leukocytes facilitate 
secondary leukocyte capture’ (Ley et al., 2007). Serine phosphorylation of L-selectin has 
also been shown to affect the positioning of the receptor on the cell surface (Wedepohl et 
al., 2012).  
Selectin-ligand interactions have a very high on/off rate (rate at which the bonds are 
formed and broken) and so facilitate leukocyte adherence to the ECs in blood flow 
conditions and create rolling (Li et al., 2007). The L-selectin function is strengthened by 
interactions between lymphocyte function associated antigen-1 (LFA-1) and intercellular 
adhesion molecule (ICAM) which reduces the velocity of rolling leukocytes by stabilising 
the initial transient contact between the leukocytes and the EC (Barreiero and Sanchez-
Madrid, 2009). Once firmly adhered leukocytes change morphology from round to 
‘polarised’ (see figure 1.7). 
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Figure 1.7 Scanning electron microscope image of leukocyte rolling and adhesion to 
an EC monolayer.  A human endothelial monolayer (treated with pro-inflammatory 
stimuli and exposed to human peripheral blood lymphocytes and monocytes under flow). 
A number of unpolarised leukocytes have been captured during the rolling process. Also 
shown is a firmly adhered lymphocyte which has changed morphology from rounded to 
polarised. (Taken and adapted from Barreiero and Sanchez-Madrid, 2009).   
 
Integrins are of great importance in the initial stages of leukocyte transmigration for 
controlling the cell-cell interactions. The activation of leukocyte integrins is chemokine 
mediated. Other than integrins and selectins, mucosal vascular addressin cell adhesion 
molecule, (MAdCAM-1) participates in capture by collaborating with L-selectin function 
to stabilise the initial capture and reduce rolling velocity (Barreiero and Sanchez-Madrid, 
2009). In particular, they can change their adherent activity by maintaining an inactive 
surface conformation until the site of inflammation is reached where rapid integrin 
activation allowing initial adherence occurs (Campbell et al., 1998). The conformational 
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changes in the integrins are induced by chemokine receptor initiated signalling pathways 
causing an increase in the integrin-ligand affinities (Hyduck and Cybulsky, 2009). 
 
1.7.1.4 Arrest and firm adhesion 
As capture of leukocytes on the vascular endothelium is achieved and the rolling rate 
slows, leukocytes are activated by contact with the EC luminal surface bound chemokines 
and integrin ligands enable leukocyte arrest in normal blood flow conditions (termed 
‘activation-dependent stable arrest’) (Tarrent and Patel, 2006; Barreiero and Sanchez-
Madrid, 2009). Once firmly adhered the leukocytes change morphology from round to 
‘polarised’ (see figures 1.7 and 1.8). The integrin-ligand interaction is key to firm 
adhesion. Each integrin is composed of an α-subunit and a β-subunit, which undergo 
conformational changes, as well as integrin redistribution on the leukocyte cell surface. 
Three conformational states have been proposed; bent conformation with low affinity, 
extended conformation with intermediate affinity and lastly, extended conformation with 
high affinity (Beglova et al., 2002; Nishida et al., 2006). The most important integrins for 
leukocyte firm adhesion to ECs are β2 subfamily members, particularly LFA-1 
(CD11a/CD18 or αLβ2) and myeloid-specific integrin Mac-1 (CD11b/CD18 or αMβ2), as 
well as α4 integrins VLA-4 (α4β1) and α4β7. LFA-1 binds to a range of intercellular 
adhesion molecules (ICAM-1to ICAM-5), the most important being ICAM-1 and ICAM-3 
(Barreiero and Sanchez-Madrid, 2009).  
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Figure 1.8 Leukocyte adhesion cascade. The original three steps in TEM  were; rolling (selectin mediated), activation (chemokine-triggered) 
and arrest (integrin dependent). Additional steps have now been added, slow rolling, adhesion strengthening and spreading, intravascular crawling and 
paracellular/transcellular migration. Boxes indicate the main molecules involved in the marked step. ESAM, endothelial cell-selective adhesion molecule; 
ICAM1, intercellular adhesion molecule 1; JAM, junctional adhesion molecule; LFA1, lymphocyte function-associated antigen 1 (also known as αLβ2-
integrin); MAC1, macrophage antigen 1; MADCAM1, mucosal vascular addressin cell-adhesion molecule 1; PSGL1, P-selectin glycoprotein ligand 1; 
PECAM1, platelet/endothelial-cell adhesion molecule 1; PI3K, phosphoinositide 3-kinase; VCAM1, vascular cell-adhesion molecule 1; VLA4, very late 
antigen 4 (also known as α4β1-integrin). VAVs, Rho family guanine nucleotide exchange factors that become tyrosine phosphorylated in response to 
adhesion. (Taken from Ley et al., 2007).  
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1.7.1.5 Crawling (figure 1.9 A) 
Prior to transmigration  across the post capillary ECs leukocytes ‘crawl’ on the luminal EC 
surface in a ‘MAC-1 and ICAM-1 dependent manner’ (Ley et al., 2007) actively seeking 
out a suitable transmigration site. This crawling is mediated by chemokines. 
 
1.7.1.6 Podosome formation and conformational changes 
It is believed that the extracellular matrix degradation and cell motility that facilitates cell 
migration are coordinated by podosomes, most probably dependent on cell matrix and cell 
type (Murphy and Courtneidge, 2012).  A range of podosome initiation mechanisms have 
been elucidated, including integrin signalling, microRNA control and ROS signalling 
(reviewed by Murphy and Courtneidge, 2012).  Concomitantly with integrin activation and 
clustering a series of actin remodelling events are triggered by chemokines, which cause 
leukocyte microvilli to collapse and formation of the polarised shape (anterior-posterior 
axis) (Brown et al., 2003).  Both lymphocytes and neutrophils use invasive podosomes to 
probe ECs during the migration process (Cinamon et al., 2004; Schulman et al., 2009). 
During paracellular migration lymphocyte podosomes probe subendothelial chemokines 
(Lee et al., 2009). Studies have suggested that these podosomes are seldom found at 
lymphocyte-EC contact points when chemokine signals are limited and shear force is not 
applied (Schreiber et al., 2007; Schulman et al., 2009).  As transmigration rarely occurs 
under these conditions podosome frequency appears to correlate with successful migration 
(Schreiber et al., 2007; Schulman et al., 2009). Podosome analysis suggests lymphocyte 
contacts with the apical EC surface are composed of LFA-1 rings that surround the base of 
the podosome (Schulman et al., 2009). These may act as signalling moieties and  
nucleating assemblies for chemokine triggered  cytoskeletal remolding on both the 
leukocyte and the endothelial sides.  
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Figure 1.9 Leukocyte crawling and 
transmigration.  A   Leukocyte membrane protrusion  
extension into the endothelial-cell body and endothelial-
cell junctions is initiated by ligation of intercellular 
adhesion molecule 1 (ICAM1) by macrophage antigen 1 
(MAC1). Ligation of ICAM1 is associated with increased 
intracellular Ca2+ and activation of p38 mitogen-
activated protein kinase (MAPK) and RAS homologue 
(RHO) GTPase, which together may activate myosin 
light-chain kinase enhancing endothelial-cell contraction 
and thus opening interendothelial contacts. 
Transmigration through ECs can also induce cell-surface 
expression of members of the β1-integrin family and 
proteases on neutrophils and other leukocytes that may 
facilitate the progression of the leukocyte through the 
vessel wall. B Paracellular migration involves the release 
of endothelial-expressed vascular endothelial cadherin 
(VE-cadherin) and is facilitated by intracellular 
membrane compartments containing a pool of 
platelet/endothelial-cell adhesion molecule 1 (PECAM1) 
and possibly other endothelial-cell junctional molecules, 
such as junctional adhesion molecule A (JAM-A). Other 
molecules involved in paracellular transmigration are 
endothelial cell-selective adhesion molecule (ESAM), 
ICAM2 and CD99. C Transcellular migration occurs in 
narrow endothelium regions, ICAM1 ligation leads to 
translocation of ICAM1 to actin- and caveolae-rich 
regions. ICAM1-containing caveolae come together as 
vesiculo-vacuolar organelles (VVOs) which develop an 
intracellular channel enabling leukocyte migration. Ezrin, 
radixin and moesin (ERM) proteins may link ICAM1 and 
cytoskeletal proteins such as actin and vimentin causing 
their localization around the channel. D Migration 
through the endothelial basement membrane and pericyte 
layer occurs through gaps between adjacent pericytes and 
areas of low protein deposition within the extracellular 
matrix. This response can be facilitated by α6β1-integrin 
and possibly proteases, such as matrix metalloproteinases 
(MMPs) and neutrophil elastase (NE), ERM, ezrin, 
radixin and moesin; LFA1, lymphocyte function-
associated antigen 1. (Figure taken from Ley et al., 2007) 
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1.7.1.7 Transmigration 
Transmigration of leukocytes from blood to tissues across the EC barrier occurs by two 
routes, the transcellular (through individual ECs) route and/or the paracellular (between 
adjacent ECs) route (Ley et al., 2007; Carmen and Spinger, 2008; Wittchen, 2009).  
 
1.7.1.8 Transcellular migration (figure 1.9 C) 
Transcellular migration occurs preferentially in several regions including HEVs of 
secondary lymphoid organs and the blood brain barrier where migration occurs without 
disturbing interendothelial junctions. As mentioned in section 1.7.1.6. this is dependent on  
the generation of protrusions known as ‘podosomes’ (~500nm in depth and diameter), 
which are dependent on actin and Src kinase as well as being Wiskott–Aldrich syndrome 
protein (WASP) activity dependent (Vijayakumar et al., 2015; Carmen and Spinger, 2008; 
Wittchen, 2009; reviewed by Carmen et al., 2007;). The podosomes (feet-like structures) 
palpate the EC surface searching for a site of low EC resistance where an invasive 
podosome of >1000nm can begin penetration. When a suitable site is located the EC 
surface is locally disrupted, initially by forcing a ‘podo-print’ into the surface membrane 
disrupting the cytoskeletal arrangement, cytoplasm and other organelles, then by driving 
pore formation in the EC membrane.  
Also reported (Barreiero and Sanchez-Madrid, 2009 and references therein), is that 
vimentin (a filament protein) plays a role in transcellular migration. In addition there is 
translocation of ICAM-1 to caveolae following the adhesion of leukocytes and subsequent 
formation of ICAM-1 and cavaolin-1 containing vesicular channels around the podosomes 
penetrating the cell. Further to this dome-shaped endothelial structures have been shown in 
vivo encapsulating the leukocyte indicating the possibility that the docking structures may 
develop into encapsulating domes allowing the podosomes to penetrate not only the EC 
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membrane and pass through the cytoplasm, but also to allow the basal membrane to be 
penetrated without disrupting EC barrier function.   
 
 
1.7.1.9 Paracellular migration (figure 1.9 B) 
Paracellular migration requires the transient disruption of EC tight junctions. Woodfin et 
al., (2009) recently ascertained that EC junctional molecules (such as ICAM-2, JAM-A, 
and PECAM-1) act sequentially and in distinct steps to facilitate/mediate neutrophil 
transmigration, which is likely to hold true for all leukocytes. ECs interact with adjacent  
T-cells via tight junction and adherens junctions which are comprised of a range of 
proteins important in facilitating paracellular transmigration (see table 1.7). Occludin is 
one such protein and was the first transmembrane protein to be positively identified in tight 
junction
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Table 1.7 Proteins seen at tight and adherens junctions involved in paracellular 
transmigration.  (Ley et al., 2007; Wittchen, 2009; Barreiero and Sanchez-Madrid, 2009) 
Junction 
type 
Protein 
Tight 
Occludin 
Involved in cytoskeleton rearrangement, postulated that 
the homophilic binding of leukocyte to EC occludin may 
preserve EC barrier function during transmigration 
Claudin-5 
A member of the claudin family. Vascular EC-specific 
transmembrane (TM) protein 
JAM 
Junction adhesion molecule. A TM protein concentrated 
at the apical region of EC tight junctions. Engages in 
homophilic interactions between adjacent T-cells  
ESAM 
Endothelial specific adhesion molecule Another TM 
protein. Can interact homophilically and heterophilically 
to maintain the junction 
ZO-1 and ZO-2 
 
Zonula occludin. Intracellular proteins forming a 
complex on the cytoplasmic side of the plasma membrane 
immediately beneath the tight junction 
Adherens 
VE-cadherin 
A TM protein forming contacts between adjacent EC cells 
and interacts with the cytoskeleton of the cell to maintain 
EC barrier function. During transmigration VE-cadherin 
is displaced from the junction and rapid relocalises once 
transmigration has occurred   
Catenins 
α-, β-, and p120-catenin form a complex with VE-
cadherin on the cytoplasmic side of the junction allowing 
VE-cadherin to interact with the cytoskeleton 
PECAM-1 
(CD31) 
Platelet endothelial cell adhesion molecule-1. A TM 
protein expressed on ECs, platelets, and some leukocytes. 
The PECAM pool at the junction is critical in cell-cell 
adhesion for adjacent ECs 
CD99 
A highly glycosylated protein expressed by most ECs and 
leukocytes. Many can interact both homophilically and 
heterophilically to maintain the junction 
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1.8. Chemokines and chemokine receptors 
1.8.1 Chemokines 
Chemotactic cytokines or ‘chemokines’ are small heparin binding proteins produced by a 
range of both tissue cells and leukocytes.  They are essential factors in immune defence 
being involved in the generation, localisation, recruitment and activation of leukocytes as a 
response to inflammatory stimuli (Pease and Williams, 2006). There are currently over 40 
chemokines (table 1.8) grouped according to structural criteria. Each is a single 
polypeptide chain of 70-100 amino acid residues which share 20-95% sequence homology, 
including a number of conserved cysteine residues. The cysteine residues have been 
utilised in the nomenclature system for chemokines (see table 1.8) and give four distinct 
chemokine subgroups (Pease and Williams, 2006; Iwamoto et al., 2008; Bonecchi et al., 
2009) 
1) CC chemokines. The first two of four cysteine residues are adjacent to each 
other. The largest of the chemokines groups whose major target is monocytes.  
2) CXC chemokines. The first two of the four cysteine residues are separated by a 
single amino acid. The genes for these are mostly clustered on two 
chromosomes, 4q12-q13 (the major cellular target being neutrophils) and 
4q21.21 (the major cellular target being lymphocytes).  
3) C (or XC) chemokines. Contain only two cysteine residues. Represented by 
only two chemokines which are specifically active on T-lymphocytes. 
4) CX3C chemokines. Only one chemokine currently resides in this subgroup. 
The two cysteine residues here are separated by three other amino acid residues. 
Structurally different to the other subgroups by having a transmembrane 
domain.  
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As chemokines are designated as being ligands in the new (2000) nomenclature system, 
namely CCL, CXCL, XCL and CX3CL with their corresponding receptors being 
designated as CCR, CXCR, XCR and CX3CR respectively (reviewed by Szekanecz et al., 
2003; Iwamoto et al., 2008; Bonnechi et al., 2009). Chemokines can be broadly grouped 
into two categories depending on their function: inflammatory (inducible), and constitutive 
(homeostatic). A less represented sub-type are the dual function chemokines.  
 
1.8.2 Chemokine receptors 
There are currently 19 identified chemokine receptors (Bonecchi et al., 2009; Bachelerie et 
al., 2014), all of which belong to the G-protein coupled receptor family subset with 7-
transmembrane domains (Pease and Williams, 2006; Bonecchi et al., 2009; Bachelerie et 
al., 2014).   
Many of the receptors bind multiple ligands (table 1.8) and are expressed on a range of 
leukocyte cell types. Whilst most CC and CXC chemokine receptors will bind only CC and 
CXC chemokines respectively, the Duffy antigen receptor for chemokines (DARC) bind 
both CC and CXC chemokines (Neote et al., 1993; Nibbs et al., 2003), but has also been 
shown to bind inflammatory rather than constitutive/homeostatic chemokines (Gardner et 
al., 2004). DARC and the receptor D6 are termed ‘atypical receptors’ as neither generate a 
signalling cascade involving G-proteins typical of all other chemokine receptors (Nibbs et 
al., 2003) and are involved in internalisation and transport. A further atypical receptor  is 
chemocentryx chemokine receptor (CCX-CRK), which along with D6 binds CC 
chemokines, targeting them for degradation and thus acting as ‘decoy receptors’ (Pruenster 
et al., 2009). 
Signal transduction is achieved by two interactions, the first being an interaction whereby 
the basic chemokine ligand is tethered by the acidic extracellular N-terminus domain of the 
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receptor. The first interaction enables the second (lower affinity) interaction whereby the 
ligand is moved to the body of the receptor, activating the G-protein subunits initiating the 
signalling cascade (Pease and Williams, 2006).   
All chemokine receptors share a number of common features (Murphy., 1994) 
 
1. 340-380 amino acid residues in length. 
2. An Asp-Arg-Tyr (DRY) motif in the second intracellular domain loop. This 
motif is not present on the atypical chemokine receptors (Pruenster et al., 
2009). 
3.  N-terminal segment containing a tyrosine sulphation motif. 
4. A disulphide bond formed from two conserved cysteine residues which 
stabilise the binding pocket. 
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Table 1.8 Human chemokines and chemokine receptors (Adapted from Filer et al., 
2008; Bonecchi et al., 2009) 
Chemokine (Ch)  
Receptor(s) 
 
Functional 
expression 
Nomenclature 
Chromosome 
Old New 
GROα CXCL1 4q21 CXCR2 Inflammatory 
GROβ CXCL2 4q21 CXCR2 Inflammatory 
GROγ CXCL3 4q21 CXCR2 Inflammatory 
PF4 CXCL4 4q21 CXCR3 splice variant  
ENA-78 CXCL5 4q12-q13 CXCR2 Inflammatory 
GCP-2/CTAP-III CXCL6 4q21 CXCR1, 2 Inflammatory 
NAP-2 CXCL7 4q12-q13 CXCR2 Inflammatory 
IL-8 CXCL8 4q13-q21 CXCR1, 2 Inflammatory 
Mig CXCL9 4q21 CXCR3 Inflammatory 
IP-10 CXCL10 4q21 CXCR3 Inflammatory 
I-TAC CXCL11 4q21.2 CXCR3 Inflammatory 
SDF-1 CXCL12 10q11.1 CXCR4 Constitutive 
BLC/BCA-1 CXCL13 4q21 CXCR5 Constitutive 
BRAK CXCL14 5q31 Unknown Unknown 
SR-PSOX CXCL16 17p13 CXCR6 Heterogeneous 
Lymphotactin XCL1 1q23 XCR1  
SCM-1β XCL2 1Q23 CXR1  
Fractalkine CX3CL1 16q13 CX3CR1 Heterogeneous 
I-309 CCL1 17q12 CCR8 Inflammatory 
MCP-1 CCL2 17q11.2 CCR2 Inflammatory 
MIP-1α CCL3 17q11 CCR1, 5 Inflammatory 
MIP-1β  CCL4 17q12 CCR5, 8 Inflammatory 
RANTES CCL5 17q11.2 CCR1, 3, 5 Inflammatory 
MCP-3 CCL7 17q11.2 CCR1, 2, 3 Inflammatory 
MCP-2 CCL8 17q11.2 CCR3, 5 Inflammatory 
MIP-1γ CCL9  CCR1 Inflammatory 
MIP-1γ CCL10  CCR1 Inflammatory 
Eotaxin CCL11 17q21.1 CCR3 Inflammatory 
MCP-5 CCL12  CCR2  
MCP-4 CCL13 17q11.2 CCR2, 3 Inflammatory 
HCC-1 CCL14 17q11.2 CCR1 Heterogeneous 
HCC-2/Lkn-1 CCL15 17q11.2 CCR1, 3  
HCC-4/LEC CCL16 17q11.2 CCR1, 2  
TARC CCL17 16q13 CCR4, 8 Heterogeneous 
DC-CK-1 CCL18 17q11.2 Unknown Constitutive 
ELC/MIP-3β CCL19 9p13 CCR7 Constitutive 
LARC/MIP-3α CCL20 2q33-q37 CCR6 Inflammatory 
SCL/6Ckine CCL21 9p13 CCR7 Constitutive 
MDC CCL22 16q13 CCR4, 8 Heterogeneous 
MPIF-1 CCL23 17q12 CCR1 Heterogeneous 
Eotaxin-2 CCL24 7q11.23 CCR3 Inflammatory 
TECK CCL25 19p13.2 CCR9 Constitutive 
Eotaxin-3 CCL26 7q11.23 CCR3 Inflammatory 
CTACK CCL27 9p13 CCR10 Constitutive 
MEC CCL28 5p12 * CCR3, 10 Heterogeneous 
* gene number supplied by NCBI Entrez gene (http://www.ncbi.nlm.nih.gov/sites/entrez) 
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1.8.3 Chemokine involvement in rheumatoid arthritis 
1.8.3.1 Inflammatory chemokines (figure 1.10) 
Inflammatory chemokines (table 1.8, and figure 1.10) such as CXCL8 and CCL1 are 
usually only expressed under inflammatory conditions, and as such are found in high levels 
in the RA joint (table 1.9). They are expressed by a wide range of cell types and frequently 
bind non-selectively, with multiple receptors accommodating multiple chemokine ligands 
(Baggiolini, 2001; Haringman et al., 2004; Loetscher, 2005; Filer et al., 2008). 
Inflammatory chemokine production can be induced in response to stimulation by pro-
inflammatory cytokines such as IL-1 and TNFα (Haringman et al., 2004) and as such they 
are important mediators in the recruitment of effector cells of both the innate and adaptive 
immune system. Inflammatory chemokines in RA include CXCL1, CXCL5, CXCL6, 
CXCL8, CXCL9, CXCL10, CCL2, CCL3, CCL5, CCL13 and CCL20 (table 1.8 and table 
1.9). 
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Table 1.9 Chemokines considered important in RA/expressed in RA joints. (Szekanecz 
et al., 2003; Szekanecz et al., 2006; Iwamoto et al., 2008) 
 
Subgroup Name 
CXC CXCL1, CXCL4, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10, 
CXCL12 
CC CCL2, CCL3, CCL5, CCL13, CCL17, CCL18, CCL20 
C CXL1 
CX3C CX3CL1 
Many of these chemokines have not been specifically investigated to assess their presence 
at RA ECs and so a range of important data in this field which may contribute to the 
chemokine address code for RA has not been ascertained.  
 
1.8.3.2 Constitutive chemokines (figure 1.10) 
Constitutive chemokines (table 1.8 and figure 1.10) are expressed continuously and direct 
essential physiological processes such as haematopoiesis (Filer et al., 2008) and 
lymphocyte and dendritic cell homing (Baggiolini, 2001; Loetscher, 2005)  and the normal 
immune surveillance of body tissues. Unlike inflammatory chemokines they usually bind 
to specific single receptors (Filer et al., 2008). Their presence in the bone marrow, thymus 
and lymph nodes indicates a role in the regulation of normal leukocyte production and 
distribution (Bonecchi et al., 2009).  
RA synovium bears resemblance to lymphoid tissue due to the generation of LFs in RA 
synovium (discussed in section 1). Constitutive chemokines, particularly CXCL13 and 
CCL21, have been implicated in the development of LFs in RA (Loetscher, 2005; Filer, 
2008). Other constitutive chemokines in RA include CXCL12, CCL18 and CCL19 (table 
1.8 and table 1.9).  
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1.8.3.3 Dual function chemokines (figure 1.10) 
Dual function chemokines have features representative of both inflammatory and 
constitutive chemokines, being involved in normal immune defence and being up-
regulated in inflammatory conditions. This group include CXCL9, CXCL10, CXCL11, 
CCL1, CCL20 and CCL25 (Moser and Willimann, 2004; Loetscher, 2005), however, these 
same chemokines are also designated as inflammatory or constitutive in other texts (Filer 
et al., 2008).  
 
1.8.3.4 The CCL chemokines and their receptors in RA 
As stated in section 1.8.3.1 the chemokines CCL2, CCL3, CCL5, CCL13 and CCL20 have 
been shown to be important in RA with their role in RA being well established.  
As prolific mononuclear cell recruiters, the following text will focus on CCL2 and CCL3. 
CCL2 (previously known as monocyte chemotactic protein-1/MCP-1) is the CCR2 ligand. 
It is expressed in both synovial tissue and fluid where macrophages are its main source 
(Koch et al., 1992) and has chemoattractive abilities in a range of cells including inducing 
the transmigration of monocytes, T-cells and NK cells (Loetscher et al., 1994; Iikuni et al., 
2006; Wang et al., 2009; Lebre et al., 2011: Melado et al., 2015) and is known to induce 
angiogenesis (Niu et al., 2008). CCR2 has also recently been linked to neutrophil 
transmigration whereby high CCR2 expression and CCL2 responsiveness were seen in the 
peripheral blood neutrophils from early RA patients (Talbot et al., 2015). Furthermore, 
monocyte chemotactic protein-1 induced protein (MCPIP) has been indicated to be 
involved in RA associated endothelial dysfunction via decreasing the generation of  nitric-
oxide (NO) synthase–derived NO (He et al., 2013). Normal vascular ECs exist at low 
levels of oxidative stress by the release of mediators such as NO (among others) (Napoli et 
al., 2001).  
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CCL3 is a ligand of both CCR1 and CCR5 (Iwamoto et al., 2008) and shows chemotactic 
activity for T-cells and monocytes (Stanford and Isseuts, 2003). The CCL3 mRNA is 
found within RA joints (Robinson et al., 1995). Furthermore, CCL3 shows a two-fold 
increase in RA SF compared to control SF (Patel et al., 2001). It has also been shown to 
stimulate neutrophil migration via CCR1, and to induce TNF generation in a mouse model 
of inflammation (Ramos et al., 2005).  
Further chemokines and their receptors are extensively discussed in a number review 
articles (Middleton et al., 2004; Szekanecz and Koch, 2007; Szekanecz, Besenyei, 
Szentpétery, and Koch, 2010; Alon and Schulman, 2011; Dye, Ullal and Pisetsky, 2013; 
Wright, Moots and Edwards, 2014). Further details from these, and other reviews and 
references therein, are discussed in later chapters.  
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Figure 1.10 Schematic showing some inflammatory, constitutive, angiogenic and 
angiostatic chemokines designated to various different groups. (Adapted from  Salcedo 
et al., 2001; Strasly et al., 2004 Hwang et al., 2004; Loetscher., 2005; Filer., 2008;; 
Szekanecz and Koch., 2008; Szekanecz et al., 2009).  *1 indicates Filer, 2008,  *2 indicates 
Loetscher, 2005, *3
  
indicates Bernardini  et al., 2001. *4 indicates Salcedo et al., 2001, *5 
indicates Hwang, 2009, *6 indicates Strasly et al., 2004.  
 
Whilst the chemokines in table 1.9 are the ones considered to be of importance in RA, a 
range of other chemokines have been established as being present in the RA joint (see table 
1.10).   The EC barrier where extravasation occurs offers a valuable source of therapeutic 
targets for leukocyte entry into the synovial tissue and thus invites more thorough 
investigation into the chemokines expressed specifically in this area. 
 
Inflammatory 
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CCL23
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Table 1.10 Human chemokines present at RA microvascular ECs 
Imf – Immunofluorescence; Imh- Immunohistochemistry.; NB – northern blot; PImh – 
peroxidise immunohistochemistry; GC LF – germinal centres in lymphoid follicles; PB – 
peripheral blood; he – healthy;  ~Y – very little observed; HUVEC – human umbilical 
vein ECs;  * indicates that while Tanaka et al (1998) showed CCL4 to be present on ECs 
its up-regulation was not established, however increases in T-cell adhesion in the presence 
of CCL4 were seen (also applies to CCL3, data not in table); ST – synovial tissue. 
Chemokine 
Present 
at RA 
ECs 
Present 
in 
control 
Control tissue 
Upregulated in 
RA 
Technique Reference 
CXCL5 Y Y OA/non RA Y Imf 
Koch et al, 
(1994a) 
CXCL9 Y N 
Isotype matched 
negative control 
_ Imh 
Tsubaki et al., 
(2005) 
CXCL12 
Y 
Y (OA) 
N ( he) 
OA/healthy 
Y (compared 
to he) 
PImh 
NB 
Pablos et al., 
(2003) 
Y Y OA Y PImh 
Santiago et al., 
(2006) 
Y ~Y 
Salivary glands 
in Sjogren’s 
syndrome 
Y Imf 
Burman et al., 
(2005)  
CXCL13 Y Y 
Non GC LF in 
RA 
_ Imh 
Takemura et 
al., (2001) 
CXCL16 Y N Non RA ST Y Imh 
Van Der Voort 
et al., (2005) 
CX3CL1 
Y N 
Control IgM 
antibody 
_ Imh 
Ruth et al., 
(2001) 
Y ~Y OA/ normal ST Y Imh 
Blaschke et al., 
(2003) 
CCL2 Y N 
Isotype-matched 
negative 
controls 
_ Imf 
Burman et al., 
(2005)  
CCL3 Y 
Y (OA) 
~Y (he) 
OA/healthy Y Imh 
Koch et al., 
(1994b) 
CCL4 Y Y 
HUVEC/ normal 
PB 
* 
Imh. 
Adhesion 
assay 
Tanaka et al., 
(1998)  
CCL8 Y ~Y OA Y Imh 
Pierer et al., 
(2004) 
CCL19 
Y ~Y 
Salivary glands 
in Sjogren’s 
syndrome. 
Y 
Imh 
 
Burman et al., 
(2005)  
Y Y 
Tonsil/ non-GC 
RA 
_ Imf 
Page et el., 
(2002) 
CCL21 
Y Y Tonsil _ Imf 
Page et el., 
(2002) 
Y ~Y Psoriasis Y 
Imf & mRNA 
hubridisation 
Weninger et al., 
(2003) 
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1.9. The Lymphatic System 
In normal conditions lymphatic (or lymph) vessels are valved EC lined vessels which carry 
lymph from the tissues (figure 1.11). APCs are also carried to the lymph nodes via the 
afferent lymph vessels as part of normal essential maintenance and immune responses. The 
lymph is formed when lymphatic capillaries collect interstitial fluid for transport to lymph 
nodes via the lymphatic vessels to the subclavian vein where it is mixed back in with the 
blood.   The lymph is pushed through the lymph vessels in a passive manner by contraction 
of body muscles during normal movement. The valves within lymph vessels prevent 
backflow of lymph fluid. 
Lymphatic vessels can be distinguished from arterioles in a number of ways, such as the 
lack of a continuous basal membrane and the presence of ‘gaps’ between LECs, and the 
absence of desmosmes between LEC cell membranes (Rovenská and Rovenský, 2012). 
Histologically both LECs and arteriole ECs will stain with pan-endothelial markers such as 
CD31. However,  LECs can be distinguished by staining for Lymphatic vessel endothelial 
HA receptor-1 (LYVE-) 1 and podoplanin. 
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Figure 1.11  Diagram showing basic blood-tissue-lymphatic exchange.  The process of 
transport from the blood to the tissue and the tissue to the lymphatic system (Taken and 
adapted (http://training.seer.cancer.gov/module_anatomy/images/illu_lymph_capillary.jpg.) 
 
  
1.9.1 The Lymphatic vessels of the synovium 
It has been shown that lymphatic vessel formation increases in RA (Xu et al., 2003) and 
should act as a compensatory mechanism for the removal of the interstitial fluid containing 
the invading lymphocytes and pro-inflammatory chemokines and cytokines (Olszewski et 
al., 2001 ). However, Zhou et al., 2010 showed that despite an increase in lymphatic flow 
during the acute phase of arthritic inflammation there is a decrease in lymphatic flow as 
new lymphatic vessels form during the chronic phase. This has also been seen in the 
human TNF transgenic mouse (hTNFtf) model where lymphatic vessels increased in 
number through the initial stages of inflammation but underwent no further significant 
increases as synovitis progressed (Polzer et al., 2008). This would lead to reduction in 
removal of the ever increasing joint interstitial fluid and is further exacerbated by the 
reduction in muscular contractions around the damaged joint that encourage flow through 
the lymph vessels.  
Arteriole 
Interstitial Space 
Venule 
Lymphatic Vessel 
Lymphatic Capillary 
Interstitial Fluid 
Tissue Cells 
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1.9.2 Chemokines and lymphatic vessels 
It has been shown that the TNF-α activated dermal lymphatic endothelial cells (DLECs) 
show >100 fold increases in production of a range of chemokines including CCL2, CCL5 
and CCL20 which attract T-cells and monocytes (Johnson et al., 2006). This indicates that 
in inflammatory conditions lymphatic vessels would be required to upregulate the 
expression of chemokines chemoactive for the effective removal of the leukocytes in the 
synovium. This would be particularly pertinent in the later stages of RA where 
lymphangiogenesis has reduced and normal lymphatic drainage is declining. However, 
Burman et al., (2005) has shown ‘inappropriately high’ levels of the same chemokine on 
both vascular and lymphatic vessels indicating that the chemokine gradient is corrupted 
within the RA synovium. Further studies to elucidate if there are correlations between the 
presence and/or absence of specific chemokines on the both vascular and lymphatic vessels 
of the synovium would be beneficial. This would further indicate the possibility that 
targeting the lymphatic system as a therapy for RA is feasible. 
 
1.10. Hypoxia in RA (figure 1.12) 
As discussed in section 1.4 angiogenesis allows for the increase in the blood supply to the 
synovium as it expands and its metabolic activity increases. Hypoxia due to increased 
oxygen requirements has been shown to upregulate angiogenesis in the RA synovium 
(Akhavani et al., 2009). Despite this the increasing need for oxygen by the tissue is not met 
and the tissue oxygen pressure (tPO) decreases. tPO in the synovial tissue of RA  patients 
has been measured to be as low as a mean of 19.35 mm Hg, an ambient oxygen tension of 
2.5% (Biniecka et al., 2010),  compared to 74mm Hg, or 10% ambient oxygen tension in 
non RA synovium (Akhavani et al., 2009).  Hypoxia is also associated with increased 
levels of lipid peroxidation (Biniecka et al., 2010) whereby membrane lipids undergo 
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oxidative degradation by the hydroxyl radical (OH) leading to cell damage due to the 
generation of toxic aldehydes (reviewed by Mapp, Grootveld and Blake, 1995). The 
aldehyde 4-hydroxynonenal (4-HNE) which is an aldehyde product of membrane lipid 
peroxidation has been shown to generate a range of inflammatory responses including 
increased levels of  IL-1β, IL-6, TNF-α transcriptions and the expression of  COX-2. It has 
also been shown that 4-HNE induces NF-κB activation and nuclear translocations resulting 
in cell apoptosis (Yin et al., 2015). Further to this cytokine-stimulated chondrocyte 
breakdown of the cartilage matrix has been shown to be primarily caused by lipid 
peroxidation (Tiku, Shar and Allison, 2000). It has also been reported that increased 
hypoxia in RA tissue can significantly delay neutrophil apoptosis (Cross et al., 2006), 
reduce vessel stability, increase damage to DNA and upregulate hypoxia-inducible factor 1 
(HIF-1) (see figure 1.12). HIF-1 is an important transcription factor in the hypoxic cell 
response as well as having involvement in angiogenesis, migration, cell survival pathways 
and reactive oxygen species (ROS) (figure 1.12) (Kennedy et al., 2010). ROS are by-
products of normal cellular metabolism and normally have defensive properties in that they 
are generated by activated neutrophils (among others) in an attempt to kill invading 
pathogens (Hitchon and El-Gabalawy, 2004).  Hypoxia has been shown to significantly 
correlate with differing macro/micoscopic inflammation sites, which affects cytokine 
production and may be part of the initial events in inflammation (Ng et al., 2010).  
In RA, as with tumours, hypoxia plays a major role in gene regulation in relation to FLS 
migration (Akhavani et al., 2009). HIF-1α is the major transcription factor by which 
hypoxia exerts its effects and is expressed in rheumatoid synovial tissue and synoviocytes 
(Zhao et al., 2013).  While little work has been done on hypoxia induced chemokine 
receptor expression,  CXC chemokine receptor 4 (CXCR4) has been shown as a key gene 
upregulated by HIF-1α. Furthermore, increased CXCR4 expression has been shown in RA 
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synovial fibroblasts (Li et al., 2013). Hypoxia has also been shown to increase chemokine 
receptor expression such as in ovarian tumours where the expression of CCR1 was 
increased 5-fold by hypoxia (Scotton et al., 2001). This indicates that regions of differing 
hypoxic microenvironments within the macro-environment of an RA joint may have 
different chemokine and chemokine/receptor profiles.  
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Figure 1.12 Diagram showing regulation of HIF-1 and nuclear factor-κB (NF-κB) 
pathways by reactive oxygen species and cytokine stimulation. Occurrences such as 
angiogenesis, leukocyte transmigration, endothelial cell activation and infiltrating cell 
survival beyond the norm in synovial inflammation in RA is perpetuated by the HIF-1 
and NF-κB activation and actions. (Diagram altered from Hitchon and El-Gabalawy, 2004) 
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1.10.1 Oxidative stress in RA 
Oxidative phosphorylation is the process by which adenosine-tri-phosphate (ATP) is 
generated by mitochondria where oxygen acts as the final electron acceptor in the process.  
By-products of this process are partly reduced oxygen metabolites which leave the 
mitochondria and react with other molecules generating a range of other ROS. The term 
‘oxidative stress’ is used when the ROS generated by an organism increases beyond its 
ability to neutralise them.  If levels of ROS are unregulated they cause damage to matrix 
components, proteins, nucleic acids and lipids (Hitchon and El-Gabalawy, 2004).  A range 
of studies have provided evidence for oxidative stress in RA including studies which 
correlate poor prognosis for RA with increased oxidant levels, and good prognosis with 
increased antioxidant levels, as well as evidence of oxidative damage to cartilage, 
hyaluronic acid and proteins (reviewed by Hitchon and El-Gabalawy, 2004).  Thioredoxin 
is a ‘cellular catalyst’ which is induced by oxidative stress and has pro-inflammatory 
effects. It has been shown to be overexpressed in RA synovial tissue where mutations to 
the regulatory genes due to oxidative stress in RA, such as p53 (Yamashishi et al., 2002), 
have also been shown, and may negatively affect the countermeasures in place to prevent 
oxidative damage (reviewed by Schett et al., 2001). 
 
1.10.2 The involvement of iron in oxidative stress and RA (see figure 1.13) 
As previously mentioned, in oxidative stress ROS are generated. An example of a ROS is 
the hydroxyl radical which is the most toxic of the ROS (Mapp, Grootveld and Blake, 
1995) and can react with the vast majority of molecules within any living cell (Morris et 
al., 1995; Mapp, Grootveld and Blake, 1995;  Hitchon and El-Gabalawy, 2004).  Free iron 
catalyses the formation of hydroxyl radicals from superoxide and hydrogen peroxide via 
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the Fenton reaction, whereby ferrous iron (Fe
2+
) reacts with hydrogen peroxide (H2O2) 
forming the hydroxyl radical (OH) 
Fe
3+
 + O
                          
Fe
2+
 + O2 
                                  Fe
2+
 + H2O2        →       Fe
3+
 + OH + OH
− 
This shows that the main force for the toxicity of ROS is due to the presence of free iron.  
Free iron is usually immobilised as ferritin or sequestered by iron binding proteins and is 
thus prevented from participating in the above reaction. The acidity of the environments 
can lead to iron metabolism dysfunction whereby iron is released from reticuloendothelial 
(RE) cells (also known as the mononuclear phagocyte system or the macrophage system). 
This may serve as a primary source of free iron in the synovium, however ‘microbleeding’ 
within the inflamed joint further exacerbates the iron levels in the synovium (Biemond et 
al., 1986; reviewed by Dabbagh et al., 1993: reviewed by Morris et al., 1995) (figure 1.13) 
with this ‘iron overload’ resulting in inadequate removal by the iron binding protein.  
There is an accepted correlation between iron concentration and arthritis, and in RA 
increased levels of free iron are found in SF and ST (Mowat et al., 1968; Biemond et al., 
1986). The iron levels in RA synovium have been measured as three times greater than in 
normal synovium, at 36g/g and 12g/g dry mass, respectively (Senator and Muirden., 
1968) Furthermore, it has been established by Telfer and Brock  (2004) that the presence of 
pro-inflammatory cytokines leads to further increases in the iron burden of the RA 
synovium.  
Lactotransferrin is an iron binding protein found in SF which is capable of remaining 
bound to iron in the acidic environment of the inflamed synovium (Guillén et al., 1998), 
has antibacterial action (Baker and Lindley, 1992) and may also have a protective function 
by collecting/holding the iron which would be released by transferrin in the same 
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conditions (Morris et al., 1995). However, lactoferrin not bound to iron has also been 
shown to prolong neutrophil survival in established RA (Wong et al., 2009).  
 
 
Figure 1.13 Schematic showing the source of iron and ROS and the cell damaging effects of 
ROS in the synovium. TIBC - total iron binding capacity; TF - transferrin; TNF - tumour necrosis 
factor; PMNs - polymorphonuclear leucocytes; IL-I - interleukin I; Fe – Iron; FLS – fibroblast like 
synoviosite;  RBC - red blood cells; o-LDL - oxidised low density lipoprotein. ATP - Adenosine-
tri-phosphate; H2O2 - hydrogen peroxide; NADPH – Nicotinamide adenine dinucleotide phosphate;  
H2O – water; DNA – deoxyribo nucleic acid; (image adapted from Dabbagh et al., 1993) 
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1.10.3 The involvement of Aluminium in oxidative stress. 
Aluminium has been found throughout the body in the same way as the metals essential to 
our survival are, yet it has no known biological functions (Exley, 2003; Perez et al., 2004). 
Aluminium toxicity is due to a range of mechanisms including inositol signalling, the 
adenylate cyclase cascade, peroxidation and iron uptake (reviewed by Abreo and 
Glass,1993) to name only four.  It has been shown to bind to both transferrin and 
lactoferrin (Congiu-Castellano et al., 1997; Rondau et al., 2006) and is an effective 
competitor for iron binding sites in biological systems (Mostaghi and Skillen, 1990).  
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1.11 Conclusion, hypothesis and objectives 
In conclusion, it appears that a small number of chemokines such as CXCL12 and 
CXCL16 have been shown to be present at RA ECs where their presentation may play a 
vital role in leukocyte extravasation. However, a large number of chemokines in table 1.10 
were not studied specifically to assess their EC presentation/expression in RA, and if 
established as present they were not necessarily assessed for degrees of up/down-
regulation in RA or the chemotactic effects exerted.  There is still therefore a need to gain 
further information on the presence/absence of such chemokines, particularly the CCL 
family chemokines which are less studied than the CXC chemokines in RA. Investigation 
of the role of chemokines currently not studied at RA ECs may add to our understanding of 
RA pathogenesis and potentially offer, as yet unexplored, therapeutic opportunities.  
 
The hypothesis for this study is synovial ECs express and/or present selected CCL 
chemokines, and may facilitate the migration of leukocytes into the synovium. The main 
aims were to: 
1. Elucidate which members of the CCL chemokine family are present at RA ECs and 
quantify the presence of the most highly represented in comparison to non-RA 
synovial ECs. 
2. Establish if there are differences in the presence of these chemokines at RA blood 
and lymphatic ECs. 
3. Investigate the potential for newly identified RA EC presented chemokines to be 
chemoactive within the RA joint. 
4. Investigate if these RA EC presented chemokines are also present in a range of sera 
and SF from a range of arthritis types. 
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2.1 Ethical approvals 
Full ethical approval for the study was granted by the Birmingham, East, North and 
Solihull Research Ethics Committee (study ID 11/WM/0035). 
 
2.2 Data presentation and approach to statistical analysis 
The data were checked for normal distribution at each stage of the analysis. Factors 
including n number, possible repetition number, numbers of field of view available for  
analyses and distribution of the data were factored into the methods finally used for both 
analysis and presentation. For example, where data were parametric mean ± SEM and for 
multiple comparison ANOVA was used, or for single comparisons T-tests. For non-
parametric data median and interquartile range and Kruskal-Wallis ANOVA was used to 
assess significant difference or Wilcoxon signed rank test for comparisons. Fisher’s exact 
test was used to obtain P values following odds ratio calculations. Appropriate statistical 
analyses for each data set are described fully in the quantitation of results sections.  
 
2.3 Materials and methods used in chapter 3 
2.3.1 Synovial tissue samples 
For all tissues used, RA (n=8) synovial tissue was obtained from patients (see table 2.1) 
who fulfilled the American College of Rheumatology (ACR) criteria for RA (see table 1.2) 
and were undergoing joint replacement surgery. Disease control (DC) tissue (n=6) was 
obtained by needle biopsy during outpatient exploratory procedures at the Robert Jones 
and Agnes Hunt Orthopaedic Hospital (see table 2.2). RA  and non-RA tissue samples 
from the suprapatellar pouch and the medial gutter were stored in HBSS for transport to 
the laboratory where they were snap frozen in liquid nitrogen cooled in iso-pentane and 
then stored in liquid nitrogen until cryosectioning. 5-6μm thick serial cryostat sections of 
the tissue were cut then dried at room temperature before being stored at -80°C. 
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Table 2.1 showing patient details for the RA tissue samples used 
 
Patient 
 
Sex 
 
Age 
Age of 
Onset 
Disease 
Duration 
(years) 
 
RF (titre) 
 
ESR* 
 
CRP* 
 
Medication 
RA1 F 77 62 16 N/A 62 N/A 
Piroxicam,  Paracetamol, Omeprazole, Diclofenac, Methylprednisolone 40mg, 
Methotrexate 10mg, Pepsid (famotidine). 
 
RA2 
F 48 33 15 N/A 86 203 
 
Diclofenac 
 
RA3  
M 54 37 17 
RF+ 
(1/640) 
N/A 8 Sulphasalazine, Methotrexate, Gold, Chloroquine 
 
RA4 
F 64 35 29 RF+ 60 109 
Leflunomide 10mg, Co-codamol, Omeprazole,  Naproxen prednisolone 5mg, 
Lisinopril (Enalopril),  Actonel (Risedronate), Calcichew D3 (calcium plus 
vitamin D) 
 
RA5  
F 72 N/A >23 N/A 42 28 
 
N/A 
 
RA6  
F 61 41 20 N/A 33-54 N/A Sulphasalazine, Azathioprine,  Methotrexate, Gold 
 
RA7 
F 83 48 35 RF+ (1/320) 74 111 Sulphasalazine,  Oruvail (ketoprofen),  Co-codamol, Dihydrocodeine 
RA 8 F 74 39 35 N/A 38 20 Didronel (Etidronate), Methotrexate 2.5mg, Prednisolone 5mg, Co-dydramol 
* Historical values taken during routine appointments prior to surgery. N/A – not available. Where patient medical notes do not list 
medication non-proprietary name, the non-proprietary name is entered in brackets. 
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Table 2.2 showing patient details for the non-RA tissue samples used 
 
Patient 
 
Sex 
 
Age 
 
Diagnosis 
 
DC1 
F 47 Tear to lateral meniscus 
 
DC2 
M 41 Patella tendon decompression. 
 
DC3 
F 45 Probable tear to lateral meniscus 
 
DC4 
M 45 Probable tear to right medial meniscus 
 
DC5 
F 41 Thickened medial plica, rest of meniscus normal. 
 
DC6 
M 41 Partial medial meniscectomy. Rest of meniscus normal. 
DC – Day case. All samples were removed during exploratory arthroscopy. No patients 
had any signs of inflammatory illness. Patients were not taking medication other than over 
counter painkillers at time of procedure. 
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2.3.2 Immunofluorescent staining 
2.3.2.1 von-Willebrand and Duffy Antigen Receptor for Chemokines (DARC) 
immunofluorescent staining to establish the endothelial cell marker for following 
experiments. 
Six 5-6μm thick cryostat sections from two RA patients were air dried and fixed in ice-
cold acetone for 10 minutes. Following rehydration in PBS (Invitrogen) for 5 minutes.  
sections were blocked using 2% BSA in PBS for 30 minutes, then washed for 5 minutes in 
PBS. Sections were incubated for one hour with the primary antibody of mouse 
monoclonal DARC or rabbit polyclonal VWF (R & D Systems) and with the secondary 
antibody, goat anti-mouse Alexa Fluor 594 IgG1 (2µg/ml, Invitrogen) and goat anti-rabbit 
Alexa Fluor 488 IgG(2µg/ml, Invitrogen) respectively (see tables 2.3 and 2.4) for 45 
minutes. Sections were washed for 5 minutes in PBS three times between each step and 
counterstained in 4’,6-Diamidino-2-Phenylindole (DAPI) (at 1:5 with PBS from a 1:5000 
working solution, Sigma Aldrich) before mounting using Hydromount (Fisher Scientific). 
Negative control slides were prepared using Isotype matched immunoglobulins instead of 
the primary antibodies. The control antibodies used in this work were:for mouse anti-
human IgG1 antibodies - mouse IgG1 (Dako); for rabbit anti-human antibodies -  rabbit IgG 
(Dako); for mouse anti-human IgG2b antibodies -  mouse IgG2b (Dako); goat anti-human 
antibodies -  goat IgG (R&D Systems); for mouse anti-human IgM– mouse IgM antibodies 
(Dako). All control antibodies were used at the same concentration as the primary 
antibody. 
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Table 2.3 showing the primary antibodies used for immunofluorescence 
 
Primary 
Antibody 
Description Code Company 
CCL1 Mouse monoclonal IgM. Anti-human 
 
LS-C4342 
 
LifeSpan Biosciences 
 
CCL2 
Mouse monoclonal IgG2b.  Anti-human MAB2791 
 
R&D Systems 
 
CCL3 
Mouse monoclonal IgG1. Anti-human 
 
MAB270 
 
R&D Systems 
 
CCL4 
Goat polyclonal IgG. Anti-human AF-271- NA 
 
R&D Systems 
 
CCL5 
Goat polyclonal IgG. Anti-human WB, IHC, ICC, B/N AF-278-NA  
 
AF-278- NA R&D Systems 
CCL7 Rabbit polyclonal IgG. Anti-human LS-B930 
 
LifeSpan Biosciences 
 
CCL8 
Goat polyclonal IgG.Anti-human Sc-1307 
Santa Cruz                  
Biotechnology Inc. 
 
CCL10 
Rabbit polyclonal IgG. Anti-human Orb13568 Biorbyte 
 
CCL11 
Mouse monoclonal IgG1. Anti-human MAB320 R&D Systems 
 
CCL12 
Rabbit polyclonal IgG. Anti-human Orb13284 Biorbyte 
 
CCL13 
Goat polyclonal IgG. Anti-human Sc-9655 
Santa Cruz 
Biotechnology Inc. 
 
CCL14 
Mouse monoclonal IgG2b. Anti-human  Sc-28388 
Santa Cruz 
Biotechnology Inc. 
 
CCL15 
Rabbit IgG. Anti-human  Orb13287 Biorbyte 
 
CCL16 
Goat polyclonal IgG. Anti-human AF802 R&D Systems 
 
CCL17 
Goat polyclonal IgG. Anti-human  AF364 R&D Systems 
CCL18 Goat polyclonal IgG. Anti-human  Sc-9781 
Santa Cruz 
Biotechnology Inc. 
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Table 2.3 continued 
 
Table 2.3 shows the details of where the anti-human chemokine antibodies used in this 
work were obtained. DARC = Duffy Antigen Receptor for Chemokines 
Primary 
Antibody 
Description Code Company 
CCL19 Mouse monoclonal IgG2b. Anti-human  
 
MAB361 
 
R&D Systems 
 
CCL20 
Goat polyclonal IgG. Anti-human  
 
AF360 
 
R&D Systems 
 
CCL21 
Goat polyclonal IgG. Anti-human  
 
AF366 
 
R&D Systems 
 
CCL22 
Goat polyclonal IgG. Anti-human  
 
Sc-12285 
Santa Cruz 
Biotechnology Inc. 
 
CCL23 
Goat polyclonal IgG. Anti-human 
 
Sc-12263 
Santa Cruz 
Biotechnology Inc. 
 
CCL24 
Goat polyclonal IgG. Anti-human 
 
AF343 
 
R&D Systems 
 
CCL25 
Goat polyclonal IgG. Anti-human 
 
Sc-12277 
Santa Cruz 
Biotechnology Inc. 
 
CCL26 
Goat polyclonal IgG. Anti-human 
 
AF653 
 
R&D Systems 
 
CCL27 
Mouse monoclonal IgG1. Anti-human  
 
MAB376 
 
R&D Systems 
 
CCL28 
Goat polyclonal IgG. Anti-human  
 
Sc-27339 
Santa Cruz 
Biotechnology Inc. 
 
VWF 
Rabbit polyclonal IgG1. Anti-human  A0082 
 
DakoCytomation, 
VWF Mouse monoclonal IgG1. Anti-human  M0616 
 
DakoCytomation 
LYVE-1 Goat IgG. Anti-human AF2089 R&D Systems 
 
LYVE-1 
Rabbit polyclonal IgG. Anti-human. Sc-28190 
Santa Cruz 
Biotechnology Inc. 
DARC Mouse monoclonal anti-human clone NAM185-2C3 R&D Systems 
CD68 Mouse anti-human C68 IR609/IS609 DakoCytomation 
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Table 2.4 showing the Secondary antibodies used for immunofluorescenc 
 
Table 2.4 shows the codes for where the secondary antibodies used in this work.  All were 
from Molecular probes, Invitrogen.  
 
 
 
 
 
 
 
 
 
 
Secondary Antibody Code 
Goat anti-mouse Alexa Fluor IgG 488 A11001 
Donkey anti-mouse Alexa Fluor IgG 488 A21202 
Goat anti- rabbit Alexa Fluor IgG 488 A21042 
Donkey anti-rabbit Alexa Fluor IgG 488 A21206 
Goat anti-mouse Alexa Fluor IgG 594 IgG2b A21121 
Goat anti-mouse Alexa Fluor IgG 594 IgG1 A21145 
Goat anti- rabbit Alexa Fluor IgG 594 A11037 
Donkey anti-mouse Alexa Fluor IgG 594 A21203 
Donkey anti-rabbit  Alexa Fluor IgG 594 A21207 
Donkey anti-goat Alexa Fluor IgG 594 A11058 
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2.3.2.2 Optimisation of immunofluorescent staining 
For each antibody used in this project it was required to optimise the antibody                
concentration, the blocking buffer and the dilution buffers to reduce non-specific and 
background staining. Isotype matched controls were utilised throughout and the procedure 
was repeated twice with 2 different samples to minimise the number of sections used. The 
basic guide followed for optimisation of the different primary antibodies is outlined in 
figure 2.1. The final blocking and dilution buffers for each antibody are listed as A, B, C or 
D in figure 2.1, table 2.5 and table 2.6. The control antibodies used in this work were as 
stated in section 2.3.2.1. 
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Figure 2.1 Schematic showing initial optimisation carried out for primary antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
24 sections cut from one patient sample 
and fixed in ice-cold acetone for 15 
minutes then washed in PBS for 5 minutes 
6 sections in blocking 
buffer A:10% donkey 
serum and 0.3% triton 
X in PBS.  
 
6 sections in blocking 
buffer B: 2 % BSA, 
10% non-fat dry milk 
0.3% triton X in PBS 
6 sections in 
blocking buffer C: 
PBS only. 
6 sections in blocking 
buffer D: 5% BSA, 
10% non-fat dry milk 
0.3% triton X in PBS 
2 sections for 
dilution buffer A: 
(1% BSA, 1% 
donkey serum and 
0.3% triton X in 
PBS) with primary 
antibody at 5µg/ml 
 
 
2 sections for 
dilution buffer A 
with primary 
antibody at 10µg/ml 
 
 
2 sections for 
dilution buffer A 
with primary 
antibody at 15µg/ml 
 
 
2 sections for 
dilution buffer B: 
(1%BSA, 1% non-fat 
dry milk 0.3% triton 
X in PBS) with 
primary antibody at 
5µg/ml 
 
 
2 sections for 
dilution buffer C: 
(PBS only) with 
primary antibody 
at 5µg/ml 
 
 
2 sections for 
dilution buffer D: 
(2% BSA, 10% non-
fat dry milk and 
0.3% triton X in 
PBS) with primary 
antibody at 5µg/ml 
 
 
2 sections for 
dilution buffer A 
with primary 
antibody at 10µg/ml 
 
 
2 sections for 
dilution buffer C 
with primary 
antibody at 10µg/ml 
 
 
2 sections for 
dilution buffer D 
with primary 
antibody at 10µg/ml 
 
 
2 sections for 
dilution buffer B 
with primary 
antibody at 15µg/ml 
 
 
2 sections for 
dilution buffer C 
with primary 
antibody at 15µg/ml 
 
 
2 sections for 
dilution buffer D 
with primary 
antibody at 15µg/ml 
 
 
Sections washed in PBS three times for 5 minutes 
All sections were incubated for 45 minutes in the appropriate secondary antibody between a 
concentration of 1:300 and 1:1000 (Alexa fluor) in a dark , humidified chamber then washed in PBS 
three times for 5 minutes 
 
All sections were incubated for 1 hour in a humidified chamber then washed in PBS three times for 5 
minutes 
All sections washed in PBS three times for 5 minutes, counterstained with DAPI, washed for a further 5 
minutes then mounted and visualised. 
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If the combinations in figure 2.1 did not produce viable images for analysis the procedure 
was repeated with the blocking and dilution buffers interchanged (such as blocking buffer 
A with dilution buffer B for example). Further optimisation at different antibody 
concentrations was performed as required. This was done until a combination which 
provided optimal primary antibody staining with minimal background staining was 
identified. 
 
 
 
2.3.2.3 Double immunofluorescent staining of synovial tissue using for VWF and CCL 
family antibodies. 
Six 5-6μm thick cryostat sections from 8 RA patients were air dried and fixed in ice-cold 
acetone for 10 minutes. Following rehydration in PBS (Invitrogen) for 5 minutes the 
sections were blocked using blocking buffer A, B, C or D (as in table 2.5) for 30 minutes, 
then washed for 5 minutes in PBS. Sections were incubated for one hour with the fully 
optimised primary antibody pairings shown in table 2.5 and for 45 minutes in the 
corresponding optimised secondary antibodies also shown in table 2.5. A full schematic is 
shown in figure 2.2. Given the fact that each of the 27 anti-human CCL antibodies tested 
with VWF in RA tissue generates the need to individually list 2 different buffer solutions 
and a total of 4 different antibodies (each of two primary antibodies and two secondary 
antibodies) the author decided to leave them properly categorised in a table separate to this 
text to prevent confusion. For full details please refer to table 2.5.The control antibodies 
used in this work were as stated in section 2.3.2.1. 
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2.3.2.4 Double immunofluorescent staining for lymphatic endothelial vessels and CCL 
chemokines in RA and non-RA synovial tissue. 
Lymphatic EC staining was performed to assess if there were differences in CCL family 
chemokine presentation on blood and lymphatic endothelial cells. As VWF is a pan-
endothelial marker and will therefore stain both blood and lymphatic ECs, the lymphatic 
specific EC marker LYVE-1 was optimised as described in figure 2.1 and double staining 
performed as set out in figure 2.2 with goat anti-human LYVE-1 antibody or rabbit anti- 
human antibody (dependant on the anti-human CCL antibody being used, see table 2.5) in 
place of the anti-human VWF antibody.    
As with section 2.3.2.1 the numbers of solutions used made listing each solution in a table  
the most feasible option. As such, please refer to table 2.5 and 2.6 for the full list of anti-
human antibodies, their concentration and the blocking and dilution buffers used 
(following the optimisation procedure described in figure 2.1) and each of their working 
concentrations. A full schematic is shown in figure 2.2.The control antibodies used in this 
work were as stated in section 2.3.2.1 
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Table 2.5 Showing solutions used for immunofluorescence  (continued on next 2 pages) 
Chemokine under 
investigation 
RA/DC 
Tissue 
Blocking 
buffer 
*Dilution 
buffer 
Primary antibodies and  
concentrations used 
Secondary antibodies and concentrations 
used 
 
CCL1 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL1, 2.5μg/ml 
Donkey anti-rabbit 594, 1μg/ml 
Goat anti-mouse 488 IgM, 3.3μg/ml 
 
CCL2 
 
RA 
 
C 
 
C 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL2,  10μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml Goat anti-
mouse 594 IgG2b, 6.6μg/ml 
 
CCL3 
 
RA 
 
C 
 
C 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL3,  10μg/ml 
Goat anti-rabbit 488, 10μg/ml 
Goat anti-mouse 594 IgG1, 10μg/ml 
 
CCL4 
 
RA/DC 
 
D 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL4 ,  10μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL5 
 
RA 
 
D 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL5 ,  15μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
CCL7 
 
RA/DC 
 
A 
 
A 
Mouse anti-human VWF, 4μg/ml 
Rabbit anti-human CCL7, 2.5μg/ml 
Donkey anti-mouse 594 IgG1, 3.3μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
 
RA/DC 
 
A 
 
A 
Rabbit anti-human CCL7, 2.5μg/ml 
Goat anti-human LYVE-1, 7.5μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 3.3μg/ml 
 
CCL8 
 
RA/DC 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL8, 2μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
 
CCL10 
 
RA 
 
A 
 
A 
Mouse anti-human VWF, 4μg/ml 
Rabbit anti-human CCL10, 4μg/ml 
Goat anti-mouse 488,  3.3μg/ml 
Donkey anti-rabbit 594, 6.6μg/ml 
 
CCL11 
 
RA 
 
B 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL11,  15μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-mouse 594 IgG1, 6.6μg/ml 
 
        CCL12 
 
RA 
 
A 
 
A 
Mouse anti-human VWF, 4μg/ml 
Rabbit anti-human CCL12, 2μg/ml 
Goat anti-mouse 488, 3.3μg/ml 
Donkey anti-rabbit 594, 6.6μg/ml 
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Table 2.5 continued 
Chemokine under 
investigation 
RA/DC 
Tissue 
Blocking 
buffer 
*Dilution 
buffer 
Primary antibodies and 
concentrations used 
Secondary antibodies and                   
concentrations used 
CCL13 RA A A 
Rabbit anti-human VWF, 3g/ml 
Goat anti-human CCL13, 4g/ml 
Donkey anti-goat 594, 6.6μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
CCL14 
 
RA/DC 
 
C 
 
C 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL14, 2μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Goat anti-mouse 594,  2.5 μg/ml 
 
RA/DC 
 
C 
 
C 
Mouse anti-human CCL14, 2μg/ml 
Goat anti-human LYVE-1, 15μg/ml 
Donkey anti-mouse 594, 6.6μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
 
CCL15 
 
RA 
 
A 
 
A 
Mouse anti-human VWF, 4μg/ml 
Rabbit anti-human CCL15, 4μg/ml 
Goat anti-mouse 488,  3.3μg/ml 
Donkey anti-rabbit 594, 6.6μg/ml 
 
CCL16 
 
RA/DC 
 
C 
 
C 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL16, 15μg/ml 
Donkey anti-goat 488 , 3.3μg/ml 
Donkey anti-rabbit 594, 6.6μg/ml 
 
RA/DC 
 
C 
 
C 
Goat anti-human CCL16, 15μg/ml 
Rabbit anti-human LYVE-1, 4μg/ml 
Donkey anti-goat 488 , 3.3μg/ml 
Donkey anti-rabbit 594, 3.3μg/ml 
 
CCL17 
 
RA 
 
B 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL17,10μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL18 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL18,4μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL19 
 
RA/DC 
 
C 
 
C 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL19, 20μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Goat anti-mouse 594,  6.6μg/ml 
 
CCL20 
 
RA 
 
B 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL20,100μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL21 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL21, 15μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
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Table 2.5 continued  
Chemokine under 
investigation 
RA/DC 
Tissue 
Blocking 
buffer 
*Dilution 
buffer 
Primary antibodies and 
concentrations used 
Secondary antibodies and  
concentrations used 
CCL22 
 
RA/DC 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL22, 4μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
RA/DC 
 
A 
 
A 
Goat anti-human CCL22, 4μg/ml 
Rabbit anti-human LYVE-1, 4μg/ml 
Donkey anti-goat 594 IgG, 3.3μg/ml 
Donkey anti-rabbit 488, 6.6μg/ml 
 
CCL23 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL23, 4μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL24 
 
RA 
 
B 
 
B 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL24,15μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL25 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL25, 2μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL26 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL26,15μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
CCL27 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Mouse anti-human CCL27, 20μg/ml 
Donkey anti-rabbit 488 IgG, 2.8μg/ml 
Goat anti-mouse 594,  5μg/ml 
 
CCL28 
 
RA 
 
A 
 
A 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human CCL28, 4μg/ml 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
 
This table shows the primary and secondary antibody solutions used following the optimisation procedures.  
*Dilution buffer - for secondary antibody solutions, 10% human serum was also included. All of the above experiments were carried out with 
isotype matched negative controls. The details of the buffers used were: 
Blocking buffer A – 10% donkey serum and 0.3% triton X in PBS.  
Blocking buffer B – 2%BSA, 10% non-fat dry milk 0.3% triton X in PBS.  
Blocking buffer C – PBS only.  
Blocking buffer D –5% BSA, 10% non-fat dry milk 0.3% triton X in PBS 
 
Dilution buffer A – 1% BSA, 1% donkey serum and 0.3% triton X in PBS  
Dilution buffer B – 1%BSA, 1% non-fat dry milk 0.3% triton X in PBS 
Dilution buffer C – PBS only 
Dilution buffer D – 2% BSA, 10% non-fat dry milk 0.3% triton X in PBS 
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Figure 2.2 Schematic showing double immunofluorescent staining process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative control slides were prepared using isotype matched IgGs instead of the primary 
antibody. For a full list of the antibodies and concentrations used refer to table 2.5 and 2.6
Air dry 5-6μm thick cryostat sections and fix in ice-cold acetone for 10 minutes  
 
Perform blocking step using optimised blocking buffer for 30 minutes (section 2.3.2.2 
figure 2.1).Wash for 5 minutes in PBS 
 
Apply primary antibody solution 
(table 2.6), for example:  
Rabbit anti-human VWF at 3μg/ml 
Mouse anti-human CCL1 at 2.5μg/ml 
made up in dilution buffer A (1% 
BSA, 1% donkey serum and 0.3% 
triton X in) 
Apply isotype matched control 
solution, for example: 
Rabbit negative control at 3μg/ml 
Mouse negative control at 2.5μg/ml made 
up in dilution buffer A (1% BSA, 1% 
donkey serum and 0.3% triton X in) 
Apply secondary antibody solution (table 2.65) to both sections, for example:  
Donkey anti-rabbit 594 at 1μg/ml and goat anti-mouse 488 at 3.3μg/ml in dilution 
buffer A (1% BSA, 1% donkey serum and 0.3% triton X in) with 10% human serum 
added. 
Rehydrate for 5 minutes in PBS 
Incubate in a humidified chamber for 1 hour. Wash for 5 minutes in PBS three times 
 
Incubate in a DARK humidified chamber for 45 minutes then wash for 5 minutes in PBS three 
times 
 
Counter stain with DAPI at  1:5 of the 1:5000 working solution in PBS for 3 minutes in a 
DARK humidified chamber then wash for 5 minutes in PBS . 
 
Mount in hydromount, allow to set for 30 minutes at 4ºC. 
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Table 2.6 showing solutions for the Duffy antigen receptor for chemokines (DARC) and VWF and CD68 with LYVE-1 staining 
 
 
Negative control slides were prepared using isotype matched IgGs instead of the primary antibodies. For a full list of the antibodies and 
concentrations used refer to table 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Tissue 
Primary antibody solution and 
Concentration used 
Secondary antibody solution 
and concentration used 
 
      DARC and VWF 
 
RA 
PBS  
Rabbit anti-human VWF, 4μg/ml 
Mouse anti-human CCL24, 15μg/ml 
PBS with 10% human serum 
Goat anti-rabbit 488 IgG, 3.3μg/ml 
Goat anti-goat 594, 6.6μg/ml 
 
       CD68 and LYVE-1 
 
RA 
PBS 
Rabbit anti-human VWF, 3μg/ml 
Goat anti-human LYVE-1, 2μg/ml 
PBS with 10% human serum 
Donkey anti-rabbit 488 IgG, 3.3μg/ml 
Donkey anti-goat 594, 6.6μg/ml 
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2.3.2.5 Quantitation of immunofluorescence 
For accurate quantitation a range of parameters were taken into consideration including the 
number of patient samples used, the number of fields of view and the number of blood       
vessels. The first 15 blood vessels positive VWF in 4 fields of view per section (figure 2.3) 
were counted (magnification X20), any of those vessels also positive for the chemokine 
under investigation were then counted. The mean number of vessels was then  calculated 
as a percentage of VWF positive vessels also stained with the chemokine. Standard errors 
were also calculated for each result.  
Immunofluorescence was visualised on a light microscope (Olympus IX51) and analysis 
was performed using CellF software (Olympus UK Ltd, Southend-on-Sea, UK).    Intensity 
of staining was done by recording the intensity of a random point per cell (n = 12 cells) in 
three separate images for a single experiment. All experiments were carried out in 
triplicate giving 108 points (n=3).  
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Figure 2.3  Diagram showing field of view layout for immunofluorescent 
quantification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first 15 blood vessels positive for von-Willebrand Factor (VWF) or LYVE-1 in each 
of the 4 fields of view per section were counted (magnification X20). Any of those vessels 
also positive for the chemokine under investigation were then counted. The mean number 
of vessels was then  calculated as a percentage of VWF+ or LYVE-1+ vessels also stained 
with the chemokine. Standard errors were also calculated for each result. It should be noted 
that given the nature of the tissue samples available the sections were not of equal size and 
so the total coverage of the 4 fields of view per sections ranged from approximately 40-
90% of the section as a whole. 
 
 
 
 
 
 
 
Tissue section was orientated to 
allow 4 fields of view to be imaged 
and the VWF+ or LYVE-1+ 
vessels to be counted.  
The 4 fields of view were 
randomly spaced throughout the 
section allowing for the maximum 
coverage of the tissue section  
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2.3.3  Microwave Synovial tissue digestion for Transverse Heated-Graphite Furnace 
Atomic Absorption Spectrometry (T H-GFAAS) 
Digest tubes, lids and plugs were rinsed x2 in ultrapure water, left immersed in ultrapure 
water overnight, then left to dry at 37
o
C.  This process reduced the chances of Fe and Al 
contamination of the tubes. The tissue samples were removed from the freezer and left to 
defrost without removing the cryotube lid. Once fully dry the digest tubes were labelled 
and their individual weights recorded. The defrosted tissue samples were removed from the 
cryotubes and placed into the dried and weighed digest tubes. Following re-weighing to 
measure the wet weight of the samples they were placed back into the incubator  (at 37
o
C)  
with the lids loosely attached and the plugs absent and left until the tissue samples were 
totally dry (~48 hours). 
Following tissue drying the samples were again weighed to measure the tissue final dry 
mass.  Following this 1ml of concentrated nitric acid was added, followed by 1ml of 
hydrogen peroxide to each tube (30% weight to volume solution). The plug and cap were 
put on the tube and it was placed in the digester carousel for 1.5 hours. Control tubes of 
acid and hydrogen peroxide only were also made. Each tube was completed before moving 
onto the next to standardise all times the tissue spent in the reagents. 
Following digestion the tubes were allowed to cool before 3ml of ultrapure water was 
added to the first tube and very gently mixed. The solution was then transferred to a 5ml 
bijou and stored at room temperature until used.  
 
2.3.3.1 TH-GFAAS determination of Iron and Aluminium content 
Total iron (Fe) and aluminium (Al) were measured as described by House et al., (2012)  
using an Analyst 600 atomic absorption spectrometer with a transversely heated graphite 
atomizer (THGA) and longitudinal Zeeman-effect background corrector and an AS-800 
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autosampler with WinLab32 software (Perkin Elmer, UK). Standard THGA pyrolitically-
coated graphite tubes with integrated L’Vov platform (Perkin Elmer, UK) were used. The 
Zeeman background-corrected peak area of the atomic absorption signal was used for the                 
determinations. 
The samples stored from 2.3.3 were diluted 20 fold by adding 9.5ml of ultrapure water to 
0.5ml of the sample in a volumetric flask (pre-washed twice with ultrapure water) giving a 
final acid concentration of 1%. This solution was gently mixed before 2ml of it poured into 
a 2ml sample cup which was then placed into the autosampler (Perkin ElmerPrecisely A5 
500 autosampler) of the spectrometer (Atomic Absorption Spectrometer AAnalyst 600) 
and the position of each sample recorded. 
The TH-GFAAS was calibrated by automated serial dilution of 40, 60 and 100 mg L
-1 
solutions of Fe and 10, 20, 40, and 60 mg L
-1
 solutions of Al with 1% HNO3. 
Iron and aluminium content was expressed as µg/ml. 
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2.4 Materials and methods used in chapter 4 
2.4.1 Cell culture, Growth and freezing 
2.4.1.1 Culturing human bone marrow endothelial cells (HBMECs)      
Medium was prepared as follows:  5ml of fungizone (amphotericin B at 250µg/ml) (Lonza, 
Wokingham, UK):  5ml penicillin (5000 I.U./ml), streptomycin (5000 µg/ml) (Lonza) and 
50ml heat inactivated foetal bovine serum (FBS; Invitrogen, Paisley, UK) were mixed with 
500ml DMEM-F12 medium (1:1 mixture with 15mM Hepes, 0.365g/L  L-glutamine and 
3.151g/L glucose) (Lonza, Wokingham, UK) and warmed to 37
o
C (herein this solution is 
known as DMEM-F12 medium solution).   Once warmed 12ml of the culture medium was 
added to two T75 Iwaki tissue culture flasks (Scientific Laboratory Supplies, Nottingham, 
UK). The cells were removed from liquid nitrogen and defrosted at room temperature 
before adding to 2ml of the DMEM-F12 medium solution and gently mixed. 1ml of the 
cell suspension was added to each of the flasks and placed in an incubator at 37
o
C. All of 
the above was carried out in aseptic conditions. Cells were fed with the same DMEM-F12 
medium solution and passaged at 80-90% confluent.  
Fungizone, Penicillin and FBS were stored at-20
o
C prior to use and the culture medium 
was stored at 4
o
c. 5% CO2was present in the incubators during cell cultures. 
 
 
 
 
Chapter 2 
 
88 
 
2.4.1.2 Passaging HBMECs 
Cells were passaged at 80-90% confluence. 5ml of trypsin-EDTA (200mg/L versene, 
170000 u trypsin/L) per flask were warmed to 37
o
C along with 10ml PBS per T75 culture 
flask and the  DMEM-F12 medium solution. The old medium was removed from the flasks 
and the cells were washed twice with 10 ml of the warmed PBS. 5ml trypsin- EDTA was 
added to each flask and the flasks were returned to the incubator for approximately 3 
minutes until the HBMECs were lifting from the surface of the flask. The trypsin-EDTA 
was neutralised by adding 15ml of the DMEM-F12 medium solution (3 times the volume 
of trypsin used). The resulting cell suspension was centrifuged at 1700rcf for 6 minutes. 
After centrifugation the supernatant was poured off and the pellet was resuspended in 2-3 
ml of fresh medium. The cells were then counted and the required number of cells 
transferred to new flasks (or wells for transmigration assays) containing the required 
volume of fresh medium. All of the above was carried out in aseptic conditions using 
sterile pipettes. 
2.4.1.3 Culturing HDLECs.  
EBM-2 medium, with the microvascular cell bullet kit (Lonza) added, was used for 
HDLEC culture and growth (herein referred to as EBM-2-MV medium). 5ml of the culture 
medium (warmed to 37
o
C) was added to two T25 Iwaki tissue culture flasks (Scientific 
Laboratory Supplies, Nottingham, UK). HDLECs were removed from liquid nitrogen and 
defrosted in a water bath at 37
o
C for no more than 2 minutes as per the Lonza protocol. 
Once defrosted the cells were added to 2ml of EBM-2-MV and very gently mixed to 
separate any clumps of cells.  1ml of the cell suspension was added to each of the flasks 
and placed in an incubator at 37
o
C. Cells were fed with the same EBM-2-MV medium 
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solution and passaged at 75-80% confluence.5% CO2was present in the incubators during 
cell cultures. 
2.4.1.4 Passaging HDLECs, 
Cells were passaged at 75-80% confluence. 2ml of trypsin-EDTA (200mg/L versene, 
170000 u trypsin/L) per flask and the EBM-2-MV medium was warmed to37
o
C.  The cells 
were washed in 5ml of PBS (X 2) and 2ml trypsin-EDTA was added to each flask for 
approximately 3 minutes. Once cells had lifted, 15ml of the EBM-2-MV (3x the volume of 
trypsin used) was added to each of the flasks and the solution was then transferred to 50ml 
tube(s) (Scientific Laboratory Supplies) and centrifuged at 1100rcf for 3 minutes. After 
centrifugation the  supernatant was poured off and the pellet was resuspended in 2-3 ml of 
fresh medium. The cells were then counted and the required number of cells transferred to 
new flasks (or wells for transmigration assays) containing the required volume of fresh 
medium 
2.4.1.5 Freezing cells in liquid nitrogen 
Cells at 75-80% confluence were detached from the tissue culture flask(s) by removing       
medium, washing twice with PBS and adding 5ml of trypsin-EDTA. The flasks were 
incubated at 37C for approximately 3 minutes until the cells were lifting. The trypsin-
EDTA was neutralised by adding 3 times the volume of trypsin-EDTA to the flasks. The 
resulting cell suspension was then centrifuged at 1700rcf for 6 minutes at room 
temperature (or at1100rcf for 3 minutes for HDLECs).  Following this the cell pellet was 
resuspended in filtered FBS containing 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich 
Company Ltd, Dorset, UK) at a density of 1 x 10
6 
cells/ml. Cells were dispensed into a pre-
cooled Nalgene cryo 1C freezing container (Fischer Scientific LTD, Leicestershire, UK) 
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containing 250ml isopentane alcohol (IPA; Fischer Scientific) prior to overnight storage at 
-80C before transfer to liquid nitrogen for long term storage. 
 
2.4.1.6 Endothelial cell lines used in this study 
The cell line HBMECs were donated by BB Weksler (Weill-Cornell University, New 
York); this immortalised, microvascular endothelial cell line is involved in haematopoietic 
progenitor cell homing to the bone marrow and their differentiation and proliferation. The 
transformed cell line needed significantly less serum concentrations and did not require 
additional growth factors for proliferation. These cells were used as a model for synovial 
endothelial cells, which were not not directly available. 
HDLECs were supplied by PromoCell (Sickingenstraße, Heidelberg, Germany) number C-
12217.The HDLECs were used as a model for synovial lymphatic endothelial cells (LECs) 
which were not commercially available at the time of the study. 
2.4.1.7 Cell viability 
To assess the numbers of live cells for use in experiments Trypan blue solution, 0.4% 
(Sigma-Aldrich) was used during cell counting. Cells were removed from flasks and 
pelleted as described in section 2.4.1.2 and 2.4.1.4 The cells were resuspended in 
approximately 3ml of growth medium and 10l of the cell suspension was added to 10l 
of Trypan blue solution. 10l of this was then placed onto a haemocytometer and cells 
were visualised using phase-contrast microscopy at x100 magnification. Densely stained 
cells were designated dead/dying and not counted. 
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2.4.1.8 Seeding and stimulating inflammatory conditions in ECs to assess ICAM 
staining 
For HBMECs 50,000 cells per well in 250l of DMEM-F12 medium solution were placed 
in each well of a chamber slide (Fisher Scientific) and were  returned to the incubator at 
37
o
C (with 5% CO2) for 24 hours until the cells were approximately 60% confluent. 
The medium was removed from the wells and control wells had 250l of of DMEM-F12 
medium solution added to them. The wells being activated had either: A, 250l total of 
TNF- at 100ng/ml in DMEM-F12 medium solution; B, 250l total of TNF- at 100ng/ml 
and IFN- at 100ng/ml in DMEM-F12 medium solution added to each well dependent 
upon the specific experiment being performed. 100ng/ml of TNF- was found to be 
optimal for activating HBMECs.  
 
 For HDLECs 100,000 cells per well in 250l of EBM-2-MV medium were placed in each 
well of a chamber slide) and the chamber slides were returned to the incubator at 37
o
C 
(with 5% CO2) for 24 hours until approximately 60% confluent. The medium was removed 
from the wells and control wells had 250l of EBM-2-MV medium added to them. The 
wells being activated had either: A, 250l total of TNF- at 100ng/ml inEBM-2-MV 
medium; B, 250l total of TNF- at 100ng/ml and IFN-  at 100ng/ml inEBM-2-MV 
medium added to each well dependent upon the specific experiment being performed. 
100ng/ml of TNF- and IFN-  was found to be optimal for activating HDLECs.  
Optomisation for transmibgratio analysis was performed in 24 well plates (see figure 2.4) 
 
For both HBMECs and HDLECs the chamber slides were then returned to the incubator 
for between 1 and 24 hours depending on the experiment being performed. 
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2.4.1.9  Optimisation of simulated inflammatory conditions using TNF-α and/or IFN-
γ for transmigration analysis (figure 2.4) 
It was required to optimise the concentration to be used for the HBMECs and HDLECs 
prior to transmigration analysis. This was achieved by activating a monolayer of the cells 
as described in section 2.4.1.8 and performing immunofluorescent staining to assess the 
degree of ICAM staining.  The solution which provided the greatest increase in ICAM 
intensity was used for transmigration analysis as the model for inflammation. Control wells 
containing no TNF- and/or IFN-γ were also assessed. 
 
For optimisation for tranmigrataion analysis (figure 2.4) 800μl of  DMEM-F12 medium 
containing 100,000 HBMECs was dispensed into each well of a 24 well plate (Scientific 
Laboratory Supplies). Once the ECs were confluent the medium was replaced with fresh 
medium containing 400l total of TNF-and/or IFN-γ at 10ng/ml, 50ng/ml, 100ng/ml, 
250ng/ml, 500ng/ml and 1000ng/ml (see figure 2.4).  Experiments were carried out in 
triplicate. The experiments were repeated whereby the cells were incubated in the 
activation solution for 1, 2, 4, 8, 16 and 24 hours prior to fixing in 4% paraformaldehyde 
and staining with the  primary antibody, mouse anti-human ICAM (Sigma) at 10µg/ml in 
PBS for 1 hour. This was followed by 3x 5 minute washes in PBS, then an incubation of 
45 minutes in the secondary antibody, donkey anti-mouse Alexa Fluor 594 (Dako) at 
3.3µg/ml. Once washed (3x 5 minutes PBS) then counterstained using DAPI at 1:5 with 
PBS(from a 1:5000 working stock, Sigma) for three minutes the cells were mounted in 
Hydromount. 
Solutions ascertained as optimal for activation and for ICAM staining are shown in table 
2.7 on page 97. 
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Figure 2.4 Schematic showing optimisation process for the activation solutions; TNF-
α; IFN-γ  and TNF-α + IFN-γ  prior to  transmigration analysis using HBMECs and 
HDLECs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 X   
 X   
 X   
    
    
 
Dispense 800μl of  DMEM-F12 medium containing 100,000 HBMECs into each well of a 24 well plate 
 
Incubate for 24 hours (or until 80% confluent) then remove medium 
 
Into top row, first 3 wells – Add 400l of 
medium with TNF- at 10ng/ml 
 
Into second row, first 3 wells – Add 400l of 
medium TNF- at 50ng/ml 
 
Into third row, first 3 wells – Add 400l of 
medium with TNF- at 100ng/ml 
 
Into fourth row, first 3wells – Add 400l of 
medium with TNF- at 250ng/ml 
 
Into fifth row, first 3 wells – Add 400l of 
medium with TNF- at 500ng/ml 
 
Into sixth row, first 3 wells  – Add 400l of 
medium with TNF- at 1000ng/ml 
Into 4
th
 well 
of 3 rows – 
Add 400l 
of medium 
with NO 
TNF- 
(control 
wells) 
 
 Incubate for *1 hour at 37ºC in 5%CO2 
 
Remove medium and wash in PBS for 5 minutes 
 
Fix cells in 4% paraformaldehyde for 15 minutes at room temperature 
 
Remove medium and wash in PBS for 5 minutes 
 
Incubate in  primary antibody solution (mouse anti-human ICAM (Sigma) at 10µg/ml) 
for 1 hour then wash in PBS (x 3) for 5 minutes.  
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*This experiment was repeated 6 times as shown above, but the activation solution was left 
on for 1, 2, 4, 6, 8, 18  and 24 hours respectively prior to adding the primary antibody. 
The  experiment  was  repeated in full using IFN-γ  in place of TNF-α,  and  repeated again 
using both  TNF-α + IFN-γ . The process was performed for both HBMECs and HDLECs. 
Solutions ascertained as optimal are shown in table 2.7.
Incubate in secondary antibody solution (donkey anti-mouse Alexa fluor 594 (Dako) at 
3.3µg/ml) for 45 minutes then wash in PBS (x 3) for 5 minutes.  
 
Incubate in DAPI for 3 minutes then wash in PBS (x 1) for 5 minutes.  
 
Mount in Hydromount.  
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2.4.2 Protein synthesis arrest 
Cells were cultured and optomised as described in section 2.4.1.1 and 2.4.1.9 (also see 
figure 2.4). Following optomisation cells were cultured in the activation solution with 
10g/ml cycloheximide added as a protein synthesis inhibitor (Sigma-Aldrich) for 0 (base 
line), 2, 3, 4, 5 and 6 hours. Following protein synthesis arrest the cells were fixed in ice 
cold 1:1  methanol: acetone then blocked for 15 minutes in PBS with 10% donkey serum 
and 2% BSA. After this cells were stained using rabbit anti-human CCL7 at 2.5μg/ml 
(Lifespan Biosciences);  mouse anti-human CCL14 at  2μg/ml (Santa Cruz); goat anti-
human CCL16 at 15μg/ml (R&D Systems) or goat anti-human CCL22 at 4μg/ml (Santa 
Cruz)  for one hour. As background staining was less evident than on human tissue 
sections all solutions were made up in 1% BSA, 1% donkey serum and 0.3% triton X in 
PBS. Following washing three times in PBS for 5 minutes the cells were incubated in the 
secondary antibody solution for 45 minutes (in a darkened humidified chamber).  The 
secondary antibody solutions were donkey anti-mouse Alexa Fluor 594, donkey anti-rabbit 
Alexa Fluor 594, and donkey anti-goat Alexa Fluor 594 respectively, all at 6.6μg/ml (all 
from  Invitrogen) and made up in  1% BSA, 1% donkey serum and 0.3% triton X in PBS. 
Following washing (as above) cells were counterstained usingDAPI at 1:5 with PBS(from 
a 1:5000 working stock, Sigma) before mounting using Hydromount (Fisher Scientific). 
The control antibodies used in this work were as stated in section 2.3.2.1. 
These experiments were performed to assess if each of the chemokines were present 
following the activation of cultured HBMECs giving a stimulated inflammatory 
environment. This would indicate that the chemokines may be generated by the ECs 
themselves in response to inflammatory conditions rather than present in tissue due to 
other cellular sources. The addition of cycloheximide would indicate if the chemokines 
were present as pre-existing proteins and released in response to inflammatory conditions 
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(as the levels in the cells would decrease); or if they were generated in an ongoing manner, 
and thus were actively produced by the HBMECs themselves by protein synthesis. 
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Table 2.7 Solutions for TNF-α, IFN- γ, (and combination) activation and staining of cultured cell monolayers. 
 
 
Dilution buffer A – 1% BSA, 1% donkey serum and 0.3% triton X in PBS.  Blocking Buffer – 2% BSA and 0.3% triton X in PBS.  
All of the above experiments were carried out with isotype matched negative controls. 
Where cell surface only staining was carried out Triton X was not used in the primary antibody dilution buffer and the cells were fixed at room 
temperature with 3.7 % paraformaldehyde. 
TNF-α, IFN- γ and anti- ICAM were supplied by Peprotech 
Where whole cell staining was carried out dilution buffer A was used as stated and the cells were fixed in 1:1 ice cold acetone: methanol at 4
o
C 
Solution Cell Type Activation solution 
Primary antibody solution  
and concentration 
Secondary antibody solution 
 Andconcentration 
TNF-α  
HBMEC 
HDLEC 
Human TNF-α (Peprotech) at 
100ng/ml in appropriate medium 
Dilution buffer A 
Mouse anti human ICAM, 10μg/ml 
(Peprotech) 
Dilution buffer A with 10% human serum 
Donkey anti-mouse 594 IgG, 2.5μg/ml 
IFN-γ 
HBMEC 
HDLEC 
Human IFN-γ (Peprotech) at 
100ng/ml in appropriate medium 
Dilution buffer A 
Mouse anti human ICAM, 10μg/ml 
Dilution buffer A with 10% human serum 
Donkey anti-mouse 594 IgG, 2.5μg/ml 
Combination 
HBMEC 
HDLEC 
Human TNF-α at 100ng/ml 
and IFN-γ at 100ng/ml in 
appropriate medium 
Dilution buffer A 
Mouse anti human ICAM, 10μg/ml 
Dilution buffer A with 10% human serum 
Donkey anti-mouse 594 IgG, 2.5μg/ml 
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2.4.3 Immunofluorescent staining of cultured HBMECs and HDLECs 
2.4.3.1 Whole cell staining in chamber slides 
The conditioned medium from each well was aspirated and stored at -20
o
C until ready for 
ELISA testing.  Cells were grown to 85-90% confluence in chamber slides at 37
o
C (with 
5% CO2) in the appropriate media as described in section 2.4.1.1 and 2.4.1.3. Following 
washing each well with 500l of room temperature PBS the cells were fixed in ice cold 1: 
1 acetone: methanol for 15 minutes.  Cells were incubated for one hour with the primary 
antibody as follows: mouse anti-human ICAM, 10μg/ml (R&D Systems), (the 
concentration of ICAM used was ascertained following the optimisation procedure for 
concentrations shown in figure 2.1); rabbit anti-human CCL7at 2.5μg/ml (Lifespan 
Biosciences);  mouse anti-human CCL14 at  2μg/ml (Santa Cruz); goat anti-human CCL16 
at 15μg/ml(R&D Systems) or goat anti-human CCL22 at 4μg/ml (Santa Cruz)  for one 
hour.  As background staining was less evident than on human tissue sections all solutions 
were made up in 1% BSA, 1% donkey serum and 0.3% triton X in PBS. Following 
washing three times in PBS for 5 minutes the cells were incubated in the secondary 
antibody solution for 45 minutes (in a darkened humidified chamber).  The secondary 
antibody solutions were donkey anti-mouse Alexa Fluor 594,  donkey anti-rabbit Alexa 
Fluor 594 or donkey anti-goat Alexa Fluor 594, all at 6.6μg/ml (all from  Invitrogen) and 
made up in 1% BSA, 1% donkey serum and 0.3% triton X in PBS. Following washing (as 
above) cells were counterstained using DAPI at 1:5 with PBS (from a 1:5000 working 
stock, Sigma) before mounting using Hydromount (Fisher Scientific). The control 
antibodies used in this work were as stated in section 2.3.2.1. 
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2.4.3.2 Cell surface staining in chamber slides  
Cells were grown to 85-90% confluence in chamber slides at 37
o
C (with 5% CO2) in the 
appropriate media as described in section 2.4.1.1 and 2.4.1.3.  Following washing each 
well using 500l of PBS per well the cells were fixed for 15 minutes in freshly made 3.7% 
paraformaldehyde. Cells were incubated for one hour with the primary antibody as 
follows: rabbit anti-human CCL7 at 2.5μg/ml (Lifespan Biosciences),mouse anti-human 
CCL14 at  2μg/ml (Santa Cruz), goat anti-human CCL16 at 15μg/ml(R&D Systems) or 
goat anti-human CCL22 at 4μg/ml (Santa Cruz)  for one hour. As background staining was 
less evident than on human tissue sections all solutions were made up in 1% BSA and 1% 
donkey serum in PBS. Following washing three times in PBS for 5 minutes the cells were 
incubated in the secondary antibody solution for 45 minutes (in a darkened humidified 
chamber).  The secondary antibody solutions were donkey anti-mouse Alexa Fluor 594,  
donkey anti-rabbit Alexa Fluor 594 or donkey anti-goat Alexa Fluor 594, all at 6.6μg/ml 
(all from  Invitrogen) and made up in 1% BSA, 1% donkey serum and 0.3% triton X in 
PBS. Following washing (as above) cells were counterstained using DAPI at 1:5 with 
PBS(from a 1:5000 working stock, Sigma) before mounting using Hydromount (Fisher 
Scientific).  The control antibodies used in this work were as stated in section 2.3.2.1. 
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2.4.4 Quantitation of Immunofluorescence 
Quantitation was performed as described in section 2.3.2.5 with the random fields of view 
being within the wells as opposed to spread over a tissue section. 
 
2.5 Materials and methods used in chapter 5 
2.5.1 Isolation of cells from human blood 
2.5.1.1 Peripheral Blood Mononuclear Cell (PBMC) isolation 
Mononuclear cells (monocytes and lymphocytes) were isolated using the density gradient 
centrifugation method. Approximately 5ml of fresh peripheral whole blood was collected 
in heparin coated vacutainers. The blood was then diluted with an equal volume of RPMI-
1640 medium with 5ml penicillin streptomycin (5000u penicillin/ml, 500u 
streptomycin/ml) (Lonza) and 5ml of fungizone (amphotericin B at 250µg/ml) (Lonza, 
Wokingham, UK) and warmed to room temperature (herein referred to as complete PBMC 
medium) in a 50ml falcon tube (Fischer Scientific).  This was carefully layered over 13ml 
of Ficoll Hyperpaque at room temperature and was centrifuged at room temperature for 30 
minutes at 1600rcf. The brake on the centrifuge was switched off for this stage, allowing 
the centrifuge to slowly come to a rest at the end of the 30 minute cycle. The PBMCs were 
slowly aspirated from the interface (see figure 2.5) into a falcon tube containing 20ml of 
the complete PBMC medium. The cells were then washed twice, first by centrifuging at 
1500rcf for 10 minutes (centrifuge brake switched on from this stage) followed by the 
supernatant being removed and the pellet being resuspended in a further 20ml of the 
complete PBMC medium and centrifuged for 8minutes at 1600rcf to complete the second 
wash. The pellet was then resuspended in 2ml fresh DMEM-F12 medium with 0.5% 
fraction V FBS (Sigma-Aldrich, UK) until  ready for use. 
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Figure 2.5. Schematic showing mononuclear cell isolation from whole blood. 
 
 
 
 
 
 
The schematic shows the Ficoll Hyperpaque gradient and the mononuclear cell layer 
following centrifugation. The plasma and red blood cell layers are also indicated. 
 
2.5.2 Transmigration  
2.5.2.1 Stimulation of inflammatory conditions in transwell systems for 
transmigration analysis across cultured cell monolayers 
The transwell system was set up by dispensing 800μl  EBM-2-MV medium for HDLECs 
or (DMEM-F12 medium solution  for HBMECs) into each well of a 24 well plate 
(Scientific Laboratory Supplies) and a 5μM pore hanging filter (Merck Chemicals, 
Nottingham, UK) was then placed into each well.  Following this 400μl of the DMEM-F12 
medium solution containing 100,000 HBMECs was placed into each hanging filter and left 
overnight until confluent. 
Once the cells ECs were >95% confluent the medium in the hanging filters was 
replaced with fresh medium containing either; 
A. 400l total of TNF- at 100ng/ml. (for HBMECs) 
B. 400l total of TNF- at 100ng/ml and IFN- at 100ng/ml. (for HDLECs) 
(concentrations of TNF- and TNF-/ IFN- ascertained as described in section 2.4.1.8 
and detailed in table 2.7). A minimum of three filters were activated using each solution 
and left for two hours.(see figure 2.4).  
Mononuclear cells 
Plasma 
Ficoll Hyperpaque 
Red Blood 
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Figure 2.6: Schematic diagram showing transwell system used to study leukocyte 
migration. ECs are shown cultured onto the filter apical surface through which the 
leukocytes migrate in response the EC activation and chemokines. (Schematic reproduced 
with the kind  consent of Dr Catherine Whittall). 
 
2.5.2.2 Optimisation of chemokine concentrations for transmigration analysis.  
Prior to transmigration analysis the optimal concentrations of the chemokines CCL7, 
CCL14, CCL16 and CCL22 for mononuclear cell chemotaxis were elucidated. The 
optimisation process is outlined in figure 2.7. Following the optimisation process 100ng/ml 
of the chemokine was shown to give optimal results in terms of numbers of migrated 
mononuclear cells and were used for all other transmigration work in this study. 
 
 
 
 
 
 
 
 
 
Activation solution or 
mononuclear cells in 
suspension 
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Figure 2.7  Schematic showing optimisation process for chemokines CCL7, CCL14, 
CCL16 and CCL22 prior to transmigration analysis using HBMECs and HDLECs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 X   
 X   
 X   
    
    
Dispense 800μl  EBM-2-MV medium for HDLECs or (DMEM-F12 medium solution  for HBMECs) into 
each well of a 24 well plate (Scientific Laboratory Supplies). Place a 5μM pore hanging filter (Merck) 
into each well. 
Incubate for 24 hours (or until 80% confluent) then remove medium from bottom well 
 
Into bottom well of top row, first 3 – Add 800l of 
medium with chemokine at 1ng/ml 
 
Into bottom well of second row, first 3- Add 800l 
of medium with chemokine at 10ng/ml 
 
Into bottom well of third row, first 3- Add 800l of 
medium with chemokine at 50ng/ml 
 
Into bottom well of forth row, first 3 – Add 800l of 
medium with chemokine  at 100ng/ml 
 
Into bottom well of fifth row, first 3 – Add 800l of 
medium with chemokine at 250ng/ml 
 
Into bottom well of sixth row, first 3 – Add 800l of 
medium with chemokine at 500ng/ml 
Into 4th 
well of 3 
rows – 
Add 
800l of 
medium 
with NO 
chemokine 
(control 
wells) 
 
Incubate for 30 minutes at 37ºC in 5%CO2 
 
Remove medium from top well and replace with medium containing 300,00 PBMCs (isolated as 
described in section 2.5.1.1) and incubate for 1 hour. 
 
Perform FACs analysis on medium from bottom wells 
 
400μl of the DMEM-F12 medium solution containing 100,000 HBMECs is placed into each hanging 
filter. 
Add 100ng/ml TNF-α to each well incubate for 1 hour 
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2.5.2.3 Transmigration of mononuclear cells across HBMEC monolayers in  
 in response to human CCL7, CCL14, CCL16 and CCL22. 
The transwells were set up as in as in section 2.5.2.1. Following addition of the activation 
medium, cells were incubated for 1.5 hours, and the medium in the bottom well was 
replaced with 800μl of the chemokine medium. The chemokine medium was made using 
RPMI-1640 medium containing 0.5% fraction V BSA with human chemokines CCL7, 
CCL14, CCL16 and CCL22 (Peprotech. Table 2.8) added, giving final chemokine 
concentration of100ng/ml and left for 30 minutes to allow the chemokine to be presented 
on the EC apical surface. Two negative controls were the chemokine only in the absence of 
activation. Following this, the medium from the hanging filter well was removed and 
immediately replaced with 400μl of RPMI-1640 medium (with 0.5% fraction V BSA)  
containing 100,000-300,000 leukocytes (freshly separated from human peripheral blood as 
previously described in section 2.5.1.1) and left for 1 hour to allow migration to occur. The 
negative control was performed using 0ng/ml chemokine over an un-activated (non-
inflammatory) HBMEC monolayer. This was carried out in triplicate for each assay, total 
number of assays; RA n = 3, non-RA n = 3. 
Following migration the medium was removed from the bottom wells and placed into a 
5ml FACS tube. The tubes were then centrifuged at 1000rcf for 10 minutes at 4
o
C.  The        
supernatant was taken off and the cells resuspended in either PBS containing 2% fraction 
V BSA (Invitrogen) and kept on ice for immediate FACS analysis, or resuspended in PBS 
with 10% cell fix and stored at ~4
o
C for later FACS analysis.  
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Table 2.8 Recombinant proteins used in transmigration analysis (section 2.5.2.3). 
Protein Code Company 
Human CCL7 300-7 PeproTech 
Human CCL14 300-38 PeproTech 
Human CCL16 300-44 PeproTech 
Human CCL22 300-36A PeproTech 
This table shows the details for where the recombinant proteins used in this work were 
from. 
 
2.5.3 Sample preparation for transmission electron microscopy (EM). 
2.5.3.1 Buffers: 
A) 0.1M sodium cacodylate (NaCac) + 2mM calcium chloride (CaCl2) 
10.7015g NaCac (Sigma-Aldrich) and 0.11g CaCl2 (Sigma-Aldrich) were added to 
500ml of distilled water and the pH then adjusted to pH7.4. This was stored at 4
o
C 
until use. 
B) 2.5% Glutaraldehyde (GTA) 
1ml GTA stock solution (25% solution, Sigma-Aldrich) was added to 9ml 
NaCac/CaCl2 solution immediately before use. 
C) 0.1% GTA 
1ml of the 2.5% GTA solution was made up to 25ml NaCac/NaCl2immediately 
before use. 
2.5.3.2 Preparation of filters for EM. 
HBMECS were grown to ~80% confluence on 5µm pore filters (as described in section 
2.5.2.2). The medium was aspirated and the filters washed with PBS after which they were 
incubated with 2.5% GTA (as in 2.5.3.1B above) for 2 hours at room temperature. 
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Following incubation the filters stored in 0.1% GTA and kept at 4
o
C prior to being sent to 
Keele University for EM processing and imaging. 
 
2.5.3.3 Post fixation and Spurr embedding of cells on filters. 
EM was performed  in collaboration with Karen Walker, Electron Microscopy Unit, Keele 
University. 
The samples were washed three times, for five minutes in 0.1M sodium cacodylate 
(NaCac) + 2mM calcium chloride (CaCl2). They were post fixed in 0.1% osmium tetroxide 
(in NaCac.CaCl2) for 1 hour. Following washing (as above) the samples were stored in 
70% ethanol overnight. The samples were dehydrated in 80% ethanol for 15 minutes, 
100% ethanol for 15 minutes and 100% dry ethanol for 15 minutes. Infiltration embedding 
in Spurr’s resin and dry ethanol was then performed. Spurr’s resin allows specimens which 
are normally difficult to embed to be successfully embedded as it is a low viscosity 
embedding medium. Infiltration and polymerisation were as follows 
 
 
 
 
 
 
 
 
90-100nm thick sections were cut from the embedded sample with a diamond knife using a 
Leica Ultracut microtome. The cut sections were floated on water and then placed onto     
copper grids ready for staining. 
(1:3) Spurr’s resin : 
100% dry ethanol 
1 hour on rotator (1:1) Spurr’s resin : 
100% dry ethanol 
1 hour on 
rotator 
overnight on rotator 
 
(3:1) Spurr’s resin : 
100% dry ethanol 
Pure Spurr’s resin 
3 x 1 
hour on 
rotator 
Pure Spurr’s resin Polymerized at 60
oC for 16 hours Embedded sample 
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2.5.3.4 Staining of ultrathin sections for EM 
A) 2% Lead Citrate 
1.33g of lead nitrate (Pb(NO3)2), 1.76g of (tri) sodium citrate (NA3[(C6H5)7].2H20) 
and 30ml of CO2 free, distilled water were added to a 50ml flask and ultrasonicated 
for 30 minutes. 8ml of 1M sodium hydroxide (NaOH) was then added and the         
solution diluted to 50ml with distilled water and well mixed. The buffer was then 
stored at 4
o
C. 
 
B) 2% Uranyl Acetate 
0.04g uranyl acetate was dissolved in 2ml of 70% ethanol using a sonicator then 
centrifuged at high speed for 5 minutes and used immediately. 
 
Materials 
A) Dental wax in petri dish 
B) Petrie dish containing potassium hydroxide pellets with a piece of dental wax on 
top. 
C) Double (grade 50) filter papers. 
D) Rinse 1.  100ml of 30% ethanol 
E) Rinses 2-6.  5 x 100ml of distilled water. 
 
One spot of uranyl acetate per copper grid was placed onto the dental wax in the petri dish 
(A). The grids were fully immersed in the spots and left for 20 minutes. The grids were 
then dipped into rinse 1 20 times, then into rinses 2 and 3 5 times. The grids were then 
washed by directing distilled water down the forceps (rather than directly onto the grids) 
from a wash bottle and excess water was carefully blotted away using the filter paper. 
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Small spots of lead citrate (1 spot per copper grid) were placed onto the petri dish B and 
again the grids were carefully fully immersed into the spots with forceps and left for 5 
minutes.  The grids were then dipped 10 times each into rinses 4-6 and then washed and 
blotted as earlier described. The stained samples were then ready to be visualised using a 
JEOL 1230 electron microscope and analysed using AnalySIS software. 
 
 
2.6 Materials and methods used in chapter 6 
 
Cultured cell stimulation was performed as previously described in section 2.4.1.8. 
Transmigration across HBMECs was performed as described in section 2.5.2.3. 
 
2.6.1 RA and non-RA blood samples. 
Peripheral blood was obtained from 24 patients with longstanding RA fulfilling the 
American College of Rheumatology (ACR) criteria for RA.  16 age matched non-RA 
peripheral blood samples were obtained from a database of previous donors who had 
expressed their willingness to be contacted for future blood samples. Full informed consent 
was obtained in all cases. 
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2.6.2 Transmigration of mononuclear cells across HDLEC monolayers in response to 
human CCL7 
Following the optimisation process 100ng/ml of the chemokine was shown to give optimal 
results and was used for all other transmigration work in this study. 
Two negative controls was again performed; one in the absence of TNF-/ IFN- and 
chemokine, and one in the absence of CCL7 only. The transwells were set up as in section 
2.5.2.1 for HBMECs only. 
 Following addition of the activation medium (serum free EBM-2mv with TNF- at 
100ng/ml and IFN- at 100ng/ml), for 1.5 hours, the medium in the bottom well was 
replaced with 800μl of the 100ng/ml CCL7 medium. The chemokine medium was made 
using EBM-2mv (Lonza) containing 0.5% fraction V BSA.  This was left for 30 minutes to 
allow the chemokine to be presented on the EC apical surface. Following this, the medium 
from the hanging filter well was removed and immediately replaced with 400μl EBM-2mv 
(Lonza) (with 0.5% fraction V BSA)  containing 100,000-300,000 mononuclear cells 
dependent on the numbers obtained from individual blood donors freshly separated from 
peripheral blood as previously described in section 2.5.1.1. It was left for 1 hour to allow 
migration to occur. The negative control was performed using 0ng/ml chemokine over an 
un-activated (non-inflammatory) HDLEC monolayer. This was carried out in triplicate for 
each assay, total number of assays: RA n = 3, non-RA n = 3. 
Following migration the medium was removed from the bottom wells and placed into 5ml 
FACS tubes. The tubes were then centrifuged at 1000rcf for 10 minutes at 4
o
C.  The        
supernatant was shaken off and the cells resuspended in either PBS containing 2% fraction 
V BSA (Invitrogen) and kept on ice for immediate FACS analysis, or resuspended in PBS 
with 10% cell fix and store at ~4
o
C for later FACS analysis.  
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2.6.3 Flow Cytometry  
2.6.3.1 Chemokine receptor staining of leukocytes from human blood. 
PBMCs were isolated as described in section 2.5.1.1 and the total number of cells 
calculated. 300,000 PBMCs per well were dispensed into a 96 round bottom well flexiplate 
(Scientific Laboratory Supplies) and centrifuged for 4 minutes at 1400rcf and at 4ºC. 
Following supernatant removal the cells were washed by adding  50l of 10%   
flebogamma diluted 1:10 in PBS (Invitrogen) to each well and carefully vortexed to mix.  
This was then left to incubate on ice for 30 minutes, centrifuged as before and the 
supernatant removed. The cells were then washed with 100l 2% BSA in PBS, vortexed 
briefly to mix, centrifuged as before and the supernatant removed. 50l of the 
unconjugated primary antibodies, mouse anti-human CCR1, CCR2, CCR4 and CCR5  (all 
from Immunotools, Germany, table 2.9) diluted in 2% BSA in PBS, was added to each 
well, vortexed and left for 30 minutes to incubate on ice. The plate was then centrifuged, 
washed, and the supernatant removed. 50l per well of the secondary antibody, goat anti-
mouse IgG
2b
 PE conjugated (Immunotools) was then added (1:100 in 2% BSA PBS), 
vortexed and left to incubate on ice for 30 minutes. The plate was then centrifuged, washed 
and the supernatant removed as before and the cells were resuspended in 50l 2% BSA 
PBS and added to 200l 2% BSA PBS in 5 ml Falcon tubes and stored on ice prior to flow 
cytometry on the FACS machine (BD FACScan; Becton Dickinson). 
      
2.6.3.2 CD marker staining of leukocytes from human blood  
PBMCs were isolated as described in section 2.5.1.1 and the total number of cells 
calculated. 300,000 PBMCs per well were dispensed into a 96 round bottom well flexiplate 
(Scientific Laboratory Supplies) and centrifuged for 4 minutes at 1400rcf and 4ºC. 
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Following supernatant removal the cells were washed by adding  50l of 10% flebogamma 
diluted 1:10 in PBS (Invitrogen) to each well and carefully vortexed to mix.  This was then 
left to incubate on ice for 30 minutes, centrifuged as before and the supernatant removed. 
The cells were then washed with 100l 2% BSA in PBS, vortexed briefly to mix, 
centrifuged as before and the supernatant removed. 50l of PE conjugated CD antibodies: 
mouse anti human IgG
1
 CD3 PE conjugated; mouse anti human IgG
1
 CD14 PE conjugated 
and mouse anti human IgG
2a 
CD14 PE conjugated (Immunotools) and controls 
(Immunotools) were added to the cells, giving a final concentration of 5l antibody per 
100,000 cells (see table 2.9), prepared with 2%BSA in PBS and vortexed briefly to mix. 
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Table 2.9 showing reagents used for CD marker and chemokine receptor staining for 
FACS analysis 
Marker 
Primary antibodies and 
volumes used 
Secondary antibodies and 
concentrations used 
 
CD3 
5l mouse anti human IgG1 CD3 PE 
conjugated per 100,000cells (500µg/ml) 
n/a 
 
CD14 
5l mouse anti human IgG1 CD14 PE 
conjugated per 100,000cells (500 µg/ml) 
n/a 
 
CD20 
5l mouse anti human IgG2a CD14 PE 
conjugated per 100,000cells (500 µg/ml) 
n/a 
 
CCR1 
 Mouse anti-human CCR1 (500 µg/ml) 
(50l per well)  
5l goat anti-mouse IgG2b PE 
conjugated (500 µg/ml) 
 
CCR2 
Mouse anti-human CCR2  (500 µg/ml) 
(50l per well)  
5l goat anti-mouse IgG2b PE 
conjugated (500µg/ml) 
 
CCR4 
Mouse anti-human CCR4 (500µg/ml) 
(50l per well)  
5l goat anti-mouse IgG2b PE 
conjugated (500 µg/ml) 
 
CCR5 
Mouse anti-human CCR5  (500µg/ml) 
(50l per well) 
5l goat anti-mouse IgG2b PE 
conjugated (500µg/ml) 
 
All of the above experiments were carried out with isotype matched negative controls. 
 
2.7 Materials and methods used in chapter 7 
2.7.1  Matched blood and synovial fluid for ELISA analysis.  
Matched serum and synovial fluid samples from 17 RA patients, 7 OA patients, 14 reactive 
arthritis (ReA) patients and 7 psoriatic arthritis (PsA) patients (exact numbers per-
experiment stated in figure legends) were kindly donated by Dr Derek Mattey (Keele 
University. Guy Hilton Research Centre, Stoke-on-Trent, UK). These samples were used 
for the analysis of the chemokines CCL7, CCL14, CCL16 and CCL22 in chapter 7. The 
synovial fluid was centrifuged at 2500rcf for 10 minutes at 4
o
C. and stored at -80
 o
c 
following flocculate removal. 
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2.7.2 ELISA of matched synovial fluid and serum samples  
DuoSet ELISA kits were used for CCL7 (DY282), CCL14 (DY1578), CCL16 (DY802) 
and CCL22 (DY336), all from R&D Systems, Abingdon, UK.  Wash buffer (WA126), 
substrate solution (DY999) stop solution (DY994) (all R&D Systems) were used 
throughout. The individual reagent diluents and blocking buffers were as recommended by 
the individual product datasheets. 
Titrations were performed to establish the optimal working concentrations for both the 
serum and synovial fluid samples. Sample standards were run for each experiment. 
 
2.7.3 Plate Preparation 
The capture antibody was diluted to 1g/ml with PBS and 100l were added to each well 
of a 96 well plate (Scientific Laboratory Supplies) which was then sealed and incubated at 
room temperature overnight. The following day, each well was washed by aspirating with 
400l of wash buffer 3 times. After the last wash the plate was inverted and tapped over 
paper towels to ensure removal of the wash buffer. 
The plates were blocked by incubating for 1 hour with the wash buffer at room temperature    
before being washed as previously stated. 
 
2.7.4 Assay procedure 
100l of the sample (diluted to working concentration with reagent diluent) was pipetted 
into each well (in duplicate) then sealed and left to incubate at room temperature for 2 
hours. The wash step was repeated as previously stated.  100l of the detection antibody 
(diluted with the reagent diluent to the working concentration of 30ng/ml) was added to 
each well and again sealed and left at room temperature for 2 hours to incubate. After 
washing (as earlier stated) 100l of the Streptavidin-HRP (at working concentration) was 
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added to each well and incubated in the dark at room temperature for 20 minutes, after 
which 50l of the stop solution was added to each well and the plate was gently tapped to 
ensure thorough mixing.  
Additional information for experimental procedures whose results are not used in this 
thesis and principles of TH-GFAAS can be found in the appendix. 
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3.1 Introduction and Aims 
Chemokines are important mediators of transmigration via the activation of leukocyte 
surface integrins which are important in the early stages of leukocyte transmigration for 
controlling cell-cell interactions. As this initial interaction occurs at the EC : blood 
interface of the microvasculature the elucidation of the chemokines  present at this 
interface may offer further insight into the pathology of RA. While there has been a 
plethora of work looking at the expression of both CXCL and specific CCL (beta) 
chemokines in RA, a literature review established that there has been little definitive work 
to demonstrate the presence of chemokines at the ECs. This is important to understand 
which chemokines are stimulating leukocyte recruitment and which to target for therapy. 
During initial work on this study the CXCL and CCL chemokines were both to be assessed 
to attempt to find a ‘chemokine address code at ECs for RA’. However, it became apparent 
within the first six months that to perform the required levels of optimisation and analysis 
with fluorescent immunohistochemistry for both types of chemokine would not be feasible 
in the time allowable. A further literature review showed that the CCL chemokines were 
less well elucidated at the ECs than the CXCL chemokines so it was decided to focus on 
the former for the remainder of the work. CCL chemokines are known to stimulate a wide 
range of leukocytes, including monocytes and lymophocytes (Mellado et al., 2015)  
While performing the analysis of the chemokines using VWF as the EC marker a paper by 
Burman et al., (2005) was identified which suggested that the dysregulation of chemokines 
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at synovial ECs led to altered leukocyte migration into the synovium. This led me to the 
hypothesis that differential expression/presentation of the same chemokine at blood vessel 
ECs and lymphatic ECs may be involved in the persistence of leukocytes within the 
inflamed joint. It was decided by the author to look at the expression of the most highly 
presented chemokines found in this study at both blood vessel ECs and lymphatic ECs to 
further analyse the dysregulation hypothesis. The tissue samples used had been previously 
categorised (Schmutz et al.,2006 ) for the degree of infiltration/hyperplasia and the 
presence of lymphoid aggregates by staining for T-cells and B-cells. Much of the following 
work was performed on the remaining sections of these tissue samples.  
A range of anti-human chemokine antibodies are available from a range of sources. The 
choices of the antibodies in this study were based on their previous use in published work 
(where possible) to prove their reliability. Lesser known antibodies were purchased where 
other sources were not available in order to assess the greatest complement of CCL 
chemokines possible. The use of the antibodies for other markers, such as VWF for blood 
ECs and LYVE-1 for lymphatic ECs as these are markers expressed by the relevant EC 
cell type and are cited extensively as such.   
 
The aims were to: 
 Establish which CCL chemokines are highly presented at RA synovial ECs and 
then compare the presence of the most highly represented chemokines (present on 
Chapter 3 
 
 
 
118 
≥60% of RA vessels) with their presence in non-RA synovial tissue to establish 
which specific chemokines are increased in RA.  
 Examine whether differences exist in blood and lymphatic vessel EC presentation 
of the most highly represented chemokines in both RA and non-RA synovial tissue 
to establish whether particular chemokines are dysregulated in RA. Such 
dysregulation could potentially lead to leukocyte persistence in the inflamed joint. 
 
3.2 Materials and Methods 
Synovial tissue was obtained as described in section 2.3.1 Immunofluorescence was 
performed and quantified as described in section 2.3.2. The counted fields cover between 
40-80% of the tissue sections. 
 
3.2.1 Quantitation of results 
Statistical analysis was performed using Graphpad (La Jolla California USA, 
www.graphpad.com).  
For chemokines present at less than 60% of VWF+ vessels the percentage of VWF and/or 
LYVE-1 vessels which were positive for the chemokine was calculated and is shown as 
mean ± SE. Where chemokines were present at greater than 60% of VWF+ vessels in RA 
synovium they were also investigated in non-RA synovial tissue and significant differences 
between the two assessed by Student’s t-test (p = <0.05).   
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3.3 Results 
3.3.1 Beta chemokines on synovial ECs.  
Each of the chemokines which had anti-human immunofluorescence antibodies 
commercially available were initially assessed on 8 RA tissue samples. A range of staining 
for each of the chemokines was elucidated whereby differing degrees of EC staining was 
observed. A high degree of heterogeneity between individual patients was also observed 
(appendix, table 1). This may be due to variations in the level of inflammation within the 
joints of different patients. Such variations may be caused by fluctuations in the disease 
course and/or differences in medication between patients. Both DMARDS and biologic 
agents have an effect on the chemokines seen in tissues, and reductions in TNF (for 
example) reduce chemokine levels within the inflamed joint (Szekanecz et al., 2010; 
Eriksson C,, Rantapää-Dahlqvist and Sundqvist, 2013). Each of the samples chosen were 
previously designated as being areolar in morphology, apart from a number of later 
sections from RA sample 8 which had fibrous regions, (Schmutz,  unpublished work). The 
sections analysed were not serial but were from the same tissue blocks. Serial cryosections 
were not technically possible. 
 
3.3.1.1 CCL1 in RA synovial tissue 
CCL1 was shown to be present on both ECs and infiltrate within the RA joint (figures 
3.1A and 3.1B).  11.9% (±4.0) of VWF+ RA vessels were CCL1+ (figure 3.1B and table 
3.1). Colocalised staining was apparent but as the CCL1 staining was quite weak merged 
images were not shown in these data.  
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3.3.1.2 CCL2 in RA synovial tissue 
CCL2 was present in both infiltrate and ECs (figure 3.2A). Particularly intense EC staining 
was observed in regions of more diffuse infiltration (figure 3.2A) with weaker EC staining 
seen in regions of lymphoid follicles and more dense infiltration (figure 3.2B). 
Colocalisation of VWF and CCL2 was seen throughout the synovial tissue (figure 3.2A) 
and was present on 51.5% (±6.9) of VWF+ vessels (table 3.1).  The negative control 
(figure 3.2C) showed no background staining.  
 
3.3.1.3 CCL3 in RA synovial tissue 
A combination of weakly CCL3+ vessel ECs and infiltrate was seen (figure 3.3A and 
3.3B). It appears that CCL3 was predominantly seen on the basement membrane of the RA 
vessel ECs. CCL3 was shown to be present on 27.4% (±6.1) of VWF+ RA vessels (table 
3.1). The negative control (figure 3.3C) showed no background staining. 
 
3.3.1.4 CCL4 in RA and non-RA synovial tissue. 
CCL4 was shown to be highly represented on RA ECs. It was identified at 62.3% (±11.0) 
of VWF+ RA vessels (figure 3.4A and 3.4B). CCL4+ infiltrate was also observed (figure 
3.4A). The negative control (figure 3.4A inset) showed no background staining. CCL4 
staining was seen within vessel walls in non-RA synovial tissue, but to a lesser degree than 
in RA tissue at only 49.2% (±16.0) of VWF+ vessels (figure 3.4C) although the difference 
was not significant (p = 0.49). See table 3.2. 
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3.3.1.5 CCL5 in RA synovial tissue. 
CCL5 staining was evident throughout the synovium, including EC basement membrane 
(figure 3.5A), luminal EC surface and on infiltrating cells and within lymphoid aggregates 
(figure 3.5B and 3.5C).  CCL5 was shown to be present on 44.9% (±7.6) of VWF+ RA 
vessels. See table 3.1. 
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Table 3.1 Chemokine present at ≤ 59.9% of VWF+ vessels in RA synovial tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage of VWF+ vessels for each RA sample (n=8) that was also chemokine+ and 
present on < 59.9% of the VWF+ vessels. * indicates novel identification on synovial ECs 
at the time of writing. Data are shown with mean ± SE. * early analysis showed this value 
to be 59.2% and so further study was not performed.  
 
 
Chemokine RA 
CCL1* 11.9 %     (±4.0) 
CCL2 51.5%      (±6.9) 
CCL3 27.4%      (±6.1) 
CCL5 44.9%      (±7.6) 
CCL10* 52.6%      (±10.0) 
CCL11* 15.8%      (±6.3) 
CCL12* 9.6%       (±3.2) 
CCL13* 56.6%      (±7.0) 
CCL15* 47.3%      (±6.3) 
CCL17* 17.4%      (±10.6) 
CCL18* 38.0%      (±6.4) 
CCL20* 18.5%      (±2.7) 
CCL21 36.1%       (±10.4) 
CCL23* 37.7%       (±4.5) 
CCL24* 28.8%       (±4.6) 
CCL25* 28.2%       (±4.5) 
CCL26* 63.6%*     (±7.5) 
CCL27* 8.3%       (±1.2) 
CCL28* 40.9%       (±6.8) 
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Table 3.2 Chemokine present at ≥60% of VWF+ vessels in RA synovial tissue 
assessed on non-RA synovial tissue.   
Chemokine RA Non-RA p =  
CCL4 62.3%   (±11.0) 49.2%   (±16.0) ▪ p = 0.49 
CCL7☻ 69.3%    (±6.1) 61.9%   (±14.8) ▪ p = 0.54 
CCL8 64.1%    (±7.4) 25.6%   (±17.0) ♦ p = 0.04 
CCL14☻ 73.0%    (±7.0) 28.4%    (±8.2) ▪ p = 0.0041 
CCL16☻ 74.1%      (±7.2) 75.3%     (±7.0) ▪ p = 0.89 
CCL19 80.0%    (±4.5) 10.3%     (±2.6) ♦ p = <0.0001 
CCL22☻ 60.1%    (±8.1) 18.7%     (±5.7) ▪ p = 0.014 
This table shows the percentage of VWF+ vessels in RA patients (n=8) that were also 
chemokine+ and were present on 60% of vessels.  These were compared with the 
percentage of VWF+/chemokine+ vessels in  non-RA samples (♦ n=6, ▪ n = 5). ☻ indicates 
novel identification on synovial ECs in RA at the time of writing. Data is shown as mean 
percentage of  VWF+ vessels also chemokine+ (n = 8),  ±SE.  Significant differences as 
assessed by t-test (p = <0.05) are shown.  
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Table 3.3 Chemokine with VWF, and chemokine with LYVE-1 in RA and non-RA 
tissue.  
Shows the percentage of VWF+ vessels for each RA and non-RA sample that was also 
positive for the chemokine.  The percentage of LYVE-1+ vessels for each RA (n=8) and 
non-RA for CCL7 (n=6), CCL14, CCL16 and CCL22 (n=5) sample that was also positive 
for the chemokine is also shown (±SE).  Significant differences as assessed by t-test (p = 
<0.05) are shown.  
 
 
 
 
chemokine 
 
VWF and chemokine 
 
LYVE-1 and chemokine 
RA non-RA p = RA non-RA p = 
CCL7 
69.3% 
(±6.1) 
61.9% 
(±14.8) 
p = 0.54 
32.3% 
(±10.1) 
83.3% 
(±10.1) 
p = 0.011 
CCL14 
73.0% 
(±7.0) 
28.4% 
(±8.2) 
p = 0.0041 
45.7% 
(±11.5) 
40.0% 
(±23.3) 
p = 0.83 
CCL16 
74.1% 
(±7.2) 
75.3% 
(±7.0) 
p = 0.89 
65.4% 
(±8.0) 
60.0% 
(±23.2) 
p = 0.80 
CCL22 
60.1% 
(±8.1) 
18.7% 
(±5.7) 
p = 0.014 
75.1% 
(±6.0) 
10.0% 
(±9.5) 
p = 0.0001 
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Figure 3.1 CCL1 and VWF staining in RA synovium.  3.1A shows a merged image of 
staining for CCL1 (red), VWF (green) and DAPI (blue). The white arrow indicates a CCL1 
negative vessel. The red arrow indicates an example of CCL1+ infiltrate. 3.1B shows an 
enlarged image of a CCL1+ vessel, the inset image shows the merged image for the same 
vessel.  3.1C show the isotype matched negative control (scale bar shows 100m in all 
images).  RA sample 1 is shown as a representative example. 
B 
C 
 
 
B 
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Figure 3.2 CCL2 and VWF staining in RA synovium.  3.2A and 3.2B show merged 
images of staining for CCL2 (red), VWF (green) and DAPI (blue). CCL2+ vessels are 
indicated with white arrows in 3.2A with yellow staining indicating strong colocalisation 
between VWF and CCL2. 3.2B shows what appear to be lymphoid follicles, indicated with 
green arrows.  3.2C shows a show the isotype matched negative control merged image 
(scale bar shows 100m in all images). RA sample 6 is shown as a representative example. 
C B 
 
 
 
 
A 
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Figure 3.3 CCL3 and VWF staining in RA synovium.   3.3A shows a merged image of 
staining for CCL3 (red), VWF (green) and DAPI (blue) on RA sample 7 as a representative 
example. The white arrow indicates a weak CCL3+ vessel, the green arrows indicate weak 
CCL3+ infiltrate. 3.3B shows the CCL3 staining only to confirm its presence as it is 
overpowered by the more intense VWF staining in 3.3A.  3.3C shows the isotype matched 
negative control merged image of a serial section at the same magnification (X20 
objective), scale bars show 100m.  
 
A 
B C 
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Figure 3.4 CCL4 and VWF staining in RA synovium. 3.4A shows CCL4+ vessel ECs 
indicated with white arrows, the green arrow shows CCL4+ infiltrates. Inset image shows 
the isotype matched negative control. 3.4B is a merged image of the region in the white 
circle with DAPI (blue) and VWF (green). The red arrow indicates colocalisation. 3.4C. 
shows CCL4 and VWF staining in the non-RA synovium, orange colouration in inset 
shows colocalisation. Scale bars show 100m (original magnification X20 objective). RA 
sample 2, and non-RA sample 5 are shown as representative examples. 
 
A 
B 
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Figure 3.5 CCL5 and VWF staining in RA synovium.  3.5A shows a merged image of 
staining for CCL5 (red), VWF (green) and DAPI (blue) on RA sample 6 as a representative 
example. In 3.5A the red arrow indicates colocalisation.  White arrows indicate CCL5 at 
the basement membrane. The yellow arrow indicates CCL5 on infiltrating cells. 3.5B 
shows a merged image where some CCL5 cells are in close association with what appears 
to be a large lymphoid aggregate (green arrow). 3.5C shows the same image as 3.5B with 
CCL5 staining only. The white arrows indicate CCL5 at the luminal EC surface of the 
vessel. (X20 objective throughout) Scale bars show 100m in 3.5A. Figures 3.5B and 3.5C 
were enlarged from and original magnification X20 objective. 
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3.3.1.6 CCL7 and VWF in RA and non-RA synovial tissue. 
CCL7 was observed throughout the RA synovium on vessel ECs as indicated by white 
arrows (figure 3.6A and 3.6B) and on a number of sub-intimal and infiltrating cells (figure 
3.6A) which appeared in many cases to be cells resembling fibroblasts (figure 3.6C). A 
high degree of colocalisation between CCL7 and VWF on vessel ECs was observed. 
Overall, CCL7 was shown to be present on 69.3% (±6.1) of VWF+ RA vessels. The 
negative control (figure 3.6B inset) showed no background staining. In the non-RA 
synovium, CCL7 staining was less evident on infiltrating cells (figure 3.7) but staining 
remained high on VWF+ ECs at 61.9% (±14.8) (figure 3.7A and 3.7B). The difference in 
the percentage of VWF+ vessels stained for CCL7 in RA and non-RA tissue was not 
significant (p = 0.54), see table 3.2. The negative control (figure 3.7C) showed no 
background staining.  
 
3.3.1.7 CCL7 and LYVE-1 in RA and non-RA synovial tissue. 
CCL7 was present on 32.3% (±10.1) of RA lymphatic vessels (figures 3.8 and 3.9A, table 
3.3). Colocalisation was identified (figure 3.8) primarily on the larger lymphatic vessels 
and intimal cells (figure 3.9A and 3.9B). CCL7 and LYVE-1 colocalisation was seen on a 
number of infiltrating cells (figure 3.8, 3.9C and 3.9D). Staining using CD68 as a marker 
showed these to be macrophages (figure 3.9C and 3.9D). In the non-RA synovium, CCL7 
was shown to be present on 80.0% (±11.6) of LYVE-1+ vessels (figure 3.10A and 3.10B, 
table 3.3). Whilst LECs were strongly CCL7 positive on larger lymphatic vessels, small 
lymphatic vessels were also weakly positive (figure 3.10B). The negative control (figure 
3.10C) showed no background staining. The difference in the percentage of lymphatic 
vessels stained for CCL7 in RA and non-RA tissue was significant (p = 0.011), see table 
3.3. 
Chapter 3 
 
 
 
131 
 
    
Figure 3.6 CCL7 and VWF staining in RA synovium. 3.6A shows the merged image for 
CCL7 (red), VWF (green) and DAPI (blue) on RA sample 1 as a representative example. 
White arrows indicate CCL7+ vessels, red arrows indicate CCL7+ intimal cells. The inset 
image (red box) is an enlargement of the area in the white box. A number of CCL7 and 
VWF+ vessels where co-localisation is evident are indicated by the green arrows. 3.6B 
shows the staining for CCL7 (red) only, indicated by white arrows. The inset image shows 
the merged negative control. Scale bars show 200m. 3.6C shows CCL7+ cells, which 
appear to be fibroblasts, and co-localisation of CCL7 and VWF at a single cell. The inset 
image shows a merged isotype matched negative control image.  Scale bars in 3.6A and 
3.6B show 200m. Scale bar in 3.6C shows 50m. 
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Figure 3.7 CCL7 and VWF staining in non-RA synovium. 3.7A shows the staining for 
CCL7 (red) only from non-RA sample 3 as a representative example. White arrows 
indicate CCL7+ vessels. 3.7B shows the merge image for CCL7 (red), VWF (green) and 
DAPI (blue). Colocalisation of CCL7 and VWF is indicated by the green arrows. 3.7C 
shows a merged isotype matched negative control image. Scale bars show 200m. 
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Figure 3.8 CCL7 and LYVE-1 staining in RA synovium.  3.8 shows the merged image 
of staining for CCL7 (green), LYVE-1 (red), DAPI (blue) from RA sample 1 as a 
representative example. White arrow indicates CCL7 and LYVE-1 colocalisation. Yellow 
arrows indicate CCL7 negative vessels. The green arrows indicate CCL7 and LYVE-1 
(weakly) on infiltrating cells.  The inset image shows the merged isotype matched negative 
control image. Scale bars show 100m 
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Figure 3.9 CCL7 and LYVE-1 staining in RA synovium .  3.9A shows the CCL7 
(green) staining only with white arrow indicating the larger vessel. 3.9B shows the same 
image for LYVE-1 only (red) with both large and smaller vessels indicated by white 
arrows. 3.9C and 3.9D show LYVE-1 (green), CD68 (red), and DAPI (blue). 3.9D is an 
enlarged image (original not shown) at an original magnification of X40 (objective), scale 
bar shows 20m. The inset in 3.9D shows the merged negative control image for CD68 
staining (X40 objective). All images are from RA sample 1 as representative examples. 
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Figure 3.10 CCL7 and LYVE-1 staining in non-RA synovium. 3.10A shows the 
staining for CCL7 (green).  3.10B shows the staining for LYVE-1 only from the same field 
of view 3.10C shows the merged isotype matched negative control image. The white 
arrows indicate CCL7+ vessels (X10 objective). Non-RA sample 4 is shown as a 
representative example. 
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3.3.1.8 CCL8 and VWF staining in RA synovial tissue.  
CCL8 was present throughout the RA synovium. Strong colocalisation as seen in VWF+ 
vessels with CCL8+ staining of other cells was also indicated (figure 3.11A) which 
appeared to be primarily on fibroblasts (3.11B). The percentage of VWF+ vessels stained 
for CCL8 was shown to be significantly increased in RA (64.1% ±7.4) (table 3.2) 
compared to non-RA  (26.6% ±17.0) (p =0.04). There was very little visible infiltrate 
staining (figure 3.12A). The negative control  showed no background staining in RA 
(figure 3.11C) and non-RA tissue (figure 3.12B). 
 
3.3.1.9 CCL10 and VWF staining in RA synovial tissue.  
CCL10 was shown to be colocalised on VWF+ vessels and also present on infiltrating cells 
(figure 3.13A). There was particularly intense staining at the intima (figure 3.13B). 
Overall, CCL10 was present on 52.6% (10.0) of VWF+ RA vessels (table 3.1). The 
negative control (figure 3.13C) showed no background staining.  
 
3.3.1.10 CCL11 and VWF staining in RA synovial tissue.  
A number of small VWF+ vessels showed weak staining for CCL11 (figure 3.14A).  
However, the staining was more intense at larger vessels where infiltrate staining was also 
present (figure 3.14B). CCL11 was shown to be present on 15.8% (6.3) of VWF+ RA 
vessels (table 3.1). The negative control (figure 3.14C) showed no background staining.  
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Figure 3.11 CCL8 and VWF staining in RA synovium.  3.11A shows the merged image 
for staining for CCL8 (red), VWF (green) and DAPI (blue). RA sample 4 is shown as a 
representative example. Strong colocalisation of CCL8 and VWF at vessels is evident as 
yellow colouration in 3.11A with CCL8+ infiltrate also being seen, examples of which are 
highlighted with white arrows 3.11B shows CCL8+ cells which appear to be fibroblast 
like. 3.11C shows a merged isotype matched   negative control image. Scale bars show 
100m throughout. 
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Figure 3.12 CCL8 and VWF staining in non-RA synovium.  3.12A shows the merged 
image for CCL8 (red), VWF (green) and DAPI (blue) from non-RA sample 3 as a 
representative example. The inset image (red box) in 3.12A shows CCL8 only from the 
region in the white box. 3.12B shows a merged isotype matched negative control image.   
Scale bars show 100m throughout. 
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Figure 3.13 CCL10 and VWF staining in RA synovium.  3.13A shows the merged 
image for staining for CCL10 (red), VWF (green) and DAPI (blue) from RA sample 4 as a 
representative example. 3.13B shows CCL10+ cells intensely stained at the intima. 3.13C 
is the merged isotype matched negative control image.  The white arrows indicate CCL10+ 
vessels. Scale bars show 100m throughout. 
A 
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Figure 3.14 CCL11 and VWF staining in RA synovium  3.14A shows the merged image 
for staining for CCL11 (red), VWF (green) and DAPI (blue) from RA sample 2 as a 
representative example, with weakly CCL11+ vessels indicated by white arrows. 3.14B 
shows much more intense CCL11 staining on a large vessel with infiltrate staining in the 
same region. 3.14C shows a merged isotype matched negative control image.  Scale bars 
show 100m throughout. 
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3.3.1.11 CCL12 and VWF staining in RA synovial tissue.  
CCL12 stained sparsely and very weakly in VWF+ vessels (figure 3.15A, 3.15B) with a 
small degree of infiltrate staining also seen.  CCL12 was shown to be present on 9.6% 
(3.2) of VWF + RA vessels (table 3.1). The negative control (figure 3.15C) showed no 
background staining.  
 
3.3.1.12 CCL13 and VWF staining in RA synovial tissue.  
Colocalisation between CCL13 and VWF was observed (figure 3.16A) in 56.6% (7.1) of 
VWF+ RA vessels (table 3.1). Numerous infiltrating cells were also CCL13+. The 
negative control (figure 3.16B) showed no background staining.  
 
3.3.1.13 CCL14 and VWF staining in RA and non-RA synovial tissue.  
Very strong staining for colocalisation of CCL14 and VWF was seen in RA vessels and on 
infiltrating cells (figure 3.17A). CCL14 was shown to be present on 73.0% (7.0) of 
VWF+ RA vessels. The negative control (figure 3.17B) showed no background staining.   
In the non-RA synovium CCL14 staining was present but was markedly weaker (figure 
3.18). Overall, CCL14 was present on 28.4% (8.2) of VWF+ non-RA vessels (table 3.2). 
The negative control (3.18B) showed no background staining. The percentage of VWF+ 
vessels stained for CCL14 was shown to be significantly increased in RA compared to 
non-RA tissue (p = 0.0041), (table 3.2)  
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3.3.1.14 CCL14 and LYVE-1 staining in RA and non-RA synovial tissue.  
Weakly positive CCL14 staining was observed on LYVE-1+ vessels with colocalisation 
being evident (figure 3.19A, 3.19B). CCL14+ infiltrate was also seen (figures 3.19A, 
3.19B). CCL14 was shown to be present on 45.7% (11.5) of LYVE-1+ RA vessels (table 
3.3). The negative control (figure 3.19C) showed no background staining. 
 In the non-RA synovium CCL14 was present (figures 3.20A, 3.20B), but to a lesser 
degree at 40.0% (23.2) of LYVE-1+ non-RA vessels. The percentage of LYVE-1+ 
vessels stained for CCL14 was not significantly different between RA and non-RA tissue 
(p = 0.83), (table 3.3).  The negative control (figure 3.14C) showed no background 
staining.  
 
3.3.1.15 CCL15 and VWF staining in RA synovial tissue.  
CCL15 staining was seen in numerous VWF+ vessels (figure 3.21A) with strong staining 
in the cells of the intima (figure 3.21 B). Infiltrate staining was seen to be primarily at cells 
near the vessels or intima.  CCL15 was shown to be present on 47.3% (6.3) of VWF+ RA 
vessels (table 3.2). The negative control (figure 3.21C) showed no background staining.  
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Figure 3.15 CCL12 and VWF staining in RA synovium.  3.15A shows the merged 
image for staining for CCL12 (red), VWF (green) and DAPI (blue) from RA sample 1 as a 
representative example,  with a weak CCL12+ vessel and a CCL12+ infiltrated cell 
indicated with a white arrow. 3.15B shows the CCL12 staining only and 3.15C shows a 
merged isotype matched negative control image.  Scale bars show 50m throughout. 
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Figure 3.16 CCL13 and VWF staining in RA synovium.  3.16A shows the merged 
image for staining for CCL13 (red), VWF (green) and DAPI (blue) from RA sample 3 as a 
representative example with colocalisation for a VWF+ and CCL13+ vessel indicated with 
a white arrow. Examples of CCL13+ infiltrate cells indicated with a yellow arrow (original 
magnification X40 objective). 3.16B shows a merged isotype matched negative control 
image (magnification X20 objective). 
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Figure 3.17 CCL14 and VWF staining in RA synovium. 3.17A shows the merged image 
for staining for CCL14 (red), VWF (green) and DAPI (blue) from RA sample 7 as a 
representative example. Strong colocalisation is seen where the vessels appear to be yellow 
and CCL14+ infiltrating cells are also seen. 3.17B shows a merged isotype matched 
negative control. Scale bars show 100m in 3.17A and 200m in 3.17B. 
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Figure 3.18 CCL14 and VWF staining in non-RA synovium.  3.18A shows the merged 
image for staining for CCL14 (red), VWF (green) and DAPI (blue) in non-RA sample 3 as 
a representative example. Weak CCL14 staining is indicated with a white arrow. 3.18B 
shows a merged isotype matched negative control. Magnification X20 objective, scale bars 
show 100m. 
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Figure 3.19 CCL14 and LYVE-1 staining in RA synovium.  3.19A shows the merged 
image for staining for CCL14 (red), LYVE-1 (green) and DAPI (blue) in RA sample 8 as a 
representative example. Weak LYVE-1 staining on a lymphatic vessel is indicated with a 
white arrow. 3.19B shows the area in the white box of 3.18A close up where colocalisation 
is evident as orange colouration marked with the green arrow (original magnification X20 
objective). 3.19C shows the merged isotype matched negative control image. 
Magnification, X20 objective. Scale bars show 100m. 
 
A 
B C 
Chapter 3 
 
 
 
148 
 
   
Figure 3.20 CCL14 and LYVE-1 staining in non-RA synovium.  3.20A shows the 
merged image for staining for CCL14 (red), LYVE-1 (green) and DAPI (blue) from non-
RA sample 3 as a representative example. White arrows indicate CCL14+ vessels. Weakly 
positive CCL14 and LYVE-1+ stromal cells are indicated with yellow arrows. 3.20B 
shows weak LYVE-1 staining on a lymphatic vessel (white arrow). 3.20C shows the 
merged isotype matched negative control image.  Scale bars show 100m. 
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Figure 3.21 CCL15 and VWF staining in RA synovium. 3.21A shows the merged image 
for staining for CCL15 (red), VWF (green) and DAPI (blue) from RA sample 2 as a 
representative example. Inset image shows the CCL15 staining only.  3.21B shows strong 
staining for CCL15 in the intima with a weakly positive vessel indicated by the yellow 
arrow. 3.21C shows the merged isotype matched negative control image. Scale bars show 
50m in 3.21A and 3.21B. Scale bar shows 100m in 3.21C. 
 
 
 
 
A 
 
B C 
Chapter 3 
 
 
 
150 
3.3.1.16 CCL16 and VWF staining in RA and non-RA synovial tissue.  
In RA synovium a high degree of CCL16 staining was seen in vessels (figure 3.22A and 
3.22B) with minimal infiltrate staining. CCL16 was shown to be present on 74.1% (7.2) 
of VWF+ RA vessels. CCL16 and VWF colocalisation was evident throughout the 
synovium (figure 3.22A). The negative control (figure 3.22C) showed no background 
staining.   CCL16 was present in the non-RA synovium at 75.3% (7.0) of VWF+ vessels 
(figure 3.23A, 3.23B). The percentage of vessels stained for CCL16 was not significantly 
different when RA and non-RA tissue was compared (p = 0.089), (table 3.3).  The negative 
control (figure 3.23C) showed no background staining.  
 
3.3.1.17 CCL16 and LYVE-1 staining in RA and non-RA synovial tissue.  
CCL16 was highly represented in the RA synovium at 65.4% (8.0) of LYVE-1+ RA 
vessels (figure 3.24A) where some infiltrate staining for LYVE-1 was also observed (table 
3.3). The negative control (3.24B) showed no background staining.  
 In the non-RA synovium CCL16 and LYVE-1 colocalisation was also apparent (figure 
3.25A, 3.25B) and CCL16 was present on 60.0% (23.2) of LYVE-1+ non-RA vessels 
which was not  significantly different (p = 0.80) (table 3.3) to the percentage in RA tissue. 
The negative control (figure 3.25C) showed no background staining.  
 
3.3.1.18 CCL17 and VWF staining in RA synovial tissue.  
Only minute amounts of CCL17 could be found on a very small number of vessel ECs 
(figure 3.26) with infiltrating cells also being CCL17+. CCL17 was shown to be present on 
17.4% (10.6) of VWF+ RA vessels (table 3.1). 
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3.3.1.19 CCL18 and VWF staining in RA synovial tissue.  
CCL18 was shown to be present on 38.0% (6.2) of VWF+ RA vessels (table 3.1). 
Infiltrate staining was primarily seen to be on cells in close association with CCL18+ 
vessels (figure 3.27).  
 
3.3.1.20 CCL19 and VWF staining in RA and non-RA synovial tissue.  
Colocalisation between CCL19 and VWF was observed at RA vessels. Overall, CCL19 
was shown to be present on 80.0% (4.5) of VWF+ RA vessels (figure 3.28A). Infiltrating 
cells were also positive for CCL19. It was also observed that more intense CCL19 staining 
appeared to be present in the regions of lymphoid follicle development. The negative 
control (figure 3.28B) showed no background staining.  In the non-RA synovium CCL19 
was only present on a small number of VWF+ vessels; primarily the larger vessels (figure 
3.29A, 3.29B). CCL19 was shown to be present on 10.3% (2.6) of VWF+ non-RA 
vessels (table 3.2). The difference in the percentage of VWF+ vessels stained for CCL19 in 
RA and non-RA was highly significant (p = <0.0001). The negative control (figure 3.29C) 
showed no background staining.  
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Figure 3.22 CCL16 and VWF staining RA synovium.  3.22A shows a merged image of 
CCL16 (red), VWF (green) and DAPI (blue) stain on RA sample 4 as a representative 
example, where white arrows indicate regions of CCL16 and VWF colocalisation which 
appear more yellow in colour. 3.22B shows the result of staining for CCL16 (red). The 
yellow arrows indicate CCL16+ vessels. 3.22C shows the merged isotype matched 
negative control. Scale bars show 100m. 
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Figure 3.23 CCL16 and VWF staining in non-RA synovium. 3.23A shows a merged 
image of CCL16 (red), VWF (green) and DAPI (blue) from RA sample 7 as a 
representative example.  An example of a CCL16+ stromal cell is indicated by a green 
arrow.  3.23B shows staining for CCL16 only. The vessels which are CCL16+ and VWF+ 
are indicated by white arrows in 3.23A and 3.23B. 3.23C is a merged isotype matched 
negative control image. Scale bars show 100m. 
B C 
A 
Chapter 3 
 
 
 
154 
 
 
Figure 3.24 CCL16 and LYVE-1 staining in RA synovium.  3.24A shows a merged 
image of CCL16 (red), LYVE-1 (green) and DAPI (blue) from RA sample 5 as a 
representative example. A number of infiltrating cells are seen to be LYVE-1+.  Scale bar 
shows 50m. 3.24B shows a merged isotype matched negative control image. Scale bar 
shows 100m. 
 
A 
B 
Chapter 3 
 
 
 
155 
 
    
Figure 3.25 CCL16 and LYVE-1 staining in non-RA synovium. 3.25A is a merged 
image of CCL16 (red), LYVE-1 (green) and DAPI (blue) from non-RA sample 2 as a 
representative example. A CCL16 and LYVE-1+ vessel is indicated by the white arrow.  
3.25B shows the same image with only the CCL16 staining. 3.25C shows a merged isotype 
matched negative control image.  Scale bars shows 100m. 
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Figure 3.26 CCL17 and VWF staining in RA synovium. 3.26 shows a merged image of 
staining for CCL17 (red), VWF (green) and DAPI (blue) from RA sample 1 as a 
representative example. Regions of CCL17+ infiltrate are indicated by the white arrows. 
Scale bar shows 100m. 
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Figure 3.27 CCL18 and VWF staining in RA synovium.  3.27 shows a merged image of 
staining for CCL18 (red), VWF (green) and DAPI (blue) from RA sample 1 as a 
representative example.  A point of colocalisation which appears orange/yellow in colour 
is indicated by the white arrow. Scale bar shows 50m. 
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Figure 3.28 CCL19 and VWF staining in RA synovium. 3.28A shows strong staining 
for CCL19 (red), VWF (green) and DAPI (blue) from RA sample 3 as a representative 
example. Colocalisation for CCL19 and VWF is seen as yellow colouration on the 
numerous vessels. 3.28B shows the merged negative control. Scale bars show 100m. 
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Figure 3.29 CCL19 and VWF staining in the non-RA synovium. 3.29A shows staining 
for CCL19 (red), VWF (green) and DAPI (blue) from non-RA sample 3 as a representative 
example. 3.29B shows the same tissue section with only the CCL19 stain. 3.29C shows a 
merged isotype matched negative control image. Scale bars in 3.29A and 3.29B show 
50m. Scale bar in 3.29C shows 100m. 
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3.3.1.21 CCL20 and VWF staining in RA synovial tissue. 
Very little CCL20 could be found on the vessel ECs but was identifiable in the intimal 
layer (figure 3.30).  CCL20 was shown to be present on 18.5% (2.7) of VWF+ RA 
vessels. See table 3.1. 
 
3.3.1.22 CCL21 and VWF staining in RA synovial tissue. 
CCL21 was observed throughout the synovium (figure 3.31A and 3.31B) and was 
particularly noticeable in the nuclei of infiltrating cells (figure 3.31B).  CCL21 was shown 
to be present on 36.1% (10.4) of VWF+ RA vessels (table 3.1). The negative control 
(figure 3.31C) showed no staining.  
 
3.3.1.23 CCL22 and VWF staining in RA and non-RA synovial tissue. 
In the RA synovium CCL22 colocalisation with VWF + vessels was strongly evident   
(figure 3.32A, 3.32B). Overall, CCL22 was shown to be present on 60.1% (8.1) of VWF+ 
RA vessels (table 3.3). The negative control (figure 3.32C) showed minimal background 
staining. In the non-RA synovium (figure 3.33) CCL22 was observed in VWF+ vessels to 
a lesser degree than in RA synovium. The majority of the staining in the non-RA synovium 
was observed on small infiltrates in close proximity to large vessels. The negative control 
(figure 3.33C) showed no background staining. CCL22 was shown to be present on 18.7% 
(5.7) of VWF+ non-RA vessels. The percentage of VWF+ vessels stained for CCL22 was 
significantly increased in RA compared to non-RA tissue (p = 0.014), see table 3.3. 
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3.3.1.24 CCL22 and LYVE-1 staining in RA and non-RA synovial tissue. 
A high degree of colocalisation between CCL22 and LYVE-1 was observed in the RA 
synovium (figure 3.34A) where CCL22 was shown to be present on 75.1% (6.0) of 
LYVE-1+ RA vessels (table 3.3). The negative control (figure 3.34B) showed no staining.  
In the non-RA synovium (figure 3.35A) CCL22 was weakly present on 10.4% (9.5) of   
LYVE-1+ non-RA vessels (table 3.3). The percentage of lymphatic vessels stained for 
CCL22 was shown to be significantly increased in RA compared to non-RA tissue (p = 
0.0001). The negative control (figure 3.35B) showed no staining. 
 
 
3.3.1.25 CCL23 and VWF staining in RA synovial tissue. 
A combination of both strongly and weakly CCL23+ vessels was observed in the RA 
synovium (figure 3.36A). CCL23+ infiltrating cells were also observed which were 
localised within aggregates (3.36B).  CCL23 was shown to be present on 37.7% (4.5) of 
VWF+ RA vessels (table 3.1).  The negative control (figure 3.36C) showed no staining.  
 
 
3.3.1.26 CCL24 and VWF staining in RA synovial tissue. 
CCL24 was observed to localise to both large and small vessels (figure 3.37). However, 
more intense staining was seen on small vessels. CCL24 was calculated to be present on 
28.8% (4.6) of VWF+ RA vessels (table3.1). 
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Figure 3.30 CCL20 staining in RA synovium. 3.30 shows staining for CCL20 (red) on 
RA sample 5 as a representative example. Positive staining is indicated by the white 
arrows. The inset image (white box) shows a close up of the area highlighted by the red 
box (original magnification X10 objective) where CCL20 is clearly stained in the 
intima/sub intima region. The scale bar shows 100m.  
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Figure 3.31 CCL21 and VWF staining in RA synovium.  3.31A shows  staining for 
CCL21 (red), VWF (green) and DAPI (blue) from RA sample 7 as a representative 
example.. Weak CCL21+ staining is indicated by the white arrows in both 3.31A and the 
inset image showing CCL21 only. 3.31B shows CCL21+ cell nuclei. 3.31C is the isotype 
matched negative control merged image. Scale bars for 3.31A and 3.31C are 100m, scale 
bar for 3.31B is 50m.  
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Figure 3.32 CCL22 and VWF staining in RA synovium.  3.32A shows staining for 
CCL22 (red), VWF (green) and DAPI (blue) from RA sample 5 as a representative 
example. CCL22 and VWF colocalisation is seen as yellow colouration. 3.32B shows 
another example of staining on a vessel in the same sample.  3.32C shows a merged 
negative control image. Scale bars show 50m throughout.  
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Figure 3.33 CCL22 and VWF staining in non-RA synovium.  3.33A shows staining for 
CCL22 (red), VWF (green) and DAPI (blue) from non-RA sample 1 as a representative 
example.  Infiltrate stained with CCL22 is seen around the large vessel indicated with a 
white arrow. 3.33B shows a merged negative control image. Scale bars show 100m. 
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Figure 3.34 CCL22 and LYVE-1 staining in RA synovium.  3.34A shows staining for 
CCL22 (red) and LYVE-1 (green) on RA sample 5. 3.34B shows the merged isotype 
matched negative control. Scale bars show 100m. 
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Figure 3.35 CCL22 and LYVE-1 staining in non-RA synovium. 3.35A shows CCL22 
(red), LYVE-1 (green) and DAPI (blue) from non-RA sample 3 as a representative 
example.  3.35B shows LYVE-1 staining only for the same image. Scale bars show 
100m. 
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Figure 3.36 CCL23 staining in RA synovium.  3.36A shows staining for CCL23 (red), 
VWF (green) and DAPI (blue) from RA sample 6 as a representative example. The inset 
image shows CCL23 staining only from the same section. A strongly CCL23+ vessel is 
indicated with a white arrow and a weakly CCL23+ vessel is indicated with a green arrow. 
3.36B shows CCL23 staining of the infiltrate where aggregates are present. 3.36C is a 
merged isotype matched negative control image. Scale bars show 100m. 
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Figure 3.37 CCL24 staining in RA synovium.  Intense staining for CCL24 (red) is 
indicated by the white arrows. RA sample 1 is shown as a representative example. 
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3.3.1.27 CCL25 and VWF staining in RA synovial tissue.  
CCL25 was present primarily on the ECs of larger VWF+ vessels (figure 3.38A, 3.38B). 
Where staining occured on smaller vessels it was seen to be much weaker.  CCL25 was 
shown to be present on 28.2% (4.5) of VWF+ RA vessels (table 3.1). The negative 
control (figure 3.38C) showed no background staining.  
 
3.3.1.28 CCL26 and VWF staining in RA synovial tissue. 
Colocalisation of CCL26 and VWF was observed (figure 3.39A) and infiltrate staining was 
also present throughout the samples with some areas being particularly intensely stained.  
CCL26 was shown to be present on 63.6 % (7.5) of VWF+ RA vessels (table 3.1). The 
negative control (figure 3.39B) showed no background staining.  
 
3.3.1.29 CCL27 and VWF staining in RA synovial tissue. 
CCL27 was seen to be mostly present in the nuclei of infiltrating cells (figure 3.40A) with 
very few examples of CCL27 and VWF colocalisation on vessel ECs (figure 3.40B). 
CCL27 was shown to be present on 8.3% (1.2) of VWF+ RA vessels (table 3.1). The 
negative control (figure 3.40C) showed no background staining.  
 
3.3.1.30 CCL28 and VWF staining in RA synovial tissue. 
Colocalisation between CCL28 and VWF was evident as orange colouration (figure 3.41A) 
and weaker CCL28 staining was observed in smaller vessels. A high degree of intima 
staining for CCL27 was observed (figure 3.41B). The negative control (figure 3.41C) 
showed minimal background staining. CCL28 was shown to be present on 40.9% (±6.8) of 
VWF+ RA vessels (table 3.1).  
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Figure 3.38 CCL25 staining in the RA synovium.  3.38A shows the merged image for 
the results of staining for CCL25 (red), VWF (green), and DAPI (blue) from RA sample 4 
as a representative example. 3.38B shows colocalisation of CCL25 and VWF at a large 
vessel, seen as yellow colouration. 3.38C is the merged isotype matched negative control 
image. Scale bars show 100m.  
A 
B C 
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Figure 3.39 CCL26 staining in the RA synovium.  3.39A shows the merged image for 
the results of staining for CCL26 (red), VWF (green), DAPI (blue) from RA sample 6 as a 
representative example. Colocalisation of CCL26 and VWF is indicated with the white 
arrows. Examples of intensely stained infiltrating cells are indicated with green arrows. 
3.39B shows the merged isotype matched negative control. Scale bars show 100m. 
 
A 
B 
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Figure 3.40 CCL27 staining in RA synovium. 3.40A shows the merged image for the 
results of staining for CCL27 (red), VWF (green), and DAPI (blue) from RA sample 4 as a 
representative example. CCL27 in the nuclei of infiltrating cells is indicated with yellow 
arrows (original image X20 objective magnification). 3.40B shows an enlarged image 
(original not shown) from an original magnification of X40 objective, indicating CCL27 
and VWF colocalisation with white arrows.  3.39C shows the merged isotype matched 
negative control image.   Scale bars show 100m. 
B 
A 
C 
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Figure 3.41 CCL28 staining in the RA synovium.  Figure 3.41A shows the merged 
image for the results of staining for CCL28 (red), VWF (green), and DAPI (blue) from RA 
sample 5 as a representative example. The inset image shows the lesser degree of EC 
staining at smaller vessels (image at same magnification, X20 objective).  3.41B shows 
staining for CCL28 at the intima. Scale bar shows 20m (original magnification X60 
objective). 3.41C shows a merged isotype matched negative control image. Scale bars in 
3.21A and 3.41C show 100m.  
 
 
 
C B 
A 
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3.4 Iron and aluminium content of RA tissue. 
Due to the degree of heterogeneity between the samples and the chemokines it was 
hypothesised that different hypoxic macro/microenvironments within the samples were 
affecting the chemokines presented by the synovium. Due to a lack of high quality tissue 
from the RA samples previously used, plans were abandoned to stain for HIF-1 (a hypoxia 
marker) and 8-Oxy-G (a marker for damage due to the generation of ROS, which are 
known to increase in hypoxic environments (Ng et al., 2010).  Instead the iron content of 
the tissue samples was measured to provide an approximate guide to the degree of 
oxidative damage present.  Aluminium content was also measured as aluminium is known 
to compete for iron binding proteins and so can exacerbate oxidative stress within tissues. 
 
No significant correlations between Fe/Al and chemokine presentation could be established 
which indicated that the aluminium content of the tissues was not related to changes in the  
iron content. It was however interesting to observe that 4 of the 5 patients who had 10 of 
the tested chemokines present in over 60% of vessels had an aluminium content of  
>1g/g-1 or an iron content of >60g/g-1.   Patient 4 had the greatest number of chemokines 
overall (13 of the 27 tested, see appendix table 1) present at 60% of vessels with seven 
chemokines at 80% of vessels.  This patient also had the highest aluminium content 
within their tissue (see table 3.4).  
 
 
 
 
 
 
Chapter 3 
 
 
 
176 
Table 3.4 Iron (Fe) and aluminium (Al) content of RA samples.  
 
 
 
 
 
 
Fe and Al content is exoressed as g per gram of the dry mass of the tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
RA sample Fe (g/g-1)  Al (g/g-1)  
2 47.11 6.12 
4 28.53 7.55 
5 35.10 1.57 
6 174.72 7.51 
8 65.13 0.23 
9 26.58 3.00 
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3.5 Discussion. 
This study is the first to assess the presence of twenty seven of the beta-family chemokines 
on RA synovial ECs. Novel findings include evidence that each chemokine was present to 
some degree, the least abundant being CCL27 which was present in 8.3% of RA ECs and 
the most being CCL19 which was present in 90% of RA ECs.  Also, of the twenty seven 
chemokines investigated, nineteen have not previously been observed at RA ECs. However 
many of them, such as CCL12 (Schmutz et al., 2004) and CCL13 (Haringman et al., 2006; 
Hintzen et al., 2009), have been observed as being in the synovial tissue as a whole 
without analysing their localisation.  From the twenty seven chemokines analysed in the 
present study CCL4, CCL7, CCL8, CCL14, CCL16, CCL19 and CCL22 were shown to be 
present on 60% of vessels, of which CCL7, CCL14, CCL16 and CCL22 have not 
previously been identified as present in RA ECs.  
The chemokines CCL4, CCL8 and CCL19 have been observed at ECs by other studies 
(Tanaka et al., 1998; Pierer et al., 2004; Burman et al., 2005; Page et el., 2002), but their 
degree of presentation was not quantified. They have been further examined by this study, 
where it was established that CCL19 was the most highly upregulated at RA ECs, followed 
by CCL8 then CCL4.  
While CCL4 has been previously identified in RA ECs (Koch et al., 1995b; Tanaka et al., 
1998) this study is the first to quantify its presentation in comparison to control non-RA 
tissue, where the control tissue is not from another arthritis type. Koch et al., (1995b) 
established CCL4 to be down-regulated in RA compared to OA; the present study shows 
that CCL4 is not significantly upregulated in RA compared to non-RA ECs.  While CCL4 
acts as a chemoattractant for a variety of leukocytes including T-cells and B-cells 
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(Krzysiek et al., 1999) as well as monocytes and NK cells (Bystry et al., 2001) the results 
of this study indicate that it may not be primarily involved in the pathology of RA. 
CCL8 activates and chemoattracts a range of cells, including monocytes, T-cells, NK cells 
and fibroblast like synoviocytes (FLS) (Proost et al., 1996; Gong et al., 1998; Haringman 
et al., 2006). This study showed that CCL8 is significantly upregulated in RA ECs 
compared to non-RA ECs, which confirms work by Pierer et al., (2004) who also 
identified a significant up-regulation of CCL8 in RA ECs compared with OA ECs. The 
present study also identified CCL8+ stromal cells which were fibroblast-like in appearance 
which concurs with data from  Haringman et al., (2006) who also observed CCL8+ FLS in 
tissue samples.  
Page et al., (2002) established that CCL19 is present at RA ECs, and Burman et al., (2005) 
showed that CCL19 is expressed on both lymphatic and vascular ECs in RA.  Page et al., 
(2002) found CCL19 to be expressed in RA tissue where germinal centres were present, 
and absent where only diffuse infiltrates were found. The present study provides evidence 
of this as it showed more intense CCL19 staining to be present in the more densely 
infiltrated lymphoid follicle regions.   
Due to time constraints it was decided to assess the four novel, most highly EC presented 
chemokines identified by this study, (CCL7, CCL14, CCL16 and CCL22), for their 
presentation by lymphatic ECs as the pan-endothelial marker VWF did not differentiate 
between the EC types. It was hypothesised that chemokines may be differentially 
expressed on blood/lymphatic ECs in RA and non-RA tissue, which would affect the 
leukocytes migration into the RA synovium and/or their removal from the tissue via 
lymphatics. Future work to test this hypothesis could include performing transmigration 
analysis over blood and lymphatic EC lines where the chemokines of interest had been 
neutralised.    
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Of these four novel chemokines CCL14 showed the most significant upregulation in RA 
synovial ECs compared to non-RA ECs. This was followed by CCL22, CCL7 and CCL16, 
with the latter two showing no significant changes.   
This study adds to the field as it is the first to show CCL14 to be present in RA ECs, and 
shows it to be the most significantly upregulated novel chemokine in RA  ECs using VWF 
as the marker (p = 0.0041). However, when LYVE-1 was used as the EC marker in RA and 
non-RA tissue it was shown that there were no significant differences between the two. 
This suggests that CCL14 may play a role in the recruitment of inflammatory cells into the 
RA synovium, but not their exit via the lymphatics.  
Of the four chemokines chosen, CCL22 was the next most significantly upregulated in RA 
ECs compared to non-RA (p = 0.014). Flylie et al., (2010) identified CCL22 ‘scattered 
throughout’ RA synovium with CCR4, the CCR22 receptor, localised on ECs but the 
current study provides further analysis of CCL22 showing there to be a significant CCL22 
increases at lymphatic ECs in RA compared to non-RA lymphatic ECs. These novel data 
indicate that CCL22 may have a role in the recruitment of inflammatory cells to the RA 
synovium but that the marked increase in CCL22 at RA lymphatic ECs may facilitate the 
removal of infiltrates.  
Haringman et al., (2006), who first identified CCL7 in RA tissue, found it to be 
‘abundantly present’ in all arthritis and control groups tested. This study provides further 
data novel to the field in that CCL7 was shown to be highly presented by RA ECs. While 
there was no significant difference in CCL7 between RA and non-RA VWF+ ECs, when 
LYVE-1 and chemokine colocalaisation was analysed a significant reduction in the 
percentage of LYVE-1 lymphatic vessels stained for CCL7 in RA synovium was observed 
(p = 0.011).  The results of this study led to the speculation that there may be a novel role 
for CCL7 in the recruitment of lymphocytes and monocytes in the synovium in both RA 
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and non-RA, but that the CCL7 reduction at lymphatic ECs may play a role in the 
persistence of inflammatory cells within the RA synovium which is of greater importance 
to RA pathology. This is the first study to identify CCL7 in lymphatic ECs in RA. 
Interestingly, higher CCL7 expression in gastric cancer tissues compared to normal tissues 
was significantly correlated with both lymph node metastasis and ‘advanced depth of wall 
invasion’ (Hwang et al., 2012). This provides further evidence for the potential increased 
cell recruitment in response to CCL7.   
While CCL16 has been previously identified in RA tissue (Radstake et al., 2005; Van-
Lieshout et al., 2005: Haringman et al., 2006), this study is the first to identify its presence 
in RA ECs. However, the results indicate that there are no significant differences at either 
VWF+ ECs or LYVE+ ECs in RA and non-RA tissue and so it is unlikely that CCL16 
plays a dominant role in the pathology of RA. Further studies to confirm the lack of 
CCL16 functionality are needed. 
When iron and aluminium content of tissue was tested no significant correlations between 
Fe/Al and chemokine presentation could be established. However, a trend was observed 
that greater abundance of iron and/or aluminium indicated that the sample would have an 
increased number of the most highly represented chemokines. The increased presence of 
iron and its association with increased inflammation is in itself not surprising, and may 
simply indicate the increased degree of oxidative damage expected in tissue removed at the 
time of joint replacement. However, there is the potential that increased aluminium and/or 
other competitors which compete for iron binding proteins (and in doing so increase the 
levels of free iron and so the oxidative damage in tissue), play a role in chemokine 
expression and the pathology of RA which remains to be elucidated. The current results 
allow only for observational, speculative analysis, and a greater number of samples would 
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need to be analysed for both iron and aluminium to reduce the sample variability seen in 
the currently available data. 
This is the first study to identify LYVE-1+ macrophages in RA. Their presence has been 
noted in tumours, particularly breast cancers (reviewed by Ran and Montgomery, 2012) 
where they play a role in tumour lymphangiogenesis. However, lymphangiogenesis in RA 
decreases as the disease progresses, exacerbating the persistence of inflammatory cells.  
The results of this study indicate that despite the reduction in lymphangiogenesis at the end 
stage of the disease there may still be a potential role of the macrophages in the generation 
of lymphatic vessels. 
 
Conclusions 
The first aim of this section of the study was to establish which CCL chemokines are 
highly presented at RA synovial ECs and to compare the most highly represented 
chemokines (present on ≥60% of RA vessels) with non-RA synovial tissue to establish 
which chemokines are specifically increased in RA.  The chemokines, CCL4, CCL7, 
CCL8, CCL14, CCL16, CCL19 and CCL22 were shown to be present at  ≥60% of RA 
vessels with CCL4, CCL8, CCL14 and CCL22 being significantly upregulated in RA 
compared to non-RA.  
The second aim of this section of the study was to establish whether there are differences 
in blood and lymphatic vessel EC presentation of the most highly represented chemokines 
in both RA and non-RA synovial tissue. Such differential expression within the 
microvasculature of the synovium could potentially  lead to leukocyte persistence in the 
inflamed joint. The study has shown there to be a significant decrease in CCL7 
presentation at RA lymphatic vessels compared to non-RA vessels, and a significant 
increase in CCL22 at RA lymphatic ECs in RA compared to those of non-RA. These 
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findings provide further novel evidence of differentially expressed chemokines on blood 
and lymphatic microvasculature. This adds to the evidence that chemokine dysregulation 
within the microvasculature in inflammatory environments plays a significant role in the 
recruitment and persistence of inflammatory cells in RA. In addition the study identifies 
particular chemokines as potential therapeutic targets on ECs. 
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4.1 Introduction and Aims 
ECs in RA are involved in angiogenesis, leukocyte trafficking and presentation/expression 
of a range of mediators and effectors involved in disease pathology. Chemokines CXCL5, 
CXCL8, CXCL9, CXCL12, CXCL13, CX3CL1, CCL2, CCL3, CCL4, CCL8, CCL19 and 
CCL21 have already been shown to be present at RA ECs (table 1.8 and references 
therein). As the role of chemokines is leukocyte integrin activation and migration the 
presence of these chemokines at ECs may be pivotal in the extravasation process. It was 
hypothesised that the chemokines CCL7, CCL14, CCL16 and CCL22, which were newly 
established at present at RA ECs in chapter 3, may be generated by the ECs themselves 
rather than merely presented by them.  If this hypothesis was true, it would indicate 
whether these EC chemokines played a role in the early stages of leukocyte transmigration 
and so were potentially functional in RA pathology.  As cycloheximide disrupts protein 
synthesis by blocking the translocation step in elongation (Schneider-Poetsch et al., 2010) 
it would affect the levels of the chemokine available for staining in a time dependent 
manner by preventing increases in chemokine intensity.  However, a chemokine which was 
constitutively present should  remain at the same intensity level, or reduce if the 
chemokine was being released by the cell into the medium in the time given.  
Xu et al.,( 2003) showed that increased lymphatic vessel formation occurs in RA, and may 
provide a compensatory mechanism for the removal of invading leukocytes (Olszewski et 
al., 2001). Furthermore, Johnson et al., (2006) showed that TNF-α activated dermal 
lymphatic endothelial cells (DLECs) show >100 fold increases in production of a range of 
chemokines including CCL2, CCL5 and CCL20 which attract T-cells and monocytes. The 
author decided that assessing both blood and  lymphatic ECs would provide further  data to 
assess EC chemokine dysregulation. In the current study HBMECs provide a model for the 
presentation/expression of chemokines to leukocytes that cross human vascular ECs into 
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the synovium; HDLECs were chosen to act as a model for the presentation/expression of 
chemokines stimulating leukocyte migration from the synovium into the lymphatic system.  
 
 
The aims of this chapter were: 
 Establish if TNF-, IFN- or a combination of the two provides optimal simulated 
inflammatory conditions for HBMECs and HDLECs.   
 
 Assess if CCL7, CCL14, CCL16 and CCL22 are present in cultured HBMECs and 
HDLECs  in the presence and absence of  TNF-, IFN- or a combination of the 
two. 
 
 Elucidate if there are changes in the intensity of  CCL7, CCL14, CCL16 and 
CCL22 in the presence of a protein synthesis inhibitor. 
 
 
4.2 Materials and Methods 
HBMECs and HDLECs were cultured as described in section 2.4.1.1 and 2.4.1.4 
respectively,  and inflammatory conditions were stimulated using human TNF-α, IFN- or 
a combination of the two (Peprotech) in DMEM-F12 medium (for HBMECs) or EBM-2-
mv medium (for HDLECs) as described in section 2.4.1.8 and section 2.4.1.9. Following 
optimisation, time dependent stimulation to establish optimal activation times for each cell 
type was performed (as described in section 2.4.1.9). The generation of chemokines by 
HBMECs was ascertained by a time dependent analysis of chemokine staining in the 
absence and presence of TNF- and the protein synthesis blocker cycloheximide as 
described in section 4.4. To inhibit protein synthesis cultured HBMECs/HDLECs were 
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simultaneously stimulated with 100ng/ml TNF-α, with the addition of cycloheximide (at 
10µg/ml) and left for 2, 3, 4, 5 and 6 hours (as described in section 2.4.2) prior to being 
fixed and stained for the chemokines (n=3). Negative controls were performed in the 
absence of TNF-α. (0 hours)  
The degree to which cell surface adhesion molecules were upregulated was ascertained by 
measuring mean cell intensity of ICAM-1 staining over 12 random points within 3 random 
fields of view for each cell type. Following this analysis, the changes in the chemokines 
CCL7, CCL14, CCL16 and CCL22 were assessed in the same manner. Minimum 
measurable intensity, where only background staining in the absence of cells was 
measured, was shown to be 8au; maximum staining was not ascertained. The conditioned 
medium was retained for ELISA testing. 
Cells were visualised using the Olympus fluorescence microscope and intensity of staining 
analysed by CellF software (NCSS, Kaysville, UT, USA).  Cell surface staining only was 
achieved by prevention of cell permeabilisation by fixing cells in freshly prepared 3.7% 
paraformaldehyde at room temperature, in the absence of Triton-X and experiments were 
performed at room temperature. Whole cell staining was performed by ensuring cell 
permeabilisation by fixing cells for 15 minutes in 1:1 ice cold acetone:methanol and the 
addition of 0.3% Triton-X to the dilution and blocking buffer solutions. 
 
4.2.1 Quantitation of results.  
Statistical analysis was performed using GraphPad.  Normality checks were performed for 
each dataset which showed all data to have a non-normal distribution, therefore non-
parametric tests were used throughout the analysis.   
Comparisons of the effect of stimulating cells with TNFα or IFNγ for a single time period 
were carried out using the Wilcoxon signed rank test. Kruskal-Wallis ANOVA was used to 
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determine whether there were any significant differences in staining intensity between at 
least two time points in a time point series. Kruskal-Wallis ANOVA was also used to 
ascertain if there were differences in the presence and absence of cycloheximide. Multiple 
comparison post hoc analysis was performed using Dunn’s post hoc test to compare 
differences between unstimulated and stimulated cells at individual time points. Data 
presented in tables were expressed as median values in arbitrary units with interquartile 
ranges included. The intensity change was calculated by subtracting median intensity of 
unstimulated cells from the median intensity following stimulation. Trend analysis was 
performed using the Jonckheere-Terpstra test. 
 
4.3 Results 
4.3.1 Cell surface ICAM-1 intensity following 16 hour simulation of HBMECs.  
4.3.1.1 Stimulation of HBMECs with 100ng/ml TNF- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
(table 4.1) with TNF- (figure 4.1). 
Under normal conditions (no TNF- stimulation) ICAM-1 intensity was 23.00au (arbitrary 
units) which increased by 23.5au to 46.50au following 16 hour stimulation with 100ng/ml 
TNF- (p value = <0.0001) giving a ~2 fold increase.  Immunofluorescent analysis of 
ICAM-1 showed a clear increase in ICAM-1 expression once stimulated (figure 4.1A). 
Unstimulated cells also showed some ICAM expression (Figure 4.1B). An Isotype 
matched control showed no non-specific staining (inset images).  
 
4.3.1.2 Stimulation of HBMECs with 100ng/ml IFN- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
with IFN- (see table 4.1).  Following 16 hour stimulation with 100ng/ml IFN-, ICAM-1 
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intensity increased from 25.00au under normal conditions to 31.50au (p value = 0.0006).  
The increase in ICAM-1 expression was clear once stimulated (figure 4.2A), despite some 
staining being observed on the unstimulated cells (Figure 4.2B). An isotype matched 
control showed no non-specific staining (inset images). 
 
 4.3.1.3 Stimulation of HBMECs with 100ng/ml TNF- and 100ng/ml IFN- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
(see table 4.1) with IFN-/TNF-.  Following 16 hour stimulation with 100ng/ml IFN-
/TNF- ICAM-1 intensity increased by 9.0au from 28.00au under normal conditions to 
37.00au (p value = <0.0001). ICAM-1 showed markedly higher expression on stimulated 
cells (figure 4.3A) than on unstimulated cells (Figure 4.3B). An isotype matched control 
showed no non-specific staining (inset images). 
 
Despite the data overlap seen between the different types of stimulation the greatest overall 
difference between unstimulated and stimulated HBMECs was when 100ng/ml TNF- was 
used to actiate the HBMECs.  Given the significance of the ICAM-1 intensity increase  
TNF- was used to stimulate the HBMECS in further studies.  
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Table 4.1. Intensity of cell surface ICAM-1 staining following HBMEC stimulation 
with TNF- , IFN- and TNF-/IFN- for 16 hours. 
 
Values for stimulated and unstimulated cells are expressed as median values and given in 
arbitrary units with interquartile range. Unstimulated analysis was performed in the 
absence of TNF-, IFN- and TNF-/IFN- as a negative control. Value for difference is 
stimulated median – unstimulated median. Data were non-parametric so p values are from 
the Wilcoxon signed rank test. 3 fields of view per chamber slide well were analysed. n=3 
wells throughout. 
 
 
Stimulation 
solution 
Unstimulated  
 (n=108 cells) 
Stimulated  
(n=108 cells) 
Difference       
   (p value) 
100ng/ml  
TNF- 
 
23.00 
 
14.00 – 31.00 
 
 
46.50 
 
35.00 - 58.75 
 
 
 
+23.50 
 
p = <0.0001 
 
 
100ng/ml  
IFN- 
 
25.00 
 
19.00 - 32.75 
 
 
31.5 
 
23.00 – 40.00 
 
+6.50 
 
p = 0.0006 
100ng/ml 
TNF-/IFN- 
 
28.00 
 
18.00 – 37.00 
 
 
37.00 
 
31.00 – 45.00 
 
 
+9.00 
 
p = < 0.0001 
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Figure 4.1 ICAM-1 staining of HBMECs stimulated for 16 hours with 100ng/ml TNF-
.  4.1A shows the merged image for the results of staining for ICAM-1 (red) and DAPI 
(blue) on stimulated HBMECs. 4.1B. shows the merged image for the results of staining 
for ICAM-1 (red) and DAPI (blue) on unstimulated HBMECs. The scale bars show 
100m. Inset images show the merged negative control. 
A 
B 
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Figure 4.2 ICAM-1 staining of HBMECs stimulated for 16 hours with 100ng/ml IFN-
. 4.2A shows the merged image for the results of staining for ICAM-1 (red) and DAPI 
(blue) on stimulated HBMEC’s. 4.2B shows the merged image for the results of staining 
for ICAM-1 (red) and DAPI (blue) on unstimulated HBMECs. The scale bars show 
100m. Inset images show the merged negative control. 
A 
B 
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Figure 4.3 ICAM-1 staining of HBMECs stimulated for 16 hours with 100ng/ml       
TNF-/IFN-.  4.3A shows the merged image for the results of staining for ICAM-1 (red) 
and DAPI (blue) on stimulated HBMECs. 4.3B shows the merged image for the results of 
staining for ICAM-1 (red) and DAPI (blue) on unstimulated HBMECs.The scale bars show 
100m.  Inset images show the merged negative control. 
 
A 
B 
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4.3.2 Time dependent stimulation of HBMECs with 100ng/ml TNF- 
A time dependent analysis was performed with TNF- stimulation at 1 hour, 2, 4, 8, 16 
and 24 hours (figure 4.4) to determine optimal stimulation time for the HBMECs to 
generate ICAM-1. Significant increases in intensity when stimulated cells were compared 
to baseline were seen at each time point. Stimulated cells were also significantly different 
to unstimulated control cells at each time point. There were no significant differences when 
unstimulated cells were compared to baseline at each time point. The difference between 
stimulated and unstimulated cells at baseline for ICAM-1 intensity at 2 hours (figure 4.5) 
did not significantly increase at further time points up to 24 hours, so 2 hour stimulation 
was accepted as optimal for ICAM-1 generation for further studies. 
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Figure 4.4 Dot plot showing ICAM-1 staining intensity at 0-24 hour TNF- 
stimulation of HBMECs. Data shows the median values for intensity of ICAM-1 
following TNF- treatment for 1, 2, 4, 8, 16 and 24 hours. Kruskal-Wallis ANOVA was 
performed as data were non parametric, the vertical red bar indicates interquartile range, 
with horizontal red line showing median. * p =<0.05, ** p =<0.01, *** p = <0.001, **** p 
= <0.0001 from baseline using Dunn’s post hoc test.  
 
 
**** *** **** **** ** 
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Figure 4.5  Image showing typical ICAM-1 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours.  4.5A shows the merged image for the results of staining 
for ICAM-1 (red) and DAPI (blue) in stimulated HBMECs. 4.5B shows the merged image 
for the results of staining for ICAM-1 (red) and DAPI (blue) on unstimulated HBMECs. 
The scale bars show 100m. Inset images show the merged negative control. 
 
A 
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4.4 Chemokine generation at activated HBMECs 
4.4.1 Time dependent CCL7 generation by HBMECs in the absence and presence of 
10ug/ml cycloheximide. 
In the absence of cycloheximide a time dependent analysis to assess the generation of 
CCL7 by HBMECs was performed. Cells were stimulated with TNF- and chemokine 
staining then performed at 0, 2, 3, 4, 5 and 6 hours post-stimulation (figure 4.6). 
Significant differences in CCL7 were observed at 2, 3, 4, 5 and 6 hours when stimulated 
and unstimulated cells were compared (table 4.2). The greatest increase was seen at 2 
hours (figure 4.7A and 4.7B) where median intensity increased by 6.00au from 17.00au 
under normal conditions (unstimulated)  to 23.00au  when stimulated (p 0.0001, table 4.2).  
No non-specific staining was seen on the negative control (figure 4.7C). Trend analysis 
showed that there was a significant trend of decreasing levels of intensity between 2 and 6 
hours post-stimulation (p = 0.016). The negative (unstimulated) control showed no 
significant changes in staining intensity over the 6 hour time course. 
 
In the presence of cycloheximide the only significant difference in CCL7 between 
stimulated and unstimulated cells was found at 2 hours (table 4.2, figure 4.6, figure 4.11A, 
4.11B).  Median intensity increased by 3.75au  from 19.25au under normal conditions to 
23.00au  when stimulated  (p = <0.001).  Trend analysis showed no significant differences 
in CCL7 intensity at 3, 4 and 5 hours post stimulation when compared to control. No 
changes were seen in the staining intensity of unstimulated cells over the 6 hour 
experimental period. 
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Table 4.2 Intensity of CCL7 staining following time dependent stimulation of HBMECs by TNF-α in the absence and presence of 
cycloheximide. 
Time 
stimulated 
(hours) 
Without cycloheximide With cycloheximide 
Unstimulated   (n=2) Stimulated  Difference Unstimulated Stimulated  Difference 
 Baseline 
16.75 
14.00 – 18.00 
- 
19.25 
16.55 – 23.30 
- 
2 
17.00 
15.00 -18.00 
     23.00**** 
17.25 - 29.00 
+6.00 
P =  0.0001 
20.00 
17.25 - 24.00 
23.00*** 
19.25 - 27.00 
+3.00 
p = 0.41 
3 
18.00 
15.00 - 21.00 
     22.50**** 
16.00 - 27.00 
+4.50 
p = 0.0001 
20.50 
18.00 - 23.00 
21.00 
18.00 - 25.00 
+1.50 
p = 0.59 
4 
17.00 
15.00 - 20.00 
20.00**** 
17.00 - 24.00 
+3.00 
p = 0.001 
20.00 
16.00 - 24.00 
21.55 
18.00 - 26.00 
+1.55 
p = 0.065 
5 
16.00 
14.00 - 18.00 
18.00*** 
16.00 - 20.00 
+2.00 
p =  0.0001 
19.25 
15.50 - 22.00 
21.50 
17.25 - 24.00 
+2.25 
   p = 0.05 
6 
16.00 
14.00  - 19.00 
17.00 
15.00 - 19.75 
+1.00 
p = 0.024 
20.00 
17.00 - 23.00 
21.00 
18.00 - 25.00 
+1.00 
p = 0.07 
Values are expressed as median values and given in arbitrary units with interquartile range. n = 3 wells throughout unless otherwise specfied.  
Value for ‘difference’ is stimulated median – unstimulated median (TNF-αabsent) and p value is from Wilcoxon signed rank test. P value for 
stimulated intensity compared with baseline (baseline perfomed in the absence of TNF-α) is from Dunn’s post hoc test,*** p = <0.001, **** p = 
<0.0001. 
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Figure 4.6 CCL7, CCL14, CCL16 and CCL22 staining intensity at 0, 2, 3, 4, 5 and 6 
hours TNF- stimulation of HBMECs in the absence and presence of cycloheximide. 
   Shows  chemokine in the absence of cycloheximide,     shows chemokine in the presence 
of cycloheximide.  A shows CCL7 in the presence and absence of cycloheximide (n = 2 for 
absence), B shows CCL14 in the presence and absence of cycloheximide, C shows CCL16 
in the presence and absence of cycloheximide, D shows CCL22 in the presence and 
absence of cycloheximide, for each experiment  n = 3 unless otherwise stated. All 
experiments were performed by stopping the experiment for the control (0 hours) in the 
absence of TNF-α,  and simultaneously adding cycloheximide to the remaining cells. The 
vertical red bar indicates interquartile range and horizontal red line shows median. 
Kruskal-Wallis ANOVA was used to show overall difference and Dunn’s post hoc test was 
used to assess differences between 0 hours and each time point.*** p = <0.001, **** p = 
<0.0001. * indicates significance in the absence of cycloheximide, *indicates significance 
in the presence of cycloheximide. 
**** 
*** 
**** 
**** 
*** 
**** 
*** 
**** **** 
**** 
*** 
**** 
*** 
**** 
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Figure 4.7 Image showing typical CCL7 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the absence of cycloheximide.  4.7A shows the image 
for the results of staining for CCL7 (red) in stimulated HBMECs. The inset image shows 
CCL7 at 5 hours stimulation.  4.7B shows the same image merged for the results of 
staining for CCL7 (red) and DAPI (blue). 4.7C shows the merged negative control. Scale 
bars shows 100m.  
A 
C B 
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Figure 4.8 Image showing typical CCL7 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the presence of cycloheximide.   4.8A shows the image 
for the results of staining for CCL7 (red) in stimulated HBMECs. 4.8B shows the same 
image merged for the results of staining for CCL7 (red) and DAPI (blue). 4.8C shows the 
merged negative control. Scale bars shows 100m.  
 
A 
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4.4.2 Time dependent CCL14 generation by HBMECs in the absence and presence of 
10ug/ml cycloheximide. 
In the absence of cycloheximide significant differences in CCL14 were observed at each 
time point when stimulated and unstimulated cells were compared. The greatest increase 
was seen at 2 hours (table 4.3, figure 4.6, figures 4.9, 4.10A and 4.10B) where median 
intensity increased by 10.00au from 24.00au under normal conditions to 34.00au in 
inflammatory conditions (p= <0.0001).  This was followed by a gradual decrease in 
intensity difference over the proceeding time periods. Trend analysis showed an overall 
significant decrease in intensity between 2 and 6 hours post-stimulation (p = 0.017). The 
negative (unstimulated) control showed no significant changes in staining intensity over 
the 6 hour time course. 
 
In the presence of cycloheximide a significant difference in CCL14 was observed only at 
the 2 hour time point when stimulated and unstimulated cells were compared (table 4.3, 
figure 4.6, figures 4.9, 4.10A and 4.10B). Median intensity increased by 4.50au from 
20.50au under normal conditions to 25.00au in inflammatory conditions (p = 0.0007). 
There were no significant differences in the intensity at the other time points.    
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Table 4.3. Intensity of CCL14 staining following time dependent stimulation of HBMECs by TNF-α in the absence and presence of 
cycloheximide. 
Time 
stimulated 
(hours) 
Without cycloheximide With cycloheximide 
Unstimulated Stimulated  Difference Unstimulated Stimulated  Difference 
 Baseline 
23.00 
19. 00– 27.00 
- 
19.50 
16.25 – 27.00 
- 
2 
24.00 
20.00 - 28.00 
34.00**** 
27.00  - 43.00 
+10 
p= <0.0001 
20.50 
17.00 - 27.75 
25.00**** 
20.00 - 31.00 
+4.5 
P = 0.0007 
3 
25.00 
20.00 - 30.00 
29.00**** 
25.00 - 35.75 
+4.00 
p = 0.001 
19.00 
15.00  - 25.00 
20.00 
17.00  - 25.00 
+1 
P = 0.35 
4 
23.00 
18.00 - 29.00 
29.5**** 
21.99  - 38.00 
+6.5 
p = 0.0003 
20.00 
17.00 - 25.75 
20.00 
17.00  - 25.00 
0 
5 
21.00 
17.00 - 25.00 
28.00**** 
23.25  - 34.00 
+7.00 
p = <0.0001 
20.00 
17.00 - 24.00 
20.00 
17.00  - 25.00 
0 
6 n/a 
28.00*** 
23.25  - 32.75 
n/a 
18.00 
14.25 - 22.00 
19.00 
15.00  - 25.00 
+1 
Values are expressed as median values and given in arbitrary units with interquartile range. n = 3 wells throughout unless otherwise specfied.   
Value for ‘difference’ is stimulated median – unstimulated median (TNF-αabsent) and p value is from Wilcoxon signed rank test. P value for 
stimulated intensity compared with baseline (baseline perfomed in the absence of TNF-α) is from Dunn’s post hoc test,*** p = <0.001, **** p = 
<0.0001.
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Figure 4.9 Image showing typical CCL14 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the absence of cycloheximide.  4.9A shows the image 
for the results of staining for CCL14 (red) in stimulated HBMECs. 4.9B is the same image 
merged for the results of staining for CCL14 (red) and DAPI (blue). 4.9C shows the 
merged negative control. Scale bars shows 100m.  
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Figure 4.10 Image showing typical CCL14 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the presence of cycloheximide.  4.10A shows the image 
for the results of staining for CCL14 (red) in stimulated HBMECs. 4.10B shows the same 
image merged for the results of staining for CCL14 (red) and DAPI (blue). 4.10C shows 
the merged negative control. Scale bars shows 100m.  
 
B 
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4.4.3 Time dependent CCL16 generation by HBMECs in the absence and presence of 
10g/ml cycloheximide.  
In the absence of cycloheximide significant differences in CCL16 were observed at the 5  
and 6 hour time points when stimulated and unstimulated cells were compared (table 4.4, p 
= 0.001, p = 0.0001,  respectively) where the intensity decreased to significantly below 
control (p = <0.0001) (table 4.4, figure 4.6, figure 4.11). There was a near-significant 
difference in intensity observed at 2 hours post-stimulation (p = 0.053) and at 3 hours post-
stimulation (p = 0.05). At 5 and 6 hours post-stimulation the intensity decreased to 
significantly below control (p = <0.001 and <0.0001 respectively) (table 4.4, figure 4.6, 
figure 4.11).  Trend analysis showed a significant decrease in intensity between 2-6 hours 
post stimulation (p = 0.001). Representative staining is shown in figures 4.15A and 4.15B. 
The negative (unstimulated) control showed no significant changes in staining intensity 
over the 6 hour time course. 
 
In the presence of cycloheximide (table 4.4, figures 4.12A and 4.12B) a significant 
difference was observed at 2 hours when stimulated and unstimulated cells were compared 
(table 4.4). Trend analysis showed no significant differences from 2-6 hours post-
stimulation (p = 0.1). As the n number for the unstimulated cells and control cells is low, 
this data requires repeating for validation and must be considered observational only. 
 
4.4.4 Time dependent CCL22 generation in HBMECs in the absence and presence of 
10g/ml cycloheximide.  
No significant differences were observed between data in the presence or absence of 
cycloheximide (table 4.5, figures 4.6, 4.13) 
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Table 4.4 Intensity of CCL16 staining following time dependent stimulation of HBMECs by TNF-α in the absence and presence of 
cycloheximide. 
Time 
stimulated 
(hours) 
Without cycloheximide With cycloheximide 
Unstimulated Stimulated  Difference Unstimulated (n=2) Stimulated  Difference 
Baseline 
27.50 
22.50 – 32.50 
- 
22.00 (n=1) 
18.50 – 26.00 
- 
2 
28.00 
22.00 – 33.00 
31.50 
21.00 - 39.00 
+3.50 
p = 0.053 
21.00 
18.00  - 24.75 
26.00**** 
21.00  - 32.00 
+5.00 
p = 0.03 
3 
26.00 
22.00 – 32.00 
29.00 
25.00  - 33.00 
+3.00 
p = 0.05 
21.00 
17 00 - 23.00 
23.50 
19.25 – 29.75 
+2.50 
p = 0.05 
4 
28.00 
22.00 - 32.00 
25.00 
21.00 – 29.00 
+2.00 
p = 0.10 
21.00 
16.00  - 25.00 
23.00 
19.00 - 28.00 
+2.00 
p = 0.06 
5 
26.00 
21.00 – 31 .00 
20.00*** 
17.00  - 24.00 
           -6.00 
p =<0.001 
19.75 
17.00 – 23.00 
23.00 
20.00  - 27.00 
+3.25 
p = 0.05 
6 
26.00 
22.00 – 31.00   
14.00**** 
11.00  - 20.00 
-12.00 
p =<0.0001 
20.00 
17.00 – 24.00 
22.00 
18.00  - 25.00 
+2.00 
p = 0.06 
Values are expressed as median values and given in arbitrary units with interquartile range. n = 3 wells throughout unless otherwise specfied.  
Value for ‘difference’ is stimulated median – unstimulated median (TNF-αabsent) and p value is  from Wilcoxon signed rank test. P value for 
stimulated intensity from baseline (baseline perfomed in the absence of TNF-α) is from Dunn’s post hoc test,*** p = <0.001, **** p = <0.0001.  
Chapter 4 
 
 
 
207 
 
 
 
Table 4.5 Intensity of CCL22 staining following time dependent stimulation of HBMECs by TNF-α in the absence and presence of 
cycloheximide. 
Time 
stimulated 
(hours) 
Without cycloheximide With cycloheximide 
Unstimulated Stimulated  Difference Unstimulated (n=2) Stimulated  Difference 
Baseline 
11.00 
8. 00 – 11.50 
- 
10.50 
9.50 – 12.50 
- 
2 
10.00 
8.00 – 11.00 
11.00 
10.00 – 13.00 
+1.00 
p = 0. 07 
11.00 
10.00 – 13.00 
11.00 
10.00 – 13.00 
0 
3 
10.00 
10.00 - 11.00 
11.00 
8.00 – 15.50 
+1.00 
p =  0.06 
10.00 
8.00 – 10.00 
11.00 
11.00 – 13.00 
0 
4 
10.00 
8.00 – 10.00 
10.00 
8.00 – 10.00 
0 
 
10.00 
8.00 – 10.00 
10.00 
8.00 - 10.00 
0 
5 
11.00 
10.00 – 11.00 
11.00 
10.00 – 11.00 
0 
10.00 
9.00 – 11.00 
10.00 
10.00 – 11.00 
0 
Values are expressed as median values and given in arbitrary units with interquartile range. n = 3 wells throughout unless otherwise specfied.  
Value for ‘difference’ is stimulated median – unstimulated median (TNF-αabsent) and p value is from Wilcoxon signed rank test. P value for 
stimulated intensity from baseline is from Dunn’s post hoc test.  
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Figure 4.11 Image showing typical CCL16 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the absence of cycloheximide.  4.11A shows the image 
for the results of staining for CCL16 (red) in stimulated HBMECs. 4.11B shows the same 
image merged for the results of staining for CCL16 (red) and DAPI (blue). 4.11C shows 
the merged negative control. Scale bars shows 100m.  
B 
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Figure 4.12 Image showing typical CCL16 staining of HBMECs stimulated with 
100ng/ml TNF- for 2 hours in the presence of cycloheximide.  4.12A shows the image 
for the results of staining for CCL16 (red) in stimulated HBMECs.  4.12B shows the same 
image merged for the results of staining for CCL16 (red) and DAPI (blue). 4.12C shows 
the merged negative control. Scale bars shows 100m.  
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Figure 4.13 Image showing typical CCL22 staining of HBMECs stimulated with 
100ng/ml TNF- for 3 hours in the absence of cycloheximide.  4.13A shows the image 
for the results of staining for CCL22 (red) in stimulated HBMECs. 4.13B shows the same 
image merged for the results of staining for CCL22 (red) and DAPI (blue). 4.13C shows 
the merged negative control. Scale bars shows 100m.  
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4.5  Cell surface ICAM-1 intensity following 16 hour simulation of HDLECs. 
 
4.5.1 Stimulation of HDLECs with 100ng/ml TNF- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
with TNF- (table 4.6, figure 4.14A). Under normal conditions (figure 4.14B) ICAM-1 
intensity was 29.00au which increased by 6.50au to 35.50au following TNF- stimulation 
(p = <0.0001).  Isotype matched controls showed no non-specific staining (inset images). 
 
4.5.2 Stimulation of HDLECs with 100ng/ml IFN- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
with IFN- (see table 4.6, figure 4.15A).  Following IFN- stimulation, ICAM-1 intensity 
increased by 11au from 25.00au under normal conditions to 36.00au (p = <0.0001).  The 
increase in ICAM-1 expression was clear once stimulated (figure 4.15A), despite some 
staining being observed on the unstimulated cells (Figure 4.15B). Isotype matched controls 
showed minimal non-specific staining (inset images) 
 
4.5.3 Stimulation of HDLECs with 100ng/ml TNF- and 100ng/ml IFN- 
There was a significant effect on the generation of ICAM-1 caused by 16 hour stimulation 
with IFN-/TNF-  (see table 4.6, figure 4.16A).  Following stimulation with IFN-/TNF-
 ICAM-1 intensity increased from 24.50au under normal conditions by 19.50au to 
44.00au (p = <0.0001) (table 4.6). ICAM-1 showed markedly higher expression on 
stimulated cells (figure 4.16A) than on unstimulated cells (Figure 4.16B). Isotype matched 
controls showed minimal non-specific staining (inset images). 
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Table 4.6 Intensity of cell surface ICAM-1 staining following 16 hour stimulation of 
HDLECs with 100ng/ml TNF-, 100ng/ml IFN- and 100ng/ml IFN-/TNF-. 
 
Values are expressed as medians and given in arbitrary units with interquartile range.     
Values for difference are stimulated median – unstimulated median. Unstimulated analysis 
was performed in the absence of TNF-, IFN- and TNF-/IFN- as a negative control. 
Data were non-parametric so p values are from the Wilcoxon signed rank test. 3 fields of 
view per chamber slide well were analysed. n=3 wells throughout. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stimulation 
solution 
Unstimulated  
 
Stimulated  
 
Difference 
(p value)          
 
100ng/ml  
TNF- 
29.00 
 
23.00 – 37.75 
 
35.50 
 
28.50 – 50.00 
 
+6.5 
 
p =  < 0.0001 
 
100ng/ml  
IFN- 
 
25.00 
 
19.00 - 33.00 
 
 
36.00 
 
29.25 – 46.75 
+11 
 
p = < 0.0001 
 
100ng/ml 
TNF-/IFN- 
 
24.50 
 
18.00 – 30.00 
 
44.00 
 
36.25 – 55.00 
+19.50 
 
p = < 0.0001 
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Figure 4.14 ICAM-1 staining of HDLECs stimulated for 16 hours with 100ng/ml 
TNF-.  4.14A shows the merged image for the results of staining for ICAM-1 (red) and 
DAPI (blue) on stimulated HDLECs. 4.14B. shows the merged image for the results of 
staining for ICAM-1 (red) and DAPI (blue) on unstimulated HDLECs. Inset images are the 
corresponding merged negative control. The scale bars show 100m.   
A 
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Figure 4.15 ICAM-1 staining of HDLECs stimulated for 16 hours with 100ng/ml IFN-
  4.15A shows the merged image for the results of staining for ICAM-1 (red) and DAPI 
(blue) on stimulated HDLECs. 4.15B. shows the merged image for the results of staining 
for ICAM-1 (red) and DAPI (blue) on unstimulated HDLECs. Inset images are the 
corresponding merged negative control. The scale bars show 100m.  
A 
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Figure 4.16 ICAM-1 staining of HDLECs stimulated for 16 hours with 100ng/ml 
TNF- and 100ng/ml IFN-  4.16A shows the merged image for the results of staining for 
ICAM-1 (red) and DAPI (blue) on stimulated HDLECs. 4.16B. shows the merged image 
for the results of staining for ICAM-1 (red) and DAPI (blue) on unstimulated HDLECs. 
Inset images show the corresponding merged negative control. The scale bars show 
100m.     
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4.5.4 Time dependent stimulation of HDLECs with 100ng/ml TNF- and 100ng/ml    
IFN- 
A time dependent analysis was performed with TNF-/IFN- stimulation at 1, 2, 4, 8, 16 
and 24 hours to determine optimal stimulation time for the HDLECs to generate ICAM-1. 
There were significant increases in ICAM-1 at 2, 4, 8 and 16 hours post stimulation 
compared to unstimulated control cells (p = <0.0001 throughout) (figure 4.17). Significant 
spontaneous changes were observed when unstimulated cells were compared to baseline 
with significant differences observed at 2, 4 and 16 hours (<0.001). However when 
stimulated and unstimulated cells were compared at each time point there were greater 
significant differences observed at 2, 4, 8, 16 and 24 hours (all <0.0001). As the 
differences between these time points when baseline and stimulated cells were compared 
were negligible the 2 hour stimulation was accepted as optimal (figure 4.18). 
 
Tests were performed to assess the chemokine presence in stimulated HDLECs for 2, 4, 6, 
8, 16 and 24 hours. However, it was noted that the cells appeared to be dedifferentiating 
from passage 5, which were the only cells available, and due to time constraints the tests 
were unable to be repeated. 
 
4.5.5 ELISA testing of conditioned medium for CCL7, CCL14, CCL16 and CCL22 
CCL7 was detected at 4799.59pg/ml in neat medium from stimulated HBMECs and at 
427.623pg/ml from simulated HMVEC (n = 1 in each case).  ELISA testing showed 
CCL14 at 644.65pg/ml in neat medium from stimulated HMVECs (n = 1), but it was not 
detected in other samples. CCL16 and CCL22 were not detected in any samples. Due to 
the low n number this data is purely observational and so must be interpreted with caution 
and repeated for validation. 
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Figure 4.17 Dot plot showing ICAM-1 staining intensity at 0-24 hour TNF-/IFN-γ 
stimulation of HDLECs. Data show the values for intensity of ICAM-1 following TNF-/ 
IFN-γ treatment for 1, 2, 4, 8, 16 and 24 hours. Kruskal-Wallis ANOVA was performed as 
data were non parametric, the vertical red bar indicates interquartile range with horizontal 
red line showing the median  **** p = <0.0001 from baseline using Dunn’s post hoc test. 
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Figure 4.18 ICAM-1 staining of HDLECs stimulated for 2 hours with 100ng/ml    
TNF- and 100ng/ml IFN-  4.18A shows the merged image for the results of staining for 
ICAM-1 (red) and DAPI (blue) on stimulated HDLECs. 4.18B. shows the merged image 
for the results of staining for ICAM-1 (red) and DAPI (blue) on unstimulated HDLECs. 
Inset images show the corresponding merged negative control. The scale bars show 
100m.   
 
 
B 
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4.6 Discussion 
Assessment of ICAM-1 expression was performed to study EC activation by cytokines. 
Chemokine mediated leukocyte ‘crawling’ before transmigration is MAC-1 and ICAM-1 
dependent (Ley et al., 2007). ICAM-1 reduces the velocity of rolling leukocytes by 
stabilising the initial transient contact between the leukocytes and the EC (Barreiero and 
Sanchez-Madrid, 2009), furthermore ICAM (among other adhesion factors), has been 
shown to regulate the elongation of microvilli (Oh et al., 2007).   
In the current study, TNF- was shown to generate the most significant increase in ICAM-
1 at the HBMEC cell surface following 16 hour stimulation compared to IFN- or TNF- 
/IFN-. This supports work by Gimbrone, and Lelke (2003) who state that TNF- 
increased ICAM expression to the greatest degree in 8 hours or less when compared to 
IFN- or a combination of the two.  
This is the first study to show that for HDLECs, TNF- in combination with IFN- 
stimulates the most significant increase in ICAM-1. The greatest ICAM-1 expression was 
observed at 16 hours post stimulation, with highly significant increases seen from 2 hours. 
Johnson et al, (2006) showed that TNF- increased ICAM expression in DLECs to the 
greatest degree when compared to IFN-, with maximal expression achieved at 6-12 hours 
post-stimulation. However, no evidence can be found of combined TNF- and IFN-  
stimulation performed on HDLECs in the literature.   
Cycloheximide disrupts protein synthesis by blocking the translocation step in elongation 
(Schneider-Poetsch et al., 2010) so in a time dependant manner would affect the levels of 
the chemokine available for staining (Figure 4.19).   
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Figure 4.19 Mechanistic model of Cycloheximide inhibition of translation elongation 
 
In the absence of Cycloheximide,  a peptide bond would be formed between the amino acid 
attached to the transfer RNA (tRNA) in site P and the amino acid attached to the  tRNA in 
site A. The growing ‘protein’ would detach from the tRNA in site P,  and as the ribosome 
moved along the mRNA to the next codon (in a 5’ to 3’ direction) the tRNA would then 
translocate from site P to site E allowing another amino acid carrying tRNA to move to the 
A site. In the presence of Cycloheximide the E site is blocked inhibiting translocation of 
the tRNA and hence elongation of the protein. 
 
The expected affect if the ECs were actively producing the chemokines in response to 
TNF-α stimulus in the absence of cycloheximide would be increasing intensity of 
chemokine staining during the time period, as the concentration of the protein increases, or 
a rise followed by a plateau in the chemokine production.  
In the presence of cycloheximide there would be no increases in intensity as the generation 
of the chemokine was inhibited at the translational level. However, if the chemokine was 
constitutively present it would be expected to remain at a ‘steady state’, or reduce in 
intensity if the cell was releasing it into the medium over the time frame of the experiment. 
The current study is the first to show an increase in intensity of CCL7 in the absence of 
cycloheximide in ECs. However, given that protein synthesis in the absence of 
cycloheximide is expected where the ECs are actively generating CCL7, the subsequent 
trend of CCL7 decreasing in intensity to near baseline suggests that while pre-synthesised 
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CCL7 may be stored in the ECs, in Weibel-Palade bodies or other secretory vesicles, it is 
not being generated in an on-going manner in response to inflammatory stimuli. However, 
given the low n numbers for this data this evidence should be considered as prelimainary 
and all conclusions drawn with caution.  The release of CCL7 is partially supported by the 
observational data from the ELISA tests which showed CCL7 to be detectable in the 
conditioned medium. The presence of chemokines and other factors such as VWF in 
Weibel-Palade bodies is well documented (Øynebråten et al., 2005; Rondaij et al., 2006; 
Hol et al., 2009).  Chemokine receptors such as D6 and CCR5 have been shown to rapidly 
internalise chemokines for recycling (Weber et al., 2004) so it is also possible that CCL7 
may have been broken down intracellularly without the cells generating further CCL7 to 
replenish stores within this timeframe. In the presence of cycloheximide the only 
significant increases in CCL7 was observed at 2 hours.  This suggests that there may be 
some pre-stimulation by TNF- occurring prior to the cycloheximide starting to inhibit 
protein synthesis.  
In the absence of cycloheximide the data for CCL14 show a significant increase in 
intensity followed by a significant decreasing trend which does not reduce to near baseline 
levels. This indicates that pre-synthesised CCL14 was stored in the ECs and either released 
into the medium and/or recycled within the cell, primarily between 2 and 6 hours 
stimulation.  These data indicate that further CCL14 was either being generated by the ECs 
to replenish stores during this process, or CCL14 was not being released and/or recycled to 
a significant degree within the timeframe. However, the lack of CCL14 in HBMEC 
conditioned medium, but its presence in HMVEC conditioned medium indicates that the 
chemokine is not being released by HBMECs. In the presence of cycloheximide the 
increase in intensity at 2 hours post-stimulation indicates that there was some pre-
stimulation occurring prior to the cycloheximide inhibition of protein synthesis. This was 
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followed by a significant decrease between 2-6 hours post-stimulation which indicates that 
the cycloheximide had successfully blocked any further chemokine generation and 
suggests that the cell surface CCL14 may have been released into the medium as the 
cycloheximide should have prevented cellular recycling.   
This study is the first to indicate that ECs may generate CCL14 in response to 
inflammatory stimuli, as shown by the significantly increased CCL14 levels throughout the 
24 hour timeframe in the absence of cycloheximide.  Further work is needed to assess the 
half-life of the different chemokines and their levels of release/recycling within the cell in 
ECs using pulse-chase experiments (e.g. with 
35
S-methionine) which would provide more 
conclusive data.  
In the absence of cycloheximide, CCL16 showed a near-significant initial increase from 
baseline to 2 hours post-stimulation (p = 0.054), followed by a significant decrease from 
baseline at 5 and 6 hours post-stimulation. Trend analysis showed a significant decrease 
between 2-6 hours post-stimulation. This suggests that pre-synthesised CCL16 was either 
released into the medium or recycled within the cell. It also suggests that further CCL16 
was not being generated by the ECs to replenish stores during this timeframe.  
As with CCL7 and CCL14 in the presence of cycloheximide, a significant increase in 
CCL16 was observed at 2 hours, and as with CCL14 this was followed by a significant 
decrease at 5-6 hours post-stimulation. However, this was not an overall significant trend 
between 2-6 hours. This suggests pre-stimulation and (as with CCL14) the release of 
CCL16 into the medium and/or its intracellular recycling. This is partially supported by 
Weber et al., (2005) who showed that CCR5 (one of the receptors for CCL16) can rapidly 
internalise chemokines for recycling. If CCL16 was preferentially bound to CCR5 it is 
highly possible that CCL16 was rapidly being internalised and degraded.    
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The significant decrease in CCL22 between 0 and 6 hours in the absence of cycloheximide 
(overall non-significant with trend analysis), without undergoing a significant increase at 
any point, indicates that pre-synthesised CCL22 was either released into the medium or 
recycled within the cell. There was a non-significant increase between 5-6 hours post-
stimulation which may be due to normal variation in CCL22 levels. However, the 
possibility that the cells were starting to generate detectable CCL22 increases at this point 
cannot be discounted.   
The failure to detect CCL16 and CCL22 in conditioned medium may be due to 
undetectable levels being released in the time frame allowed, or further evidence that these 
chemokines are recycled intracellularly rather than released. 
 
A number of factors which have a bearing on the analysis of these data became apparent 
during this section of the study.  The first was the low n numbers. Given further time it 
would be important to increase the sample size throughout this section to assess if 
reductions in the variation seen within the groups were possible.  
The second was the loss of HDLECs viability prior to being able to assess their generation 
of the chemokines.  They began to dedifferentiate at around their 15
th
  population doubling 
and showed a lower than expected survival rate between passages. This led to them 
becoming unusable for the last part of the study. Given further time I would have 
attempted to retrieve primary synovial LECs to provide a more sustainable source of cells 
with the possibility of immortalisation.  
The third major problem was the pre-stimulation of the cells prior to the cycloheximide 
beginning to inhibit protein synthesis. If the work was to be repeated the cycloheximide 
would be added to the cells for a minimum of 30 minutes prior to the addition of TNF-α to 
allow the cycloheximide time to arrest protein synthesis. It would also have been beneficial 
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to have assessed the EC presence of a chemokine such as CXCL8, which is established as 
being secreted by ECs (Utgaard et al., 1998; Wolff et al., 1998; Øynebråten et al., 2004), 
in the presence and absence of cycloheximide to act as a posiive control for the 
chemokines investigated in this study. This section of the study would also greatly benefit 
from repeating the ELISA analysis on the conditioned medium to further elucidate if the 
chemokines are released into the medium. Further to this, running ‘pulse chase’ 
experiments would be able to track chemokine synthesis, to elucidate where they were 
localised and how they were cycled through the cell in response to stimuli. 
 
Conclusions 
The first aim of this section of the study was to establish which cytokine (TNF-, IFN- or 
a combination) provides optimal simulated inflammatory conditions for HBMECs and 
HDLECs.  The HBMECs were shown to undergo the greatest ICAM-1 intensity increases 
at two hours stimulation and beyond in the presence of TNF-. The HDLECs were shown 
to undergo the greatest intensity increases at two hours stimulation and beyond by a 
combination of TNF- and IFN-γ. This is the first study to show such an ICAM increase 
using these cytokines simultaneously. 
The second and third aims of this section of the study were to assess if CCL7, CCL14, 
CCL16 and CCL22 are present in cultured HBMECs and HDLECs, and  if there are 
changes in the intensity of  their expresion in the presence of a protein synthesis inhibitor.  
The data shows that each chemokine is present with CCL14 being present to the greatest 
degree and CCL22 at the lowest levels.  Of each of the chemokines CCL14 underwent the 
greatest increase in response to TNF-α in the absence of cycloheximide which indicates it 
to have the greatest potential of the chemokines under investigation to be produced by ECs 
leading to leukocyte recruitment in RA. The lack of significant changes in the levels of 
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CCL22 in either the presence or absence of cycloheximide taken with its presence being 
just within the limits of detection, indicate that CCL22 is least likely of the chemokines 
under investigation to have an active role in RA pathology via its generation within ECs. 
These novel findings offer further evidence into the generation of chemokines by ECs.  
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5.1 Introduction and Aims 
It has been shown that ECs and mononuclear cells undergo morphological changes in 
response to inflammatory conditions which facilitate transendothelial migration of 
inflammatory cells into the tissue (Geiger and Bershadsky, 2002; Barrierro and Sanchez-
Madrid, 2009; Whittall et al., 2013).  Leukocytes are activated by contact with the EC 
luminal surface bound chemokines and integrins and their ligands enable leukocyte arrest 
in normal blood flow conditions (Tarrent and Patel, 2006; Barreiero and Sanchez-Madrid, 
2009). Once firmly adhered the leukocytes change morphology from round to ‘polarised’ 
whereby a greater proportion of their surface area is in contact with the EC surface 
(Barreiero and Sanchez-Madrid, 2009). Prior to transmigration across the post capillary 
ECs leukocytes ‘crawl’ (mediated by chemokines) on the luminal EC surface in a MAC-1 
and ICAM-1 dependent manner (Ley et al., 2007) actively seeking out a suitable 
transmigration site. Additional evidence from Middleton et al., (1997) using CXCL8 (IL-8) 
injections into rabbit skin showed that the chemokine was not only internalised 
abluminally into caveolae by postcapillary and small vein ECs but was also transcytosed 
and presented on the EC luminal surface, predominantly in association with EC microvilli.   
As well as the chemokines and chemokine receptors, adhesion molecules such as the 
selectins, integrins and VCAM are present at the EC surface. Each of these can be 
localised on microvilli projections of the  leukocytes and ECs, and a range of work 
indicating the importance of microvilli localised adhesion molecule distribution in 
leukocyte migration has been carried out (reviewed by Middleton et al., 2002).   
As well as microvilli providing a greater surface area allowing the presentation of more 
chemokines and receptors, they have been seen to elongate mediated by specific molecules 
such as ICAM-1. This was observed by Oh et al., (2007) where ICAM was seen to regulate 
de novo microvilli elongation allowing its clustering at the most apical region of the EC.  
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The hypothesis from this evidence is that ECs and/or monocuclear cells, in the presence of 
CCL7, CCL14, CCL16 and CCL22, will increase their generation of microvilli or other 
microstructures such as podosomes and filopodia. Leukocyte podosomes palpate the EC 
surface and facilitate transcellular-migration by identifying sites of low EC resistance 
where an invasive podosome (of >1000nm) can begin penetration (Vijayakumar et al., 
2015; Carmen and Spinger, 2008; Wittchen, 2009; reviewed by Carmen et al., 2007). 
Filopodia are generated by ‘activated’ ECs such as those undergoing angiogenesis 
(Jakobsson et al., 2010). Furthermore ‘filopodia-like’ protrusions are generated by cerebral 
ECs, which ‘engulf’ mononuclear cells before forming pores through which the 
mononuclear cells migrate (Wolburg et al., 2004).  
It is further hypothesised that greater numbers of firmly adhered/polarised or actively 
migrating mononuclear cells may be observed following addition of CCL7, CCL14, 
CCL16 and CCL22 These effects on EC microstructures would initially enable better 
presentation of the chemokines to mononuclear cells, followed by crawling and firm 
adhesion of mononuclear cells to the EC surface, which would in turn better enable 
transendothelial migration. As inflammatory chemokine production can be induced in 
response to stimulation by TNF-α (Haringman et al., 2004), it was necessary to reduce the 
likelihood of increased microvilli generation by ECs being due to the generation of 
endogenous chemokines in the presence of TNF-α rather than the chemokine under 
investigation. This was achieved by performing the experiments in the presence of TNF-α 
and the chemokine rather than with the TNF-α or the chemokine alone. This negates 
effects on the results due to endogenous chemokine generation and allows more robust 
comparisons between the presence and absence of each of the chemokines under 
investigation. By performing the experiments in co-culture rather than monoculture the cell 
to cell interactions more closely resemble those found in vivo.  
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The aims were to: 
 Activate HBMEC monolayers using TNF-α and perform transendothelial migration 
assays in the presence and absence of CCL7, CCL14, CCL16 and CCL22 to 
establish if structural changes occur to the mononuclear cells and/or ECs.  
 Differentiate between the structural changes to establish if specific microstructures 
(for example microvilli and podosomes) are preferentially induced on ECs or 
mononuclear cells to assess which stage in transmigration the chemokine may be 
functional. 
 
5.2 Materials and Methods 
HBMECs were cultured to approximately 80% confluency on 5μm hanging filters in 
transwells and then activated for 16 hours using 100ng/ml TNF-α. For further details see 
chapter 2 section 2.4.  Mononuclear cells were isolated as described in section 2.5.1.1 and 
used immediately. Transmigration was carried out as described in section 2.5.2.  
Preparation for electron microscopy was carried out as in section 2.5.3.  Experiments were 
performed in triplicate and specific n numbers for images provided are given below tables. 
The transmission electron microscope images for each data set were scored as positive for 
the microstructure under investigation (N1) and negative for the microstructure under 
investigation (N2). 
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5.2.1 Quantitation of results 
Statistical analysis was performed using NCSS (NCSS, Kaysville, UT, USA) software. 
Mononuclear cells and ECs were scored as being microstructure positive (N1) or 
microstructure negative (N2) and two proportion tests were performed to calculate the odds 
ratio (OR) for microstructure generation being due to the presence of the chemokine rather 
than the TNF- alone. The confidence interval for the OR was also calculated. Further 
calculations were carried out to assess podosomes, filopodia, cells in the process of 
migrating, and firmly adhered cells. Fisher’s exact test was also utilised to give P values 
throughout.  
For measurements of microstructures the nm per mm of scale bar from the original images 
were calculated for each image and the microstructure length and width was calculated 
using Adobe Illustrator (Adobe Systems Software, Ireland, UK).  
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5.3 Results 
5.3.1 Transmission electron micrograph description. 
5.3.1.1 Microstructures on mononuclear cells and HBMECs. 
The mononuclear cells were seen to have numerous finger like projections (MCPs), or 
microvilli, continuous with the cell membrane ranging from 200nm in length and 50nm 
wide (see figure 5.1) to 7500nm in length and 330nm wide (figure 5.2). 
Podosomes were also seen to be generated by the mononuclear cells and to be penetrating 
the EC membrane. The usual size range was up to 660nm long and 2660nm in width 
(figure 5.2) and from 880nm in length and 440nm wide at their widest (figure 5.3). The 
very wide but shorter podosomes appeared to be associated with transcellular migration 
and appeared ‘foot’ like in structure having a flattened base (penetrating end) that appeared 
to be extending laterally through the EC once it had penetrated by approximately 50% 
through the EC.  The longest podosome observed was 1765nm in length but only 529nm at 
the widest point, narrowing to 60nm wide at their leading edge (figure 5.4) and had 
penetrated most of the way through the EC.  
Filopodia protruded from the EC apical surface then extended laterally across the surface 
of the cell, and over the adjacent cell surface (figure 5.5). These reached 12,727nm in 
length and were 226nm wide. Endothelial cell microvilli like projections were seen to 
protrude from the apical EC surface and extend into the medium which contained the 
mononuclear cells. These projections were 266nm long and 200nm wide (figure 5.6). In 
the absence of the chemokine the EC surface was primarily smooth and lacked microvilli 
(figure 5.7). 
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5.3.1.2 Interactions between mononuclear cells and ECs 
Mononuclear cell microvilli and endothelial cell microvilli were seen to interact prior to 
the mononuclear cell becoming adhered to the ECs. In these early interactions the 
endothelial cell microvilli are seen to ‘reach’ towards the mononuclear cell microvilli (or 
vice-versa, as seen in figure 5.6, 5.9 and 5.10). Mononuclear cell microvilli were also seen 
to be in direct contact with the EC surface prior to adherence (figure 5.6).  
 
For statistical analysis mononuclear cells were not categorised as being firmly adhered to 
the ECs unless the length of mononuclear cell membrane equivalent to approximately 1/3 
its overall length was flattened to, and thus in direct contact with, the EC surface (figures 
5.2, 5.3 and 5.4). The presence of podosomes at these junctions was also regarded as being 
evidence of firm adherence. 
 
Mononuclear cells were defined as migrating only if they were in the process of moving 
through a single EC or between adjacent ECs and/or had podosomes. 
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Figure 5.1 TNF-α stimulated HBMEC’s (EC) grown on a 5μm transwell filter (F) in 
close association with mononuclear cell (MC) in the absence of chemokine. An 
example of a mononuclear cell microvillus like projection of 200nm length and 50nm 
width is indicated (MCP). 
 
 
 
 
Figure 5.2  Mononuclear cell (MC) with long (7500nm long) microvillus (MCP) like 
projection. A wide (>2660nm) podosome like structures (P) in the process of migration in 
the presence of CCL22 and TNF-α. 
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Figure 5.3 Mononuclear cell (MC) seen in the polarised conformation with podosome 
like microstructures (P) (880nm length) protruding into the EC in the process of migrating 
through a HBMEC in the presence of  CCL14 and TNF-α.  
 
 
 
Figure 5.4  Mononuclear cell (MC) in the process of migrating through HBMEC 
monolayer (EC).  A podosome like structure (1765nm length) is indicated (P). Performed 
in the presence of  CCL7 and TNF-α.  
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Figure 5.5 Mononuclear cell (MC) in close association with an EC with a filopodia like 
microstructure (FP) (12,727nm length, measured from A-B) in the presence CCL16 and 
TNF-α. F = filter. 
 
 
Figure 5.6 Mononuclear cell (MC) with microvilli like projections (MCP) in close 
association with microvilli like structures of endothelial cells (ECP) in the presence of 
CCL22  and TNF-α.  ECP and MCP appear to be ‘reaching’ towards each other in lower 
left of micrograph. 
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Figure 5.7 TNF-α stimulated HBMEC’s (EC) grown on a 5μm transwell filter (F) 
showing lack of microstructure formation. Chemokine absent. 
 
 
 
 
Figure 5.8 Mononuclear cell (MC) with podosome like microstructures (P). 
Microstructures are seen protruding into an EC in the process of migrating through an 
HBMEC monolayer in response to CCL16 and TNF-α. 
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Figure 5.9 A mononuclear cell (MC) near HBMEC’s where CCL14 was added to the 
basal transwell filter compartment for 30 minutes.  Both endothelial and mononuclear 
cell microvilli are seen (MCP and ECP) in the presence of CCL14 and TNF-α. 
 
 
Figure 5.10 A mononuclear cell (MC) in association with HBMEC’s where CCL7 was 
added to the basal transwell filter compartment for 30 minutes.  A mononuclear cell 
with numerous microvilli like protrusions (MCP) in early association with an endothelial 
cell which is also showing microvilli like protrusions (ECP) in the presence of  CCL7 and 
TNF-α. 
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5.3.2 Microvilli generation on mononuclear cells in response to chemokines. 
A number of chemokines had an effect on generation of microvilli like microstructures on 
mononuclear cells. The OR and Fishers Exact test results indicated that both CCL14 and 
CCL22 had a significant effect on the generation of the microvilli on mononuclear cells 
placed over TNF- stimulated HBMECs (table 5.1). CCL14 appeared to have the greatest 
effect. CCL16 showed a non-significant trend towards an increase in microvilli production. 
CCL7 did not reach significance. 
 
5.3.3 Microvilli generation on HBMECs. 
A number of chemokines had an effect on generation of microvilli like microstructures. 
The OR for CCL16 and CCL22 showed a significant effect on the generation of microvilli 
on HBMECs stimulated with TNF- (table 5.2). The OR and Fisher’s exact test also 
indicated a strong positive trend for microstructure generation in the presence of CCL7 and 
CCL14 with TNF- compared to TNF- alone (table 5.2) although the results did not quite 
reach significance (p = 0.057 and 0.054) 
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Table 5.1 Microvilli generation on mononuclear cells in the presence of TNF-  
stimulated HBMECs with and without chemokines  
Chemokine 
Figure 
reference 
Chemokine 
treated 
N1:N2 
Control 
N1:N2 
OR 
(95% CI) 
Fisher's Exact 
Test (p value) 
CCL7 5.10 18:8 5:6 
2.57 
 (0.06 – 1.95) 
p = 0.26 
CCL14 5.9 22:0 5:6 
53.18  
(3.30 – 263.80) 
P = 0.0004 
CCL16 5.8 9:1 5:6 
7.48  
(0.78 – 319.51) 
p  = 0.070 
CCL22 5.6 17:2 5:6 
8.27  
(1.20 – 109.09) 
 p = 0.014 
 
Chemokine treated - mononuclear cells incubated with HBMECs which were TNF- 
stimulated and had the chemokine placed in the lower transwell chamber for 30 minutes to 
allow time for the chemokine to be presented by the ECs prior to addition of the 
mononuclear cells. N1 = number of mononuclear cells with microstructures; N2 = number 
of mononuclear cells without microstructures. Control – mononuclear cells incubated with 
HBMECs cultured in the absence of chemokine but stimulated with 100ng/ml TNF-.  OR 
= odds ratio.  CI - confidence interval. For Fisher’s exact test P<0.05 is significant. For 
each chemokine overall n=3. For CCL7, CCL14, CCL16 and CCL22,  26, 22, 10 and 19 
individual images were produced and analysed respectively. The control experiments 
produced 11 images for analysis. 
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Table 5.2 Microvilli generation on HBMECs in response to TNF- stimulation in the 
presence of chemokines.  
Chemokine 
Figure 
reference 
Chemokine 
treated 
N1:N2 
Control 
N1:N2 
OR 
(95% CI) 
Fisher's Exact 
Test (p value) 
CCL7 5.10 12:14 1:10 
6.03 
(0.86 – 205.86) 
p = 0.057 
CCL14 5.9 10:12 1:10 
5.90 
(0.9 – 205.31) 
p = 0.054 
CCL16 5.5 7:3 1:10 
15.00 
 (1.52 – 787.30) 
p = 0.007 
CCL22 5.6 10:9 1:10 
7.74 
(1.03 –281.39) 
p = 0.023 
 
Chemokine treated - HBMECs which were TNF- stimulated and had the chemokine 
placed in the lower transwell chamber for 30 minutes to allow time for the chemokine to be 
presented by the ECs prior to addition of the mononuclear cells. N1 = number of HBMECs 
with microstructures; N2 = number of HBMECs without microstructures. Control cells – 
HBMECs which were cultured in the absence of chemokine but stimulated with 100ng/ml 
TNF-. OR - odds ratio. CI - confidence interval. For Fisher’s exact test P<0.05 is 
significant. For each chemokine overall n=3. For CCL7, CCL14, CCL16 and CCL22,  26, 
22, 10 and 19 individual images were produced and analysed respectively. The control 
experiments produced 11 images for analysis. 
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5.3.4 Filopodia generation on TNF- stimulated HBMECs in the presence of 
chemokine. 
There was a non-significant positive trend in the generation of filopodia by HBMECs in 
the presence of each chemokine as indicated by the OR in table 5.4 (see figure 5.5 for 
filopodia image).  The low number of micrographs showing sufficient EC surface area 
available for analysis of filopodia is likely to have affected the resulting data. Further 
analysis of micrographs taken at lower magnification may provide more adequate results 
for statistical analysis of filopodia generation. 
 
5.3.5 Podosome generation, migration and adherence of mononuclear cells. 
The number of mononuclear cells firmly adhered to HBMECs in the presence of CCL16 
showed a highly positive trend for mononuclear cell adherence with an OR of 6.59 (CI 
0.93-87.12) supported by a significant Fisher’s exact test giving p=0.039 (table 5.3). OR 
for all other results indicated a positive trend for the generation of podosomes (figures 5.2, 
5.4 and 5.8, table 5.3), cells actively migrating and cells firmly adhered, although these 
were not significant (table 5.3).   
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Table 5.3 Data for podosome-like structure generation of mononuclear cells, 
mononuclear cells actively migrating and mononuclear cells adhered to HBMECs 
treated with TNF- alone, and in the presence of chemokines.  
Chemokine 
Structure or 
activity 
Chemokine 
treated 
N1:N2 
Control 
N1:N2 
OR 
(95% CI) 
Fisher's 
Exact Test  
(p  value) 
CCL7 
Podosomes 1:25 2:9 
0.22 
(0.01 – 3.06) 
p = 0.978 
Migrating 4:22 1:10 
1.40 
(0.14 - 48.56) 
p = 0.528 
Adhered 12:14 3:8 
2.26 
(0.44 – 15.16) 
p = 0.207 
CCL14 
Podosomes 4:18 2:9 
0.92 
(0.11 – 9.81) 
p = 0.692 
Migrating 5:17 1:10 
2.20 
(0.25 - 76.63) 
p = 0.328 
Adhered 10:12 3:8 
2.04  
(0.37 – 14.40) 
p = 0.267 
CCL16 
Podosomes 2:8 2:9 
1.12 
 (0.08– 15.47) 
p = 0.669 
Migrating 2:8 1:10 
2.05 
(0.13 - 85.48) 
p = 0.462 
Adhered 9:3 3:8 
6.59  
(0.93 – 87.12) 
p = 0.039 
CCL22 
Podosomes 5:14 2:9 
1.44 
(0.20 – 15.32) 
p = 0.485 
Migrating 7:12 1:10 
4.20 
(0.52 - 148.8)  
p = 0.107 
Adhered 9:10 3:8 
2.19 
(0.38 – 16.31) 
p = 0.442 
 
Chemokine treated - mononuclear cells incubated with HBMECs which were TNF- 
stimulated and had the chemokine placed in the lower transwell chamber for 30 minutes to 
allow time for the chemokine to be presented by the ECs prior to addition of the 
mononuclear cells. N1 = number of mononuclear cells with microstructures; N2 = number 
of mononuclear cells without microstructures. Control – mononuclear cells incubated with 
HBMECs cultured in the absence of chemokine but stimulated with 100ng/ml TNF-.  OR 
- odds ratio.  CI - confidence interval. For Fisher’s exact test P<0.05 is significant. For 
each chemokine overall n=3. For CCL7, CCL14, CCL16 and CCL22, 26, 22, 10 and 19 
individual images were produced and analysed respectively. The control experiments 
produced 11 images for analysis. 
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Table 5.4. The generation of filopodia like structures on HBMECs in response to 
TNF- stimulation in the presence of chemokines.  
Chemokine 
Chemokine 
treated 
N1:N2 
Control 
N1:N2 
OR 
(95% CI) 
Fisher's Exact 
Test (p value) 
CCL7 6:20 1:10 
2.22 
(0.27 - 75.53) 
p = 0.309 
CCL14 7:15 1:10 
3.38 
(0.43 - 117.15) 
p = 0.158 
CCL16 3:7 1:10 
3.26 
(0.27 - 133.78) 
p = 0.255 
CCL22 7:12 1:10 
4.20 
(0.53  - 148.83) 
p = 0.199 
 
Chemokine treated - HBMECs which were TNF- stimulated and had the chemokine 
placed in the lower transwell chamber for 30 minutes to allow time for the chemokine to be 
presented by the ECs prior to addition of the mononuclear cells. N1 = number of HBMECs 
with microstructures; N2 = number of HBMECs without microstructures. Control cells – 
HBMECs which were cultured in the absence of chemokine but stimulated with 100ng/ml 
TNF-. OR - odds ratio. CI - confidence interval. For Fisher’s exact test P<0.05 is 
significant. For each chemokine overall n=3. For CCL7, CCL14, CCL16 and CCL22, 26, 
22, 10 and 19 individual images were produced and analysed respectively. The control 
experiments produced 11 images for analysis. 
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5.4 Discussion 
Middleton et al., (1997) and  Pruenster et al.,(2009) suggested that membrane bound 
chemokines acted as facilitators for effective leukocyte transmigration from circulating 
blood and showed that transcytosed chemokines were presented on EC microvilli.  
Chemokines in association with EC microvilli, bound via glycosaminoglycans, generate 
signals via the G protein coupled receptors on leukocytes causing integrin conformational 
changes contributing to leukocyte activation and arrest (Barrierro and Sanchez-Madrid, 
2009). Activated leukocytes have been shown to change morphology from round to 
‘polarised’ which allows the intracellular coordination required for crawling and eventual 
transmigration (Geiger and Bershadsky, 2002). 
This study has provided novel data to the field by showing that morphological changes 
occur in the presence of CCL7 (which generated a positive trend response), and in the 
presence of CCL14, CCL16 and CCL22 (which generated a significant response). These 
morphological changes are conducive to transmigration, including the formation of 
leukocyte and/or EC microvilli which indicates that these chemokines have a functional 
role in mononuclear cell migration into the synovium. A number of leukocytes were also 
observed to be in the ‘polarised’ state. Mononuclear cells were observed to interact with 
EC microvilli and filopodia like projections.  Carmen et al., 2007; Carmen and Spinger, 
2008 and Wittchen, 2009 showed that podosome formation is also indicative of 
transmigration. The podosome palpation of the EC surface identifies suitable migration 
sites and forces a ‘podo-print’ into the membrane prior to pore formation. While podosome 
generation in the presence of the chemokines was not seen to reach significance compared 
to the absence of chemokine their generation was observed to be increased.  
A range of chemokine receptors and adhesion molecules such as L-selectin, P-selectin, 
PGSL-1 and integrins have been shown to be distributed on leukocyte microvilli where 
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they facilitate early leukocyte to EC interactions (reviewed by Middleton et al., 2002) 
important in transmigration. This study is the first to quantify microvilli formation on 
mononuclear cells due to the presence of chemokines CCL7, CCL14, CCL16 and CCL22.  
In this study it was shown that CCL14 generated microvilli on mononuclear cells to the 
greatest degree with CCL22 also having a significant, but lesser effect. CCL16 generated a 
positive trend in microvilli formation and CCL7 had little effect on mononuclear cell 
microvilli generation. CCL16 and CCL22 had significant positive effects on HBMEC 
microvilli formation with CCL16 having the greatest effect. Both CCL7 and CCL14 
generated a strong positive trend in HBMEC microvilli formation which fell just short of 
being statistically significant.  Therefore, overall CCL14 was the most effective at 
generating microvilli on mononuclear cells and CCL16 was the most effective at 
generating them on ECs. 
It has been shown by Brown et al., (2003) that CXCL12 caused lymphocyte microvilli 
retraction during firm adherence allowing for the conformation to change to a polarised 
state, further facilitating transmigration. While this study did not find significant increases 
in adherence in the presence of the chemokine, sampling problems may have affected the 
data gathering. These problems were low numbers of micrographs showing leukocyte 
adherence. Thus, increasing the n number and the number of micrographs available for 
analysis would benefit the study and help confirm these results. CCL16 did increase 
adherence in the present experiments. 
It is known that TNF- induces the production of a range of chemokines, including 
CXCL8 and CCL5, and also induces the upregulation of other adhesion factors on ECs 
(Zhao et al., 2005; Szekanecz and Koch, 2008). Further to this Whittall et al., (2013) 
showed that CXCL8 increased EC microvilli and filopodia formation. This study extends 
current knowledge in this field by showing significant increases in microvilli formation of 
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ECs in the presence of chemokines CCL14, CCL16, CCL22 and TNF-, compared to the 
presence of TNF- alone. Whilst this indicates that  the increases may be due to the 
chemokine alone, the study would have been improved by repetition of the work in the 
absence of TNF- but in the presence of the chemokine alone, to assess possible 
synergistic effects between the chemokine and TNF-α which affected the cell-cell 
interactions 
 
By performing the experiments in co-culture rather than monoculture the potential 
synergistic effects between each cell type were not removed from the experimental 
environment. This allowed for the ‘normal’ generation of a range of factors such as 
adhesion molecules vital to transmigration and for cell-cell interactions to more closely 
resemble those seen in vivo .  
 
In conclusion 
The first aim of this section of the study was to establish if structural changes occur to the 
mononuclear cells and/or ECs associated with transmigration mechanisms. The data show 
that each of the chemokines have the ability to generate structural changes on both ECs 
and mononuclear cells to differing degrees 
The second aim of this section was to differentiate between structural changes to establish 
if specific microstructures are preferentially induced on ECs or mononuclear cells to assess 
which stage in transmigration the chemokine may be functional. The data show that 
CCL14 preferentially generates microvilli formation on mononuclear cells and CCL16 
preferentially generating microvilli formation on ECs. No significant differences could be 
ascertained for the generation of podosomes, filopodia or the numbers of firmly 
adhered/migrating cells. This suggests that these chemokines  are involved in the activation 
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of cells prior to firm adherence, however the sampling problem may have negatively 
affected the data and so this finding should be interpreted with caution until such time as 
further work has been performed to quantify it. 
These findings provide novel evidence of differential activation of ECs and mononuclear 
cells by these chemokines in an inflammatory environment. Furthermore, it indicates a 
direct link between the presence of these chemokines and increases in structural changes 
which may be mechanistic in transmigration.  
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6.1 Introduction and aims 
As discussed in 1.8.2 there are currently 19 identified chemokine receptors (Bonecchi et 
al., 2009; Bachelerie et al., 2014), many of which bind multiple ligands and are expressed 
on a range of leukocyte cell types.  CCL7 is the ligand for CCR1, 2 and 3; CCL14 is the 
ligand for CCR1 and CCR5; CCL16 is the ligand for CCR1 and CCR2 and CCL22 is the 
ligand for CCR4 and CCR8 (Filer et al., 2008; Bonecchi et al., 2009).  As the beta 
chemokines’ major targets are monocytes and lymphocytes the hypothesis for this section 
of the study was that each of the chemokines of interest will generate increases in the 
transmigration of mononuclear cells across activated HBMEC monolayers. Elucidation of 
the degree to which transmigration is affected, and the chemokine receptor via which the 
chemokine may be functional, would identify new potential therapeutic targets. 
Previously discussed in chapters 1 and 3 are the increases in production of a range of 
chemokines including CCL2, CCL5 and CCL20 at blood vessel ECs. In a normal model of 
inflammation Johnson et al., (2006) showed that TNF-α activated dermal lymphatic 
endothelial cells (DLECs) show >100 fold increases in CCL2, CCL5 and CCL20. This 
indicates that in inflammatory conditions lymphatic vessels would be required to 
upregulate the expression of chemokines chemoactive for the effective removal of the 
leukocytes in the synovium. Burman et al., (2005) provided evidence of chemokine 
gradient corruption within the RA synovium and data from chapter 3 showed CCL7 to be 
markedly decreased on the LECs of RA sufferers while a number of other chemokines 
were markedly increased on blood vessel ECs. The second hypothesis is that this reduction 
in CCL7 at RA lymphatic ECs leads to inflammatory cell persistence within the synovium.  
In order to substantiate this hypothesis it was important to perform transmigration 
experiments in response to chemokines across both HBMECs, which provide a model for 
the migration of leukocytes across human vascular ECs into the synovium, and HDLECS 
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(in the case of CCL7) as they act as a model for the migration of leukocytes from the 
synovium, into the lymphatic system (as discussed in chapter 4). 
 
The aims of this chapter were to: 
 Isolate CD3+, CD14+ and CD20+ leukocyte populations and investigate the 
presence of chemokine receptors CCR1 (the receptor for CCL7 and CCL14), CCR2 
(the receptor for CCL7 and CCL16), CCR4 (the receptor for CCL22), and CCR5 
(the receptor for CCL14 and CCL16) in both RA and non-RA blood to determine if 
the receptors are expressed, and via which receptor(s) CCL7, CCL14, CCL16 and 
CCL22 may be functional in RA. 
 
 Determine the functionality of CCL7, CCL14, CCL16 and CCL22 in the 
transmigration of mononuclear cells across vascular HBMECs. 
 
 Determine the functionality of CCL7 in the transmigration of monocytes,   B-cells 
and T-cells from RA blood across HDLECs in inflammatory conditions to establish 
if CCL7 downregulation on lymphatic ECs in RA may lead to reduced 
transmigration of mononuclear cells from the synovium and so result in 
mononuclear cell persistence within the synovial tissue. 
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6.2 Materials and Methods 
Mononuclear cells were separated from whole blood of RA sufferers and normal controls 
as described in chapter 2, section 2.5.1.1. 
CCR and CD marker staining of mononuclear cells was carried out as described in chapter 
2, section 2.6.3.1 and 2.6.3.2. Transmigration was carried out as described in section 2.4. 
All migrations were carried out 37C for 1 hour. Flow cytometry was carried out on a 
Becton Dickinson FACscan flow cytometer (FACs) 
 
6.2.1 Quantitation of results 
Statistical analysis was performed using GraphPad. Normality checks were performed for 
each dataset which showed normal distribution for CD marker staining. Therefore unpaired 
T-test was utilised for CD analysis. Where normality tests showed non-normal distribution 
non-parametric analysis was utilised, thus Mann-Whitney U test was used for CCR 
analysis. RA n=3 and non-RA n=3. Kruskal-Wallis one-way ANOVA on ranks was used 
for statistical analysis of transmigration data (significant result at p =<0.05) followed by 
Dunn’s post hoc test. Details of the precise analysis method are reiterated at the start of 
each section. 
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6.3 Results 
6.3.1 CD and CCR analysis. 
6.3.1.1 Establishing T-cell, B-cell and monocyte populations by flow cytometry.       
Forward and side scatter was used to differentiate between the monocyte and lymphocyte 
populations of RA and non-RA PBMCs (figure 6.1).  The percentage of CD3+ (T cells), 
CD14+ (monocytes) and CD20+ (B cells) cells (section 6.4) was determined as was the 
percentage of CCR+, CCR2+, CCR4+ and CCR5+ cells for each population (section 6.5). 
The mean fluorescent intensity (MFI), which shows the cell surface expression of each 
marker, for CCR1, CCR2, CCR4 and CCR5 for each population was also determined 
(section 6.5) 
 
Figure 6.1 Sample dot plot showing forward scatter (FSC) versus side scatter (SSC) 
for freshly isolated RA mononuclear cells. FSC depicts relative size of cell; SSC depicts 
relative granularity/density of the cell. These enable the differentiation of different 
leukocyte populations. R1 gates the B/T cell population, R2 gates the monocyte 
population. R3 gates total population. 
 
 R3 
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6.3.1.2 Establishing the percentage of cells positive for each marker in the gated 
populations by FACs. 
To establish the percentage of positive cells the quadrant was placed at the point where 
95% of the control cells were negative leaving the 5% in the upper right quadrant positive. 
The stained cells were then superimposed on this dot plot to determine the percentage of 
positive cells (figure 6.2).  
 
  
 Figure 6.2 Sample dot plots showing FSC versus fluorescence for isotype control and 
stained cells in PBMCs.  A shows an isotype matched control dot plot. B shows the dot 
plot for stained cells from, for example, RA PBMCs, using an antibody to CCR1. 
 
 
 
 
 
 
A 
5% 
B 
65.31% 
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6.4 Results of CD3+, CD14+ and CD20+ marker staining on peripheral blood 
mononuclear cells (PBMCs). 
The pink peak shift to the right in each histogram indicates a positive result. Data are given 
as percentage population (±SD). The pink peaks within the control peak indicate a degree 
of background (non-specific) binding. Data were parametric so Student’s T-test was 
utilised for statistical analysis.  
 
6.4.1 CD3+ marker staining on RA and non-RA PBMCs. 
Some background staining was seen using anti-human CD3+ antibodies to stain 
T-cells (figure 6.3). However, a clear peak shift was still visible.  Unpaired T-test showed a 
significant difference in CD3+ cells observed in RA  (figure 6.3A) and non-RA (figure 
6.3B) PBMC populations; RA = 64.59% (±1.79), non-RA = 74.40% (±1.28), p =0.014 
(figure 6.6). 
 
6.4.2 CD14+ marker staining on RA and non-RA PBMCs  
Only small numbers of monocytes were found during FACs analysis following PBMC 
isolation, transmigration and staining. It is likely that the low volume of blood that it was 
possible to obtain from patients, followed by cell death during the staining phase of these 
experiments contributed to the low numbers. Despite the low numbers, and a degree of 
background staining, a peak shift is still clearly visible. Unpaired T-test showed no 
difference in CD14+ monocytes in RA (figure 6.4A) and non-RA (figure 6.4B) PBMC 
populations; RA 75.41% (±5.52), non-RA 81.40% (±2.18), p = 0.39 (figure 6.6). 
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6.4.3 CD20+ marker staining on RA and non-RA PBMCs  
Some background staining was seen using anti-human CD20+ antibodies to stain 
B-cells. However, a clear peak shift was still visible. Unpaired T-test showed no difference 
between CD20+ cells in RA (figure 6.5A) and non-RA (figure 6.5B) PBMC populations; 
RA 20.50% (±0.47), non-RA 16.02% (±4.08), p = 0.38 (figure 6.6). 
 
 
6.4.4 Monocyte, T-cell and B-cell expression on RA and non-RA monocytes.  
In summary, for monocytes (gated in the R2 region), T-cells and B-cells (gated in the R1 
region) in PBMCs, only the numbers of T-cells (CD3+) present showed a significant 
difference between RA and non-RA blood with 74.40% of non-RA PBMCs and 81.40%  
of  RA PBMCs staining for T cells (combined data shown in figure 6.6).  There were no 
significant differences seen in the percentage of B-cell and monocyte populations of RA 
and non-RA blood. 
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Figure 6.3 Expression of (A) CD3+ on RA blood PBMCs and (B) non-RA blood 
PBMCs. The histograms in pink show the expression of CD3+ (B/T-cell gated population, 
R1) with their isotype matched controls (blue line),  n = 3. The pink peak shift to the right 
in each histogram indicates a positive result.  
  
Figure 6.4 Expression of (A) CD14+ on RA blood PBMCs and (B) non-RA blood 
PBMCs. The histograms in pink show the expression of CD14+ (monocyte cell gated 
population, R2) with their isotype matched controls (blue line), n = 3. The pink peak shift 
to the right in each histogram indicates a positive result.  
 
 
B A 
A B 
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Figure 6.5 Expression of (A) CD20+ on RA blood PBMCs and (B) non-RA blood 
PBMCs. The histograms in pink show the expression of CD20+ (B/T-cell gated 
population) with their isotype matched controls (blue line), n = 3. The pink peak shift to 
the right in each histogram indicates a positive result.  
 
 
Figure 6.6 Chart showing percentage of CD3+, CD14+ and CD20+ positive RA and 
non-RA PBMCs. Percentage expression of PBMCs (± SD) from RA (n=3) and non-RA 
(n=3) PBMCs. Data are given as percentage population (±SD). Unpaired student’s T-test 
was utilised for statistical analysis.  * p= <0.05 
 
 
A B 
Percentage 
positive 
cells 
CD20+ CD14+ 
* 
CD3+ 
Non-RA                RA Non-RA                RA Non-RA                RA 
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6.5 Results of CCR marker staining on PBMCs 
The pink peak shift to the right in each histogram (figures 6.7-6.10) indicates a positive 
result.  MFI = mean fluorescent intensity.  Gating was performed as described in section 
6.3.1.1, figure 6.1. The percentage population positive was ascertained as described in 
section 6.3.1.2, figure 6.2. Mann-Whitney U test and Kruskal-Wallis ANOVA was utilised 
for statistical analysis as data were non-parametric.  
 
6.5.1 CCR1 expression in RA and non-RA blood 
Both lymphocytes and monocytes expressed CCR1 in RA and non-RA. Unpaired T-test 
showed no significant difference in CCR1 expression by monocytes (defined in R2) in RA 
(figure 6.7A) and non-RA (figure 6.7 B); RA 65.31% (±5.46), non-RA 65.01% (±13.65), p 
=0.98 (figure 6.11). In addition, no difference was seen in CCR1 expression in B/T-cells 
(defined in R1) in RA (figure 6.7C) and non-RA (figure 6.7D); RA 27.25% (±13.7), non-
RA 10.96% (±3.74), p =0.31 (figure 6.12).  
Whilst the percentage of monocytes expressing CCR1 showed no significant differences 
between RA and non-RA PBMCs the mean fluorescent intensity, indicating the cell 
surface expression of CCR1, was significantly increased on RA monocytes (p = <0.001) 
compared to non-RA monocytes, as shown by the Mann-Whitney U test (figure 6.13).  No 
significant differences were observed in CCR1 cell surface expression on B/T-cells (figure 
6.14). 
 
 
 
 
 
 
 
Chapter 6 
 
259 
 
6.5.2 CCR2 expression in RA and non-RA blood  
As with CCR1, both RA and non-RA monocytes and lymphocytes expressed CCR2. The 
unpaired T-test showed no difference in CCR2 expression by monocytes in RA (figure 
6.8A) and non-RA (figure 6.8B); RA 77.42% (±7.14), non-RA 85.71% (±3.01), p =0.34 
(figure 6.11).  Further to this no difference was seen in CCR2 expression by B/T-cells in 
RA (figure 6.8C) and non-RA (figure 6.8D); RA 24.74% (±8.05) non-RA 24.42% (±2.85),    
p = 0.97 (figure 6.12).  
Despite the lack of difference in the percentage population expression of CCR2, the cell 
surface expression on monocytes showed significant differences with CCR2 being 
increased on non-RA monocytes  (p =<0.001) compared to RA monocytes (figure 6.13). 
No significant differences were observed in B/T-cell surface expression of CCR2 (figure 
6.14) 
 
6.5.3 CCR4 expression in RA and non-RA blood 
CCR4 was seen to be expressed on both RA and non-RA lymphocytes and monocytes. It 
was ascertained that the difference seen in CCR4 expression by monocytes in RA (figure 
6.9A) and non-RA (figure 6.9B); RA 81.68% (±2.93), non-RA 60.20% (±21.05), p = 0.37 
was not statistically significant (figure 6.11). Whilst not reaching significance the results 
indicate a positive trend in increased CCR4 expression by RA (figure 6.9C) B/T-cells; RA 
66.69% (±12.01), non-RA (figure 6.9D) 32.38% (±6.39), p = 0.065 (figure 6.12).  
However, the MFI showed that CCR4 cell surface expression was significantly increased 
on RA monocytes (p =<0.001) compared to non-RA monocytes (figure 6.13), and also on 
RA B/T-cells (p = 0.049) (figure 6.14). 
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6.5.4  CCR5 expression in RA and non-RA PBMCs  
CCR5 was expressed by both RA and non-RA PBMCs. A statistical difference was seen in 
CCR5 expression by monocytes in RA (figure 6.10A) and non-RA (figure 6.10B); RA 
59.18% (±6.08) non-RA 91.15% (±2.95), p = 0.009 (figure 6.11). The results show a 
significant increase in CCR5 expression by B/T-cells in RA (figure 6.10C) compared to 
non-RA (figure 6.10D); RA 44.81% (±10.6) non-RA 36.01% (±5.17), p =0.049 (figure 
6.12). 
The MFI showed a significant increase in CCR5 cell surface expression on non-RA 
monocytes (p =<0.001) compared to RA monocytes (figure 6.13). No significant 
differences were observed in B/T-cell surface expression of CCR5 (figure 6.14). 
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Figure 6.7 Expression of CCR1 in RA and non-RA PBMCs  
(A)shows CCR1 on RA monocytes (B) shows CCR1 on non-RA monocytes (C) shows 
CCR1 on RA B/T-cells. (D) shows CCR1 on non-RA B/T- cells. The histograms in pink 
show the expression of CCR1 with their isotype matched controls (blue line), n = 3. The 
pink peak shift to the right in each histogram indicates a positive result.  
 
 
 
 
 
 
C D 
A B 
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Figure 6.8 Expression of CCR2 in RA and non-RA PBMCs  
(A) shows CCR2 on RA monocytes. (B) shows CCR2 on non-RA monocytes. (C) shows 
CCR2 on RA B/T-cells. D shows CCR2 on non RA B/T-cells.  The histograms in pink 
show the expression of CCR2 with their isotype matched controls (blue line), n = 3. The 
pink peak shift to the right in each histogram indicates a positive result.  
  
 
 
 
 
C 
A 
D 
B 
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 Figure 6.9 Expression of CCR4 in RA and non-RA PBMCs  
A shows CCR4 on RA monocytes, B shows CCR4 on non-RA monocytes. C shows CCR4 
on RA B/T-cells. D shows CCR4 on non-RA B/T-cells. The histograms in pink show the 
expression of CCR4 with their isotype matched controls (blue line), n = 3. The pink peak 
shift to the right in each histogram indicates a positive result.  
 
 
 
 
 
 
 
 
A B 
C D 
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 Figure 6.10 Expression of CCR5 in RA and non-RA PBMCs  
A shows CCR5 on RA monocytes. B shows CCR5 on non-RA monocytes. C shows CCR5 
on RA B/T-cells.  D shows CCR5 on non-RA B/T-cells. The histograms in pink show the 
expression of CCR5 with their isotype matched controls (blue line).  The pink peak shift to 
the right in each histogram indicates a positive result.  
 
 
 
 
 
 
 
 
C 
D 
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Figure 6.11 Chart showing percentage of CCR1, CCR2, CCR4 and CCR5 positive 
monocytes in RA and non-RA. Showing average percentage expression of monocytes (± 
SE) from RA (n=3) and non RA (n=3) monocytes.  Mann-Whitney U test was utilised, ** 
p = <0.01 
 
 
 
 
 
 
CCR1 CCR2 CCR4 CCR5 
Percentage 
positive 
cells 
** 
   RA             non-RA     RA            non-RA   RA         non-RA    RA            non-RA 
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Figure 6.12 Chart showing percentage of CCR1, CCR2, CCR4 and CCR5 positive 
B/T cells in RA and non-RA. Percentage expression of  B/T-cells (± SE) from RA (n=3) 
and non-RA(n=3) PBMCs. Mann-Whitney U test was utilised,   * p= <0.05 
 
 
 
 
 
 
 
Percentage 
positive 
cells 
CCR1  CCR2 CCR4  CCR5 
* 
   RA            non-RA    RA            non-RA    RA            non-RA    RA            non-RA 
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Figure 6.13 Box plot showing mean fluorescent intensity (MFI) of CCR1, CCR2, 
CCR4 and CCR5 on RA and non-RA monocytes. The vertical red bar indicates overall 
range, yellow box shows interquartile range with horizontal red line in yellow box showing 
median values. RA n =3, non-RA n=3. IgG controls were subtracted from the data. Mann-
Whitney U test was utilised,   *** p = <0.001. 
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Figure 6.14 Box plot showing mean fluorescent intensity (MFI) of CCR1, CCR2, 
CCR4 and CCR5 on RA and non-RA B/T-cells. The vertical red bar indicates overall 
range, yellow box shows interquartile range with horizontal red line in yellow box showing 
median values. RA n =3, non-RA n=3. IgG controls were subtracted from the data. Mann-
Whitney U test was utilised,   * p = <0.05 
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6.6 PBMC migrations across HBMEC’s 
Having found expression of the receptors for the chemokines of interest it was decided to 
assess the functionality of each chemokine with HBMECs using non-RA blood PBMCs 
which were more readily available at the time.  Following these tests it was decided to test 
the functionality of CCL7 for migration across HDLECs using RA blood as a better 
example of the total inflammatory environment to test potential lymphatic clearance in RA,  
and due to the significant increases in the CCL7 receptors CCR1 and CCR4 seen in RA 
blood monocytes (figure 6.13). As CCL7 was the only chemokine to show a significant 
decrease on RA LECs it was decided to only assess CCL7 chemokine in this way due to 
time constraints. Kruskal-Wallis ANOVA was used for statistical analysis as data were 
non-parametric. 
 
6.6.1 Mononuclear cell migration across TNF- activated HBMECs. 
A comparison was made between the different chemokines for monocyte migration (figure 
6.15) and B/T-cell migration (figure 6.16).  
Kruskal-Wallis ANOVA test showed an overall significant difference in monocyte 
migration in the presence of 100ng/ml chemokine (p =0.002). When data were compared 
using Dunn’s post hoc test it was shown that CCL7 gave the greatest response for 
monocyte migration (p = 0.0045) followed by the positive control CCL2 (p = 0.014), 
CCL14 (P =0.026) and CCL22 (p =0.026) when compared to the 0 ng/ml chemokine 
control.  Statistical analysis for CCL16 did not reach significance (figure 6.15).  
 Kruskal-Wallis one-way ANOVA on ranks showed no overall significant difference in 
B/T cell migration (figure 6.16) in the presence of 100ng/ml chemokine (p = 0.28).  
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Figure 6.15 Box plot showing numbers of monocytes migrated in response to 
100ng/ml chemokine across TNF- activated HBMECs. Negative control (neg) was 
performed in the presence of TNF-α and the absence of chemokine. Positive control 
(CCL2) was performed in the presence of TNF-α and 100ng/ml CCL2. The vertical red bar 
indicates overall range, yellow box shows interquartile range with horizontal red line in 
yellow box showing median, and the outlier values are shown in green (n = 3). Kruskal-
Wallis ANOVA was used followed by the Wilcoxon signed-rank test * p = <0.05,     ** p 
= <0.01, *** p = <0.001. 
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Figure 6.16 Box plot showing numbers of B/T-cells migrated in response to 100ng/ml 
chemokine across TNF- activated HBMECs. Negative control (neg) was performed in 
the absence of chemokine. Positive control (CCL5) was performed in the presence of  
TNF-α and CCL5. The vertical red bar indicates overall range, yellow box shows 
interquartile range with horizontal red line in yellow box showing median, and the outlier 
values are shown in green (n = 3). Kruskal-Wallis ANOVA was used followed by the 
Wilcoxon signed-rank test. 
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6.7 CCL7 HDLEC dose response. 
In section 3.3.1.7 it was shown that there was a significant reduction in the percentage of 
LEC’s stained for CCL7 in RA synovium (p = 0.011). TNF-α/IFN-γ was used to activate 
the cells as this was shown to generate the greatest ICAM increase in HDLECs (section 
4.5). 
In this section of the study when HDLECs were incubated with increasing concentrations 
of CCL7 in transwells significant increases in RA monocyte migration were observed. 
Kruskal-Wallis one way ANOVA on ranks showed a significant difference in monocyte 
migration in response to CCL7 (p = 0.002) The Mann-Whitney U test was also performed 
and showed the greatest increase to be at 250ng/ml CCL7 (p = 0.013) with a significant 
increase in monocyte migration also seen at 100ng/ml CCL7 (p = 0.037) compared to 
0ng/ml (see figure 6.17). 
In the same conditions increases in B/T-cell migration which peaked at 10ng/ml were 
observed. Kruskal-Wallis one way ANOVA on ranks showed no significant differences 
when compared to 0ng/ml, however a significant difference in B/T cell migration in 
response to CCL7 (p = 0.030) compared to the negative control was observed using the 
Mann-Whitney U test (figure 6.18).   
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Figure 6.17 Box plot showing numbers of monocytes migrated in response to CCL7 
through TNF-/IFN- activated HDLECs. Negative control (neg) was performed in the 
absence of TNF-α/IFN-γ and CCL7. Positive control (CCL2) was performed in the 
presence of TNF-α/IFN-γ and 100ng/ml CCL2. The vertical red bar indicates overall 
range, yellow box shows interquartile range with horizontal red line in yellow box showing 
median (n = 3).  Kruskal-Wallis ANOVA was used followed by the Wilcoxon signed-rank 
test  * p = <0.05 compared to 0ng/ml CCL7. 
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Figure 6.18 Box plot showing numbers of B/T-cells migrated in response to CCL7 
across TNF-/IFN- activated HDLECs. Negative control (neg) was performed in the 
absence of TNF-α/IFN-γ and CCL7. 0ng/ml was performed in the presence of TNF-α/IFN-
γ. Positive control (pos) was performed in the presence of TNF-α/IFN-γ and 100ng/ml 
CCL5. The vertical red bar indicates overall range, yellow box shows interquartile range 
with horizontal red line in yellow box showing median, and the outlier values are shown in 
green. Kruskal-Wallis ANOVA was used followed by the Wilcoxon signed-rank test * p 
=<0.05 compared to negative control. 
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6.8 Discussion 
Monocytes differentiate into macrophages, which in the normal intima are a minority cell 
type. However, they have been shown to increase to up to 80% of the intimal cell 
population  in RA (Bartholome et al., 2004). Macrophages express a range of chemokines, 
cytokines, chemokine receptors, and secrete a range of cytokines, chemokines, growth 
factors, proteases and further mediators (reviewed by Szekanecz and Koch, 2007). 
 In this study transmigration analysis of non-RA mononuclear cells across TNF- 
stimulated HBMECs in response to CCL7, CCL14 and CCL22 indicated that whilst each 
have a positive effect on monocyte migration the greatest effect was seen to be in response 
to CCL7. However, the similar degrees to which CCL7 were identified on both RA and 
non-RA ECs (as shown in chapter 3) indicates that synovial infiltration via CCL7 is most 
likely not primarily responsible in driving the pathology of RA. This is the first study to 
show the significant increase in the cell surface expression of CCR1 in RA monocytes  and 
indicate that CCR1 is the preferential receptor through which CCL7 functions in RA.  
CCR1 and CCR5 are known CCL14 receptors. The high expression of CCR1 by RA 
monocytes and the significant increases in the percentage of B/T-cells expressing CCR5 in 
non-RA in this study indicate that monocyte recruitment most likely occurs via CCR1. 
However, the lack of significant response by B/T-cells to CCL14 indicates that B/T-cells 
migrating via CCL14 are not of great significance to RA pathology.  
Increases in the numbers of monocytes migrating, such as seen in this study with CCL22, 
suggest that CCL22 may be functional in monocyte migration in RA, and hence the 
presence of large numbers of macrophages in the synovium. Furthermore, CCR4 (the 
receptor for CCL22), was significantly increased in RA; specifically in RA monocytes. 
This indicates that CCL22 may be important in driving monocyte migration in RA.  
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In RA, monocytes also differentiate into osteoclasts via signals from activated T-cells and 
synovial fibroblast-like cells. Osteoclasts are essential for bone remodelling throughout life 
as the primary bone resorbing cells, enabling remodelling and old age bone loss (Schett, 
2007 and references therein).  It is possible that the increases in monocyte recruitment seen 
in the current study due to CCL7, CCL14 and CCL22 may be exacerbating the generation 
of osteoclasts, which have been shown to be abundant in the RA synovial membrane 
(Schett, 2007 and references therein) and hence increasing bone loss in RA. Further work 
to substantiate this hypothesis is required, 
 No significant effects on monocyte migration or B/T-cell migration in response to CCL16, 
and no significant B/T-cell migration in response to CCL7, CCL14 or CCL16 were 
observed in the same conditions.  
Whilst not reaching significance when compared to 0ng/ml where TNF-α was present, 
CCL7 generated a positive trend in T-cell migration at 10ng/ml. This trend declined after 
this point and it is possible that the T-cell receptors became saturated and desensitised at 
this point resulting in the decline in migratory response. The transmigration analysis of RA 
monocytes across TNF-/IFN- stimulated HDLECs in response to CCL7 showed 
significant increases at 100ng/ml and 250ng/ml CCL7 when compared to 0ng/ml 
The data presented here have shown higher numbers of T-cells (CD3+) and monocytes 
(CD14+) in the PBMCs of both RA sufferers and normal control blood, compared with B-
cells (CD20+) in both populations, but proportionally similar values to Eggleton et al., 
(2011). 
However, the results show that non-RA PBMCs have more T-cells (CD3+) and monocytes 
(CD14+) present. It is likely that increased trafficking of these cells into the rheumatoid 
joints is resulting in fewer numbers being present in the blood.   
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In agreement with Katschke et al., (2001) the data presented here indicate that a high 
percentage of both RA and non-RA monocytes express CCR1 and CCR2 with no 
significant differences in the values. However, the present study also analysed the MFI of 
the monocytes for the receptors and showed a significant increase in the MFI for CCR1 
(the receptor for CCL7 and CCL14) in RA monocytes and a significant increase in the MFI 
for CCR2 (the receptor for CCL7 and CCL16) in non-RA monocytes. However, CCR1 cell 
surface expression in RA was lower than that of each of the other tested receptors. While 
this study showed that CCR4 is expressed by a greater percentage of RA monocytes 
compared to non-RA monocytes, the increase is not significant, unlike the results in 
Katschke’s study. However, this study showed a significant increase in the monocyte MFI 
for CCR4 (the receptor for CCL22) in RA blood.  The present study shows a significant 
increase in both the percentage of RA monocytes expressing CCR5 compared to non-RA 
monocytes, and a significant increase in the monocyte MFI for CCR5 in non-RA blood. 
However, the increase in CCR5 expressing CD14+ monocytes in normal blood shown in 
this study is supported by a study carried out by Harringman et al., (2006). This group who 
also found lower CCR5 expression in the RA group compared to healthy controls with the 
paired synovial tissue samples and showed ‘abundantly expressed’ CCR5. CCR5 positive 
macrophages have been found to accumulate in the synovial tissue. It is likely that in RA, 
CCR5 positive monocytes are being actively trafficked into the joint where they have been 
implicated to be involved in monocyte/macrophage retention (Katschke., et al, 2001). 
Further to this, differences in circulating cytokine population between the RA and non-RA 
groups may be affecting CCR5 cell surface expression.  
This section of the study was limited by the low n number and volume of blood allowed by 
the ethical approval. These issues reduce the reliability of the data and hence the 
conclusions which are drawn from it. This low n number and blood volume was 
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particularly pertinent in the analysis of the CD/CCR data as monocyte numbers were 
particularly low, potentially due to their increased trafficking to the joints.  Given more 
time this section would benefit from repetition using increased sample numbers and greater 
volumes of blood from each participant to allow for greater monocyte numbers to be 
analysed. This would also have allowed for greater numbers of transmigrations to be 
performed to further benefit the study.  
It was not possible to put the histograms on the same axis due to changes in the computer 
system where not all data transferred. Further work would be carried out to repeat these 
analyses prior to their use in publications.  
In conclusion: 
The first aim of this section of the study was to establish if the receptors for the 
chemokines CCL7, CCL14, CCL16 and CCL22 were expressed in RA. The data suggested 
that CCR1 was the preferential receptor through which B/T cells are recruited by CCL14 in 
RA and that monocyte recruitment most likely occurs via CCR1 also. No conclusions can 
be drawn as to CCR2 or CCR5 being the preferential receptor for CCL16. As the MFI for 
CCR4 (the receptor for CCL22) was increased in RA blood this is the best candidate for 
the CCL22 receptor in RA. As stated earlier, further work is required to substantiate these 
conclusions.  
The second aim of this section of the study was to quantify the potential of CCL7, CCL14, 
CCL16 and CCL22 to act as chemoattractants within the rheumatoid synovium. It was 
shown that CCL7 has the greatest effect on monocyte migration, but that synovial 
infiltration via CCL7 is most likely not primarily responsible in driving the pathology of 
RA. 
The third aim of this section of the study was to determine the functionality of CCL7 
across HDLECs. This chemokine stimulated monocyte migration. When considered with 
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the decreased expression of CCL7 at synovial LECs ascertained in chapter 3, this section 
of the study indicates that the decreased expression of CCL7 at LECs in inflammatory 
conditions may reduce CD14+ cell removal from synovial tissue via migration across 
lymphatic ECs as part of lymphatic clearance. This provides further novel evidence for the 
role of blood:lymphatic vessel dysregulation in the persistence of  inflammatory cells 
within the synovium.  
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7.1 Introduction and Aims 
The presence of CCL7, CCL14, CCL16 and CCL22 in RA synovium and cultured ECs 
were studied in chapter 3 and chapter 4. The effects of the same chemokines on 
mononuclear and endothelial cell morphological changes conducive to leukocyte migration 
were analysed in chapter 5, while chapter 6 analysed the functionality of these chemokines 
in mononuclear cell migration. The relationship of the levels of these particular 
chemokines with disease pathogenesis has not been previously examined so it was 
important to determine their levels within the circulation and the joint, and to investigate 
whether particular chemokine profiles are associated with disease features and/or different 
types of arthritis.  
It is fully accepted that certain chemokines are found in the serum and/or synovial fluid 
(SF) of arthritis sufferers (Opdenakker et al., 1993; Koch et al., 1995; Flytie et al., 2010; 
McNearny et al., 2011). Furthermore, it is accepted that the chemokine profiles in 
serum/SF differ between different arthritides which allows for the identification of 
potential disease markers.  For example, SF levels of cytokines in patients with early RA 
have been shown to have differing cytokine profiles at different disease stages (Raza et al., 
2005; Yoshihara et al., 2000).  However, CCL7, CCL14, CCL16 and CCL22 have not 
previously been studied in the range of arthritide SF and serum seen in the current study. 
A wide range of clinical variables are assessed in arthritis patients. Variables such as 
erythrocyte sedimentation rate (ESR), joint scores and disease activity scores (DAS44) are 
used to assess systemic inflammation and overall disease activity. Further variables such as 
early morning stiffness (EMS), grip strength and Health Assessment Questionnaire  (HAQ) 
can be used to assess pain and loss of function at the different disease stages, while the 
damage scale of the Overall Status in Rheumatoid Arthritis (OSRA) has been strongly 
correlated with articular damage as determined by radiographs using the Larsen score. 
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The hypothesis is that the chemokines CCL7, CCL14, CCL16 and CCL22 occur in RA 
serum and SF and show differential expression between arthritides. These chemkines may 
have correlations with specific clinical variables of the diseases and may indicate a role in 
the pathology of later stage disease.  
The aims of this section were to; 
 Examine if CCL7, CCL14, CCL16 and CCL22 occur in human RA serum and SF 
in support of chapters 3-6 showing their expression in RA synovium and function 
in stimulating leukocyte migration. 
 Compare the presence of CCL7, CCL14, CCL16 and CCL22 in matched samples 
of serum and SF from patients with RA, psoriatic arthritis (PsA), OA and reactive 
arthritis (ReA) to establish whether different chemokine profiles are associated with 
different types of arthritis.  
 Examine correlations between levels of these chemokines and clinical variables to 
ascertain their potential role in disease pathogenesis. 
7.2 Materials and Methods 
Matched SF and serum were collected as described in section 2.7.1. All samples were 
kindly donated by Dr Derek Mattey (Keele University. Guy Hilton Research Centre, 
Stoke-on-Trent, UK). ELISA was performed as described in section 2.7.2 -2.7.4. 
 
7.2.1 Quantitation of results 
Statistical analysis was performed using GraphPad software and WinPepi (Abramson, 
2011). Normality testing showed the data was not normally distributed. Kruskal-Wallis 
ANOVA followed by the Holm-Bonferroni post hoc test was utilised to analyse differences 
in serum and SF levels for each chemokine between each arthritis type. The Mann-
Whitney U test was used to assess differences in chemokine serum and SF levels within 
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each disease type. Spearman’s rank correlations were performed followed by the Holm-
Bonferroni post hoc test. 
 
7.3 Results 
7.3.1 CCL7 in the serum and SF of RA, OA, PsA and ReA patients. 
In serum CCL7 was detected almost solely in RA, being detected in the serum of only 1 
OA (table 7.1), 1 PsA and no ReA sufferers (table 7.2). Kruskal-Wallis ANOVA for non-
parametric data indicated a significant difference between groups (p = 0.0025). Further 
analysis showed significant difference between CCL7 levels in RA and ReA serum, p 
=0.021, (figure 7.1A).  In the SF, CCL7 was present in the majority of RA but no OA 
(table 7.1), and the majority of ReA but only 1 PsA sufferer (table 7.2). CCL7 in the SF 
was shown to be significantly different between groups (p = 0.0005). Further analysis 
showed significant differences between CCL7 SF in RA and OA (p = 0.028), RA and ReA 
(p = 0.020) and RA and PsA (p = 0.0042) (figure 7.1B). 
There was a significant differences between CCL7 levels in serum and SF (median levels,  
23.78 pg/ml in serum v 345.37 pg/ml in SF, p = 0.0045) in both RA and ReA sufferers. No 
significant differences were seen in the serum and SF in OA and PsA. 
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Table 7.1 Chemokines present in serum and synovial fluid from RA and OA.  
Median values are given as pg/ml with inter-quartile range. ♦ indicates CCL7 was present in only 1 of the samples tested,  
indicates chemokine not present in any sample. For RA n=17 and OA serum n=6, OA SF n=7, unless otherwise stated in table, p 
value by Mann-Whitey U test. 
 
Test 
RA OA 
Serum SF p value Serum SF p value 
CCL7 
23.78 
0.00 – 109.78 
(n=16) 
345.37 
80.98 – 1379.36 
(n=15) 
0.0045 
0.00♦ 
0.00 -  2.81 
 
 - 
CCL14 
91510.7 
52527.8 – 142502.3 
63059.5 
49237.8 – 91143.4 
0.15 
107170.0 
93376.6 – 221806.8 
55688.7 
44517.8 – 91335.0 
p = 0.010 
CCL16 
15264.5 
11945.85 – 22827.2 
3185.9 
2277.3 – 8198.2 
0.00016 
17892.6 
14556.3 – 35236.1 
7863.7 
6971.1 – 9426.1 
p = 0.0042 
CCL22 
662.65 
519.13 – 1004.58 
363.21 
280.5 -  470.21 
 0.010 
 526.7 
340.3 – 934.1 
189.2 
161.3 – 205.4 
p = 0.010 
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Table 7.2 Chemokines present in serum and synovial fluid from ReA and PsA.  
Median values are given as pg/ml with inter-quartile range. ▪ indicates CCL7 was detected in 4 of the samples tested, ♦ indicates 
CCL7 was present in only 1 of the samples tested.  indicates chemokine not present in any sample. For ReA n=14 and PsA n=7 
unless otherwise stated in table, p values calculated by Mann-Whitney U test.
Test 
ReA PsA   
Serum SF p value Serum SF p value 
CCL7 
 
(n=12) 
322.84▪ 
196.47 – 438.80 
(n=13) 
0.040 
0.00♦ 
0.00 – 467.5 
(n=6) 
 0.00♦ 
0.00– 0.001 
0.82 
CCL14 
78426.7 
73365.25 – 92636.25 
47401.6 
40058.1 – 72219.7 
0.0019 
 72447.3 
68221.1 – 84806.3 
40565.8 
56388.8 – 42911.6 
0.0017 
CCL16 
11093.3 
9497.68 – 14887.0 
6663.44 
5368.29 – 8175.63 
0.000053 
12696.5 
9925.2 - 17995.1 
8160.5 
4452.9 – 11706.4 
0.14 
CCL22 
498.06 
353.21 – 655.42 
299.4 
160 .8 – 342.9 
0.0044 
480.8 
272.7 – 621.4 
(n=13) 
226.06 
183.42 – 272.24 
(n=13) 
0.010 
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Figure 7.1 CCL7 in RA, OA, ReA and PsA serum and synovial fluid. 7.1A shows the 
median values for CCL7 in pg/ml in serum. RA n = 16, OA n = 6, ReA n = 12, PsA n = 6. 
7.1B shows the median values for CCL7 in pg/ml in synovial fluid.  RA n = 15, OA n = 7, 
ReA n = 13, PsA n = 7.  The yellow boxes show interquartile range with horizontal red in 
box showing median and the outlier values are shown in green * p =<0.05, ** p =<0.01, as 
calculated by Holm-Bonferroni post hoc test.  
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7.3.2 CCL14 in the serum and SF of RA, OA, PsA and ReA patients. 
CCL14 was detected in the serum and SF of RA, OA (table 7.1), ReA and PsA (table 7.2) 
at comparatively high levels.  The results indicated no significant differences between the 
groups for CCL14 in serum (p = 0.20), (figure 7.2A). 
CCL14 in the SF was shown to be significantly different between groups (p = 0.034) and 
further analysis showed significant differences between CCL14 SF in RA and PsA (p = 
0.012), (figure 7.2B). Significant differences in SF levels of CC14 were not observed 
between the other groups 
Within the disease groups, OA, ReA and PsA, CCL14 was observed to be significantly 
higher in the serum compared to the SF (table 7.1 and 7.2). 
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Figure 7.2 CCL14 in RA, OA, ReA and PsA serum and synovial fluid. 7.2A shows the 
median values for CCL14 in pg/ml in serum. RA n = 16, OA n = 6, ReA n = 12, PsA n = 6. 
7.2B shows the median values for CCL14 in pg/ml in synovial fluid. RA n = 17, OA n = 7, 
ReA n = 14 , PsA n = 7.  The yellow boxes show the interquartile range with the horizontal 
red line in the box showing median, and the outlier values are shown in green. * p =<0.05, 
as calculated by Holm-Bonferroni post hoc test.  
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7.3.3 CCL16 in the serum and SF of RA, OA, PsA and ReA patients. 
As with CCL14, CCL16 was detected in both the serum and SF of RA, OA (table 7.1), 
ReA and PsA (table 7.2).  Kruskal-Wallis ANOVA showed a significant difference 
between groups for serum CCL16 (p = 0.049). However, further analysis showed no 
significant differences between CCL16 levels in the serum of any group (figure 7.3A).  A 
significant difference in CCL16 in SF as analysed by Kruskal-Wallis was observed (p 
=0.049). However, further analysis again showed no significant pair-wise differences 
(figure 7.3B).  
Within the disease groups there was a significant difference between CCL16 levels in 
serum and SF in RA, OA and ReA (tables 7.1 and 7.2) with higher levels being present in 
the serum.  There was no significant difference observed for CCL16 in PsA serum and SF.  
 
7.3.4 CCL22 in the serum and SF of RA, OA, PsA and ReA patients.  
CCL22 was detected in the serum and SF of RA, OA (table 7.1), ReA and PsA (table 7.2).  
Kruskal-Wallis ANOVA analysis indicated no significant differences between the groups 
for CCL22 in serum (p = 0.29), this was supported by Mann-Whitney U test (figure 7.4A).  
CCL22 in the SF was shown to be significantly different between groups (p = 0.049) 
(figure 7.4B). While further analysis showed no significant differences in SF CCL22 
between individual groups, the difference between RA and PsA was approaching 
significance (p = 0.058). 
Within the disease groups, CCL22 was observed to be significantly higher in the serum 
compared to the SF (table 7.1 and 7.2). 
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Figure 7.3 CCL16 in RA, OA, ReA and PsA serum and synovial fluid. 7.3A shows the 
median values for CCL16 in pg/ml in serum. RA n = 16, OA n = 6, ReA n = 12, PsA n = 6 
7.3B shows the median values for CCL16 in pg/ml in synovial fluid. RA n = 17, OA n = 7, 
ReA n = 14, PsA n = 7 The yellow boxes show the interquartile range with horizontal red 
line in the box showing median. Outlier values are shown in green. No significant 
differences were observed. 
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Figure 7.4 CCL22 in RA, OA, ReA and PsA serum and synovial fluid. 7.4A shows the 
median values for CCL22 in pg/ml in serum. RA n = 16, OA n = 6, ReA n = 12, PsA n = 6. 
7.4B shows the median values for CCL22 in pg/ml in synovial fluid. RA n = 17, OA n = 7, 
ReA n = 14 , PsA n = 7 The yellow boxes show the interquartile range with horizontal red 
line in the box showing median.  The outlier values are shown in green. No significant 
differences were observed. 
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7.3.5 Analysis of correlations in RA, ReA and PsA SF and serum.  
7.3.5.1 CCL7, CCL14, CCL16 and CCL22 in RA  
Spearman rank correlation analysis followed by the Holm-Bonferroni test on serum and SF 
showed a significant correlation between serum levels of CCL7 and CCL16 (p = 0.001).  A 
highly significant correlation between CCL7 levels and anti-CCP units was also observed 
(p = 0.001) (table 7.3). No correlations were observed between levels of CCL14, CCL16 or 
CCL22 and clinical variables. 
7.3.5.2 CCL7, CCL14, CCL16 and CCL22 in ReA 
For CCL7 in ReA there were no significant correlations for serum. However, there were a 
number of significant correlations for SF. The most significant correlations were between 
CCL7 SF levels and the number of tender joints (p = 0.009), and the number of swollen 
joints (p = 0.006). There were also correlations with the damage index (p = 0.01) and the 
Richie index (p = 0.021).  Further correlations for SF CCL7 levels were observed with 
DAS44 (p = 0.024), the health assessment questionnaire (HAQ) (p = 0.031), early morning 
stiffness (EMS) (p = 0.031) and erythrocyte sedimentation rate (ESR) (p = 0.036) (table 
7.3). No correlations were observed between levels of CCL14, CCL16 or CCL22 in ReA  
and clinical variables. 
7.3.5.3 CCL7, CCL14, CCL16 and CCL22 in PsA 
No significant correlations were observed. However serum CCL14 levels approached a 
significant correlation with grip strength (p = 0.050), as did SF CCL22 levels with the 
numbers of monocytes and macrophages (p =0.050) (table 7.3). No correlations for CCL7 
or CCL16 levels were observed. 
7.3.5.4 CCL7, CCL14, CCL16 and CCL22 in OA. 
No significant correlations between chemokines or clinical variables were found. 
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Table 7.3 List of correlations for serum and SF CCL7, CCL14, CCL16 and CCL22 in 
serum RA, ReA and PsA.   
 
R value given by Spearman Rank correlation analysis with p value following Holm-
Bonferroni post hoc test. S – serum. SF – synovial fluid. ESR – erythrocyte sedimentation 
rate, EMS – early morning stiffness, HAQ – health assessment questionnaire. DAS44 – 
disease activity score (44 joint). GRIP – grip strength, MO/M – monocyte and macrophage 
numbers in SF, OSRA-D – damage scale of the  “Overall Status in Rheumatoid Arthritis”. 
No correlations for OA were observed. 
 
 
Chemokine (SF/S) Correlation p value  (R value) 
Rheumatoid arthritis 
CCL7 (SF) anti-CCP units p = 0.001    (R = 0.93) 
CCL7 (S) CCL16 (S) p  = 0.016   (R = 0. 64) 
Reactive arthritis 
CCL7 (SF) ESR p  = 0.036      (R = 0.69) 
CCL7 (SF) EMS p  = 0.031      (R = 0.57) 
CCL7 (SF) Tender joints p  = 0.009      (R = 0.76) 
CCL7 (SF) Swollen joints p  = 0.006     (R = 0.79) 
CCL7 (SF) OSRA-D p  = 0.010      (R = 0.73) 
CCL7 (SF) Richie index p  =  0.021    (R = 0.72) 
CCL7 (SF) HAQ p  = 0.030     (R = 0.69) 
CCL7 (SF) DAS44  p  = 0.024     (R = 0.73) 
Psoriatic arthritis 
CCL14 (S) GRIP p  =  0.05     (R =0.68) 
CCL22 (SF) MO/M p  =  0.05    (R =0.097) 
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7.4 Discussion 
McNearny et al., (2011) showed that a number of chemokines and chemoattractants are 
found in the SF of RA patients and a number of chemokines, such as CCL3 and CCL5, 
have been shown to be upregulated in RA compared to other arthropathies (reviewed by 
Iwamoto et al., 2008). Further to this CCL7 has been shown to be upregulated in the serum 
of systemic sclerosis patients and associated with the severity of sclerosis and pulmonary 
fibrosis (Yanaba et al., 2006). 
Whilst comparisons have been made for levels of CCL7, CCL14 and CCL16 in paired 
synovial tissue and peripheral blood mononuclear cells in RA, ReA and OA (Haringman et 
al., 2006) this is the first study to compare levels of these chemokines in paired serum and 
SF from RA, ReA, OA and PsA. CCL7 level was shown to be significantly increased in 
the serum of RA compared to ReA, and approached a significant difference with OA 
serum. Furthermore, the CCL7 level was significantly increased in the SF of RA compared 
to OA, ReA and PsA. This study is also the first to show significant correlations between 
CCL7 levels in RA SF and anti-CCP antibodies in RA. This finding, combined with the 
lack of CCL7 in OA and PsA, suggests that CCL7 may be a novel marker for RA. 
However, the current study also shows that SF CCL7 levels correlate with a range of both 
clinical variables (such as tender joints, swollen joints and the Richie index) and 
inflammatory variables (such as ESR, DAS and EMS) in ReA. This suggests that SF CCL7 
may be a novel general marker for inflammation in ReA and RA.  
The significant increase in CCL7 in the SF compared to the serum of RA and ReA 
suggests that CCL7 may be active in the recruitment of mononuclear cells to the inflamed 
joint. This relates to work by Koch et al., (1994) who showed that SF CCL3 in RA was 
significantly increased compared to OA, and significantly increased monocyte recruitment 
to the RA joint. The increase in SF CCL7 in RA and ReA may also be due to CCL7 
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generation by macrophages (Opdenakker et al., 1993) which are abundant in the RA joint 
(Kinne et al., 2000).  
The current study is the first to assess the levels of CCL14 and CCL16 in serum and SF of 
RA, OA, ReA and PsA.  It shows no significant differences in serum CCL14 levels 
between patient groups. However, in SF, the CCL14 level was significantly higher in RA 
than in PsA which would suggest that it may be chemoactive in the RA joint.. The data 
showing that the CCL14 level in OA, ReA and PsA was significantly greater in serum than 
SF suggests that it is generated within the circulation rather than in the joint   
CCL16 in serum and SF showed no significant differences between the patient groups, 
although it was significantly higher in the serum of RA, OA and ReA compared to the 
matched SF. As with CCL14, this suggests that it is generated within the circulation rather 
than the joint.  
CCL22 in serum and SF also showed no significant differences between the patient groups. 
This may be due to insufficient patient numbers as Flytie et al., (2010) showed significant 
differences in SF CCL22 levels between RA and PsA, as well as CCL22 levels being 
increased in RA and PsA plasma compared to OA and healthy plasma. The current study 
showed that CCL22 levels were significantly increased in the serum of RA, OA, ReA and 
PsA compared to the matched SF with no significant correlations other than CCL22 SF 
levels approaching a significant correlation with SF monocyte and macrophage numbers in 
PsA. Like CCL14 and CCL16 this suggests that CCL22 is generated within the circulation 
rather than being locally produced at the site of any specific joint disease.  
This section of the study was limited by only having access to samples from a relatively 
small number of patients, and mainly those with late stage disease. It would benefit from 
repetition using larger numbers of patients as well as early serum  samples to compare 
chemokine levels and clinical variables. Furthermore, the SF tested was removed from a 
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single joint (knee), and so it is impossible to assess if the levels would be significantly 
different for any of the chemokines had it been removed from other joints. Ideally the same 
analysis would be performed in a longitudinal study whereby serum samples were taken at 
baseline (at diagnosis or before) and then at set intervals over 5 years. This would help to 
establish chemokine profile alterations in line with the clinical manifestations and changes 
in clinical variables.  
 
In conclusion: 
The first aim of this section of the study was to establish whether CCL7, CCL14, CCL16 
and CCL22 were present in RA, OA, ReA and PsA and whether there were any differences 
in chemokine profile between the different arthritides. The study is the first to indicate that 
serum CCL7 is seen almost solely in RA where it may be a novel RA disease marker. No 
significant differences were observed between patient groups for levels of CCL14, CCL16 
and CCL22 in serum or SF apart from a difference between RA and PsA in the level of SF 
CCL14. The levels of these 3 chemokines were higher in serum than SF, suggesting their 
generation within the circulation rather than the joint. 
The second aim was to examine whether there were any correlations between clinical 
variables and SF and serum levels of these chemokines. Apart from significant correlations 
between SF CCL7 levels and anti-CCP levels in RA and  a range of clinical variables in 
ReA there was little or no correlation of CCL14, CCL16 and CCL22 levels in serum or SF 
with any clinical variables. These data suggest that CCL14, CCL16 and CCL22 have little 
or no association with disease pathology in different types of arthritis, although CCL7 may 
be a general marker for inflammation in ReA. Further work is required to substantiate this 
hypothesis. 
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8.1 General discussion 
8.1.1 Background 
Whilst much is known about the functionality of a range of chemokines in RA, a 
significant proportion remain unstudied at the blood vessel endothelial cell wall across 
which all transmigration occurs. The work in this study aimed to elucidate the RA 
endothelial presentation of the beta-family (CC) chemokines, and to establish the potential 
functionality of the most highly represented, novel, chemokines. 
The CC chemokines are so named because the first two of four cysteine residues are 
adjacent to each other. They constitute the largest of the chemokines groups whose major 
target is monocytes and lymphocytes (Bonecchi et al., 2009) and are represented in the 
constitutive, inflammatory, dual function/heterologous and angiogenic sub groups (Filer et 
al., 2008; Bonecchi et al., 2009). 
CCL7 (MCP-3) is an inflammatory chemokine which is a chemoattractant for  
mononuclear cells, specifically monocytes (Oppenheim et al., 1991; Taub et al., 1993) and 
T-cells  (Taub et al., 1995) and plays a role in macrophage regulation (Opdenakker et al., 
1993). It is produced by a range of cells including FLS, macrophages (Harringman et al., 
2006), cancerous tumour cells (Jung et al., 2010) and astrocytes (Renner et al., 2011), 
where it has been suggested as the primary source for increased monocyte trafficking to the 
CNS in neuroAIDS. CCL7 belongs to the MCP monocyte chemoattractant protein (MCP) 
subfamily which includes CCL2 (MCP-1), CCL8 (MCP-2) and CCL13 (MCP-4). It binds 
the receptors CCR1, CCR2, CCR3 and CCR5, which allows it to activate numerous cell 
types, including monocytes, T-cells and basophils (Menten et al., 2001).  
CCL14, originally known as haemofiltrate CC-1 (HCC-1), is found in high levels in 
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plasma and was initially detected during protein isolation of haemofiltrate (Schulz-Knappe 
et al., 1997). It has been found in a range of tissue types, including liver, muscle and 
kidney (Schulz-Knappe et al., 1997) and requires post-translational modification to 
enhance biological activity for receptor binding to CCR1, CCR3 (low affinity binding 
only) and CCR5 (Detheux et al., 2000; Forssman et al., 2001; Mortier et al., 2008; Richter 
et al., 2009). Furthermore, it has been shown to chemoattract monocytes, eosinophils and T 
cells (Munch et al., 2002).  
CCL16, previously known as liver expressed chemokine (LEC) is expressed in a range of 
tissues including the liver and spleen and is expressed by hepatocytes (Youn et al., 1998). 
Via binding to CCR1, CCR2, CCR5 and CCR8 (Howard et al., 2000; Nomiyama et al., 
2001) CCL16 can activate a range of inflammatory cells and shows chemotactic ability for 
both lymphocytes and monocytes (Youn et al., 1998).  It is an angiogenic chemokine 
(Strasly et al., 2004; Filer., 2008) but has not yet been designated as being inflammatory, 
constitutive/heterologous or dual-function. 
CCL22 is a dual-function chemokine (Loetscher., 2005) which is produced by 
macrophages and monocyte derived dendritic cells. It is also expressed in the thymus, 
lymph nodes, appendix and Langerhans' cell histiocytosis with a functional role in atopic 
dermatitis. (Vulcano et al., 2001; Kwon et al., 2011; Hirota et al., 2011). 
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8.1.2 Presence of CCL7, CCL14, CCL16 and CCL22 in RA and non-RA ECs. 
In RA, both CCL7 and CCL14 were first observed within the synovial tissue by 
Haringman et al., (2006). The  current study provided novel data to the field by showing 
that both CCL7 and CCL14 are widely expressed by the ECs of both RA and non-RA 
synovial vessels and throughout the RA synovium on infiltrates, with CCL7 not showing a 
significant difference between RA and non-RA synovial ECs. The current study shows 
CCL14 to be significantly upregulated on RA ECs compared to non-RA ECs (p = 0.0041) 
indicating that CCL14 may play a role in the recruitment of inflammatory cells to the RA 
synovium.  This study shows that CCL7 is significantly decreased on lymphatic ECs in RA 
compared to non-RA lymphatic ECs. These findings are in contrast with the findings for 
CCL14, which the current study shows to be upregulated in RA blood vessel ECs but to 
have no significant differences between RA and non-RA lymphatic ECs.  The non-
significant difference between RA and non-RA ECs presence of CCL7 suggests that CCL7 
may not be of primary importance in the transmigration of monocytes and T-cells into the 
synovium in RA. However, this is the first study to show CCL7 on RA lymphatic ECs, 
furthermore, it shows CCL7 to be significantly decreased in the RA lymphatic vessel ECs 
compared to non-RA lymphatic ECs. This indicates that CCL7 may be of greater 
importance in the removal of infiltrates via lymphatic vessels. T22 experiments he lack of 
significant differences between RA and non-RA lymphatic ECs for CCL14 indicates that 
while CCL14 may be of importance in the recruitment of monocytes and T-cells into the 
RA joint, it may not be responsible for their lymphatic removal.   
CCL16 was identified in RA tissue in multiple studies (Radstake et al., 2005; Van-
Lieshout et al., 2005: Haringman et al., 2006), however this is the first study to identify its 
presence in RA ECs. With the current study there were no significant differences in 
CCL16 in RA and non-RA ECs, thus monocyte and lymphocyte recruitment via CCL16 at 
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the EC: blood interface is not likely to be primarily responsible for their elevated 
recruitment in RA. The presence of CCL16 in infiltrates (Radstake et al., 2005; Van-
Lieshout et al., 2005: Haringman et al., 2006) is most likely the source of the CCL16 
mediated transmigration.  
In contrast to the other chemokines CCL22 was not only significantly increased in RA 
blood vessel ECs compared to non-RA ECs but also significantly increased in lymphatic 
RA ECs compared to non-RA. The significant increase seen in RA in the current study is 
supported by Flytie et al., (2010) who found abundant CCL22 in the RA synovium. This 
may indicate that CCL22 is important in the pathology of RA inflammatory cell 
recruitment from the blood.  It may also be an example of lymphatic EC CCL22 
upregulation in response to inflammatory stimuli as a compensatory mechanism for 
increased CCL22 on blood vessel ECs. In order to analyse these hypothesis further work is 
required to compare early and late RA tissue for differential blood vessel and lymphatic 
EC chemokine expression. 
The differential expression of the chemokines on blood vessel ECs and lymphatic ECs led 
to the possibility that synovial dysregulation of chemokine expression has a greater role 
than previously discerned in the pathology of RA. The dysregulation of the chemokine 
gradient was documented by Burman et al., (2005) who showed chemokines to be present 
at high levels on both lymphatic and blood vessel ECs within the rheumatoid synovium, 
and suggested that the chemokine gradient disruption plays a vital role in RA. Further 
evidence that lymphatic ECs are of vital importance in RA came from Johnson et al., 
(2006) who showed >100 fold increases in inflammatory chemokines such as CCL5 and 
CCL20 in TNF-α activated HDLECs. As synovial lymphatic vessel formation has been 
shown to decrease during the chronic phase of RA (Zhou et al., 2010), this compensatory 
mechanism of chemokine upregulation in lymphatic vessels may be less effective. 
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Particularly if chemokines, such as with CCL7, are also downgraded in RA lymphatic ECs. 
The current study is the first to show CCL7, CCL14, CCL16 and CCL22 in RA lymphatic 
ECs. It shows significant decreases in lymphatic CCL7 (chapter 3) and provides further 
evidence that in RA the chemokine gradient is disrupted. Furthermore, the current study 
shows that blood: lymphatic dysregulation of CCL7 may play an important role in the 
pathology of RA.  The importance of lymphatic CCL7 in relation to transmigration 
analysis was explored in chapter 6. Following activation of HDLECs a dose response was 
performed using PBMCs isolated from RA blood. The results showed that at increasing 
concentrations of CCL7 generated increasing monocyte migration across activated 
HDLECS, with the greatest responses being significant at 100ng/ml and 250ng/ml 
chemokine compared to the absence of CCL7. There were no significant differences in T-
cell migration seen under the same conditions, however a significant difference in T-cell 
migration at 10ng/ml compared to unstimulated HDLECs in the absence of CCL7 was 
observed.  It is possible that the receptors became desensitised in the case of T-cell 
migration at each CCL7 dose and for monocyte migration at over 250ng/ml. It is known 
that TNF- induces the generation of a range of chemokines in ECs (Haringman et al., 
2004) and HDLECs (Johnson et al., 2006) and the presence of TNF-/IFN- would most 
likely generate the release of endogenous chemokines and/or other factors which were pro-
migratory. This may also account for the significant difference in T-cell migration in 
response to CCL7 at 10ng/ml when compared only to the negative control which was 
performed in the absence of both TNF-/IFN- and the chemokine.  
These experiments show that CCL7 is functional in monocyte migration across LECs. 
Thus that the reduced expression of CCL7 on lymphatic ECs in RA may have functional 
significance, whereby reduced lymphatic clearance of monocytes leads to their 
accumulation and persistence in the RA synovium. This hypothersis is partially supported 
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by Ibrahim et al., (2014) who showed that CCL7 reduction in the lymph nodes of 
malnourished mice results in reduced dendritic cells and monocytes/macrophages in the 
same area which suggested the importance of CCL7 in their clearance in this disease state. 
Further work to establish the effect of CCL7 on monocyte lineage cell migration in RA 
would be beneficial.  
8.1.3 CCL7, CCL14, CCL16 and CCL22 in cultured cells 
As CCL7, CCL14, CCL16 and CCL22 were so highly represented in ECs in RA ECs; it 
was decided to establish if they were present in cultured ECs in simulated inflammatory 
conditions. These experiments would provide evidence for the potential of ECs to 
synthesise, store and release the chemokines under inflammatory conditions. Following 
establishing the optimum conditions for HBMEC stimulation, it was decided to perform 
whole cell staining to establish the presence of chemokines to establish their cellular 
expression as chemokines and other factors, such as VWF, in Weibel-Palade bodies are 
well documented (Øynebråten et al., 2005; Rondaij et al., 2006; Hol et al., 2009). In 
chapter 4 of this study it was shown that in the absence of cycloheximide, over a six hour 
time frame, CCL7 staining increased in intensity with TNF- from 0-2 hours before a 
significant decreasing trend in intensity occurred. In order for the observed decrease in 
CCL7 to occur the chemokine must have been either released in to the medium or 
otherwise recycled intracellularly. The data also indicates that CCL7 is pre-synthesised in 
HBMECs prior to TNF- stimulation and released/recycled in response to inflammatory 
stimuli. This is supported by the non-significant reductions in CCL7 in the presence of 
cycloheximide due to protein synthesise arrest. However, there was a significant increase 
in CCL7 intensity over the first 2 hours of combined stimulation and cycloheximide 
addition. CCL14 was also observed to undergo significant intensity increases, followed by 
a non-significant trend in decreasing CCL14 intensity. As with CCL7 this indicates that 
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ECs pre-synthesise and store CCL14 which is mobilised under inflammatory stimuli. 
Unlike CCL7, the decrease in CCL14 intensity did not reduce to near baseline levels, 
instead remaining significantly increased at each time point compared to baseline. This 
indicated that the ECs were either synthesising more CCL14 which was replenishing the 
stores as they were depleted, or it was being recycled intracellularly. In this study ELISA 
tests showed that CCL14 was detectable in HMVEC conditioned medium at 644.65pg/ml 
at 2 hours, but was not detectable in HBMEC conditioned medium at 2 hours. It is possible 
that it was simply not at a detectable level in the HBMEC medium within this time frame. 
However, the fact that a 2 hour time frame provided detectable CCL14 levels in HMVEC 
conditioned medium which was not detectable in HMBEC conditioned medium suggests 
that ECs differentially generate chemokines. Further work to assess the potential of 
different EC types to generate each of the tested chemokines to confirm these conclusions 
are required. Unlike CCL7 and CCL14, CCL16 and CCL22 showed no initial significant 
increase in intensity. This would indicate that while pre-synthesised CCL16 is present 
within HBMECs, it was not significantly synthesised in response to inflammatory stimuli. 
There was, however, a significant trend in decreasing CCL16 which reduced to below 
baseline. This suggests that while CCL16 was being released into the medium or 
intracellularly recycled, it was either not being synthesised, or was being synthesised at 
levels below those required to adequately replenish intracellular stores. This is supported 
by the lack of detectable CCL16 in the HBMEC and HMVEC conditioned medium. 
CCL22 showed only a significant decrease from baseline which was not a significant trend. 
As with CCL7, CCL14 and CCL16 the evidence may suggest that there is CCL22 being 
released into the medium or that is being recycled/ degraded without intracellular stores 
being replenished in a timely manner. Alternatively CCL22 may be being 
released/recycled while the intracellular stores are replenished in an ongoing process over 
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the tested timeframe.  However, given that CCL22 was not detected in the conditioned 
medium it is likely that it is recycled rather than released. In order to better analyse the 
generation of these chemokines it would be beneficial to perform pulse chase experiments 
with radiolabelled amino acids (e.g. 
35
S-methionine). This would be followed by 
immunoprecipitation to establish the half-life and/or release of newly synthesised 
chemokines in primary microvascular ECs and HDLECs. 
Further research indicates that the stimulation in the presence of cycloheximide seen in 
chapter 4 for each tested chemokine was due to a delay in the protein synthesis arrest effect 
of cycloheximide, during which time stimulation by TNF- would have generated the 
initial intensity increases. This delay is most likely responsible for the initial increases seen 
throughout these particular experiments for CCL7, CCL14, CCL16 and CCL22. In future 
work I would pre-incubate with cycloheximide before the addition of the TNF- to 
reduce/remove this effect. 
Following the exploration of cellular CCL7, CCL14, CCL16 and CCL22 in chapters 3 and 
4 it was decided to establish the effects the chemokines had on the microvilli formation of 
stimulated HBMECs and non-RA PBMCs. Microvilli formation on ECs in arthritis was 
first observed by Sattar et al., (1986) and has since been reported by numerous sources. 
Middleton et al., (1997) showed that EC microvilli appear to present CXCL8 to leukocytes, 
and most recently, Whittall et al., (2013) showed that CXCL8 stimulates cytoskeletal 
remodelling in ECs which lead to microvilli formation and preferential chemokine 
presentation. Further to this, the presence of chemokines such as CXCL8 in the rheumatoid 
synovium (Szekanecz and Kock., 2008; Whittall et al., 2013) indicates that chemokine-
stimulated microvilli formation may be relevant to leukocyte transmigration in RA and that 
the chemokine stimulation may lead to preferential chemokine presentation at the apical 
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tips of microvilli (Middleton et al., 1997; Whittall et al., 2013). The current study showed 
that CCL7 generated a positive trend for EC microvilli formation that did not reach 
significance (p = 0.057) and had little observed effect on leukocyte microvilli formation. In 
the presence of CCL14, significant increases in mononuclear cell microvilli generation 
occured (P = 0.0004) and the generation of microvilli by HBMECs approached 
significance (p = 0.057). This potential for monocyte microvilli formation is supported by 
Schulz-Knappe et al., (1997), who showed that CCL14 was capable of monocyte 
activation. CCL16 generated a positive trend in mononuclear cell microvilli formation 
which was non-significant, but had the greatest significant effect on EC microvilli 
generation of each of the tested chemokines (p = 0.007). CCL22 gave a significant 
increase in both mononuclear cell and EC microvilli formation (p = 0.023 and 0.014 
respectively). This is the first study to show microvilli generation in response to CCL7, 
CCL14, CCL16 and CCL22 and their preferential stimulation of HBMECs or leukocytes. 
It is known that chemokines respond differently in response to inflammatory activators 
such as TNF- and IFN-γ. For example, CCL16 is induced strongly by IFN-γ (Nomiyama 
et al., 1999) and it is therefore highly possible that different results may have been 
obtained had the experiments been performed under a range of conditions such as 
assessing each chemokine using TNF- and IFN- rather than TNF- alone. Further work 
would include further optimisation of the conditions with a range of EC types.  
The generation of podosomes which are also influential in transmigration processes 
(Carmen et al., 2007; Carmen and Spinger, 2008; Wittchen, 2009), were also examined. 
Increases in the numbers of podosomes formed in the presence of the chemokines were 
observed, however they failed to reach significance. This may have been due to sampling 
errors. In future work, greater numbers of micrographs at a greater range of magnifications 
would provide more data for better analysis, as would scanning electron microscopy 
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(SEM), in addition to the  TEM in this thesis, to better analyse the topography of the 
leukocyte: EC interactions. SEM would also aid the examination of filopodia.  
While little work has been done on the chemotactic responses to CCL7 in inflammatory 
disease, Ali et al., (2005) showed significant increases in leukocyte migration in response 
to CCL7 across human microvascular endothelial cells (p < 0.001), supporting the findings 
of this study which shows that CCL7 generates significant increases in monocyte migration 
across HBMECs in a dose dependent manner at 100ng/ml (p = 0.037) and 250ng/ml (p = 
0.031).  Again, this would suggest that CCL7 is active in the recruitment of monocytes to 
the RA joint. However, as stated earlier, the RA and non-RA blood vessel ECs showed 
similar degrees of CCL7 expression (chapter 3) and so monocyte recruitment via CCL7 is 
unlikely to be a pathological driving factor in RA. This is partially supported by the 
presence of other chemokines such as CCL5 and CCL2, which have been shown to be 
highly expressed in the RA synovium and are also adept at monocyte and T-cell 
recruitment (Charo and Ransohoff., 2006).  
Schulz-Knappe et al., (1997) stated that CCL14 generated no chemotactic response for 
monocytes, however the methods and actual results which provided that conclusion were 
not shown and no further work showing chemotactic responses to CCL14 could be found. 
The data in this study opposes that data, as it shows that at a concentration of 100ng/ml 
CCL14 generates a significant increase in monocyte migration.  Furthermore, the 
significant upregulation of CCL14 at RA ECs compared to non-RA ECs suggests that 
CCL14 may be active in monocyte recruitment in RA. Further work to assess CCL14 
chemotactic responses in a dose dependent manner are required to further elucidate the full 
potential of CCL14 to act as a chemoattractant in RA. CCL16 showed no significant effect 
on either monocyte or B/T-cell migration in the presence of TNF-. As stated earlier, 
CCL16 is most strongly induced by IFN- (Nomiyama et al., 1999) and so it is possible 
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that significant effects on migration in response to CCL16 would be seen under different 
conditions which time restraints prevented analysis of during this study.   
CCL22 was shown to stimulate significant increases in monocyte migration across 
activated HBMECs compared to the absence of CCL22, further to this CCR4 (the receptor 
for CCL22), was significantly increased in RA monocytes. While this indicates that 
CCL22 may be of importance in driving monocyte recruitment in RA, the significant 
increase in CCL22 at blood vessel ECs in RA was accompanied by a significant increase in 
RA lymphatic vessel ECs. This would likely act as a compensatory factor where CCL22 
mediated transmigration is occurring. However, this mechanism would be beneficial 
during the earlier stages of RA only, as during latter stage RA lymphangiogenesis has 
stopped and normal lymphatic drainage has reduced as movement has become more 
restricted (Polzer et al., 2008). 
This is the first study to observe the presence of LYVE-1 macrophages in the RA 
synovium (chapter 3). While their presence is well documented in cancer cells, particularly 
those with a high metatastic rate (reviewed by Ran and Montgomery, 2012), they are 
believed to be involved in lymphangiogenesis (reviewed by Ran and Montgomery, 2012), 
which plays a role in the lymphatic movement of cancerous cells around the body. The 
presence of these cells implies that even in the very end stage of RA there is the potential 
for lymphangiogenesis within the RA joint. However, given the reduction in lymphatic 
vessels seen in the RA tissue (Zhou et al., 2010) in comparison to the blood vessels these 
‘lymphatic progenitors’ do not appear to develop into mature vessels. This may be due to a 
number of factors, such as a downstream signalling cascade failure which prevents 
maturation of the progenitors, or environmental factors within the joint which are anti-
lymphangiogenic. Further work to assess these cells in synovial tissue would be beneficial. 
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8.1.4 CCL7, CCL14, CCL16 and CCL22 in matched serum and synovial fluid  
Following analysis of CCL7, CCL14, CCL16 and CCL22 in synovial tissue and cultured 
cells it was decided to assess their presence in matched serum and synovial fluid samples 
(chapter 7).  The demonstration of the chemokines by ELISAs supported the detection of 
the chemokines by immunofluorescence. While CCL7 did not reach significant difference 
between RA and OA serum it was approaching significance at p = 0.054, and given that 
CCL7 was only detectable in one of the OA patients tested it would be expected the data to 
become significant given greater patient numbers. CCL7 was also shown to be 
significantly increased in RA SF compared to OA, ReA and PsA.  This relates to work by 
by Piere et al., (2004) who showed that CCL5 was significantly increased in RA compared 
to OA, ReA and PsA.  As with CCL7, CCL5 is an inflammatory chemokine which is a 
ligand for CCR1 and CCR3. The current study shows significant correlations of SF CCL7 
in RA with anti-CCP antibodies, and a range of clinical markers in ReA (table 7.3), 
including ESR, disease activity score, and tender and swollen joints. Given the lack of 
serum CCL7 in the other arthropathies tested, and the significant correlation with anti-CCP 
in RA, CCL7 may be a novel marker for RA diagnosis. However, due to the numbers of 
correlations for CCL7 in SF in ReA, it is likely to be a general inflammatory marker in this 
disease. The presence of CCL7 in SF at significantly greater concentrations than in serum, 
indicates that the synovial tissue is a primary source of CCL7, which may be released into 
the serum via ECs  
The current study shows CCL14 to be significantly increased in the serum of RA, ReA and 
PsA compared to the SF, the OA levels were approaching significance. CCL14 has been 
shown to be expressed at high concentrations of 10nM in the plasma of healthy individuals 
which significantly increases up to 80nM in patients with renal disease (Schulz-Knappe et 
al., 1997). It is unusual for a chemokine to reach such levels, even in a disease state (Koch 
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et al., 1992). However, the serum CCL14 concentration observed in the current study of up 
to 91510.7pg/ml are still surprisingly high when compared to serum levels of chemokines 
such as CCL2 who Koch et al., (1992) showed to be present at ~251500.0pg/ml and CCL5, 
which has been shown to be ~1000pg/ml in RA (Hidaka et al., 2001). It is possible that the 
high levels of CCL14 observed in the serum in this study are the result of interplay 
between normally occurring levels and disease exacerbated levels. Also, the increased 
likelihood of renal complications in arthritis patients taking certain drugs (such as disease 
modifying anti-rheumatic drugs, DMARDS) may relate to the very high plasma CCL14 
concentration seen in this study. High levels were also observed in SF which were 
significantly increased in RA compared to PsA, however the lack of significant differences 
with OA and ReA indicate that CCL14 would not be a suitable disease marker. 
As with CCL14, CCL16 was shown to be present at relatively high concentrations in 
serum at up to 15264.5g/ml in RA. This is lower than chemokines such as CCL2, which 
was found at ~251500pg/ml by Koch et al., (1992) but as it is higher than CCL5 at 
~1000pg/ml in RA (Hidaka et al., 2001). However, there were no significant increases in 
CCL16 in RA serum compared to OA, PsA or ReA shown in the current study, suggesting 
it is not a marker of RA. Due to a lack of correlations between serum/SF levels and clinical 
variables it is unlikely to be of significance as a marker of disease activity or severity, but 
may be a general marker of inflammation. As with CCL14, CCL16 is generated by the 
liver it is also possible that the high levels were the result of liver complications 
exacerbated by the use of DMARDS (Selmi et al., 2011). 
CCL22 was shown to be significantly increased in serum compared SF in RA, OA, ReA 
and PsA at up to 662.65pg/ml (in RA), however these levels are below chemokines such as 
CCL2 at ~251500pg/ml (Koch et al., 1992). However, different studies have shown other 
chemokines of importance in RA such as CCL5 (~1000pg/ml) to be at much lower levels 
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in RA serum. The significant increases in serum CCL14, CCL16 and CCL22 compared to 
SF indicate that the synovial tissue of the joints sampled are not the primary source of 
these chemokines in RA. 
 
Overall, this study has identified a range of chemokines to be present in RA ECs and has 
shown that the functionality of a number of them, particularly CCL7, may have 
significance in the RA disease process.  
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8.2 Final main conclusions  
 
1. There is known to be a high degree of heterogeneity between the chemokines present in 
RA, which is reflected by high heterogeneity in synovial ECs. The most highly represented 
7 chemokines in RA ECs are (in increasing prevalence in RA ECs): 
CCL22 - CCL4 - CCL8 - CCL7 - CCL14 - CCL16 - CCL19. 
 
2. While each of the chemokines studied are pre-synthesised in ECs, CCL14 has the 
greatest potential to be synthesised in an ongoing manner in response to inflammatory 
stimuli. Furthermore, as well as generating the most significant effect on leukocyte 
microvilli formation, CCL14 generated significant increases in monocyte migration. This 
suggests that CCL14 may be highly active in RA pathology. 
 
3. The significant decrease of CCL7 in lymphatic ECs, combined with it having the 
greatest chemotactic ability for monocytes suggests it may of importance in the lymphatic 
removal of infiltrates in the inflamed RA synovium. This would lead top leukocyte 
persistence and accumulation in the RA synovium. Further to this serum CCL7 may be a 
novel marker for RA.  
 
4. The presence of LYVE-1+ macrophages indicate the potential for lymphangiogenesis in 
later stage RA and with further study may prove to be a target in RA to increase 
lymphangiogenesis and thus reduce inflammation. 
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8.3 Further work 
 Establish if the chemokines are present in HDLECs in response to inflammatory 
stimuli. 
 Perform pulse chase experiments with radiolabeled amino acids (e.g. 35S-
methionine) followed by immunoprecipitation to establish the half-life and/or 
release of newly synthesised chemokines in primary microvascular ECs and 
HDLECs. 
 Assess the effects of the chemokines on primary synovial ECs  and lymphatic ECs. 
 Increase the sample number for further micrograph analysis of firm 
adherence/filopodia. 
 Assess the effect of CCL7, CCL14 and CCL22 on monocyte differentiation to 
macrophage using CD68+ marker.  
 Assess the effect of CCL7 on macrophage migration across HDLECs. 
 Assess the effect of CCL7, CCL14, CCL16 and CCL22 on migration of 
mononuclear cells from RA blood across HBMECs in a dose response assay. 
 Assess the effect of CCL7 on  the migration of mononuclear cells from non-RA 
blood across HDLECs 
 Increase monocyte numbers for repeat CCR and CD14+ analysis. 
 Analysis of SF and serum from healthy controls to establish if the levels present 
were the result of upregulation in the disease or reflected the steady state in 
circulation at any given time. 
 Assess the prevalence of LYVE-1+ macrophages in a range of arthritis tissue 
sample to better establish if they are increased in specific environments. 
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Appendix 
 
Materials and methods additions 
Monocyte isolation using NycoPreoTM  
Monocytes were isolated using the density medium NycoPrepTM 1.068 (Nycomed Pharma 
AS Diagnostics, Oslo, Norway). The osmolality of this density medium generated a 
slightly hypertonic solution that enabled the monocytes to be separated from the 
lymphocytes. Because lymphocytes are more susceptible to this hypertonicity, they expel 
more water and increase in density, thus they migrated and sedimented further during 
centrifugation.  Following this the monocyte layer at the interface of the NycoPrep and the 
plasma was  aspirated. The density gradient centrifugation procedure was performed using 
full sterile technique in a biological safety cabinet.  Approximately 12ml of fresh 
peripheral blood was collected, transferred to a universal tube and 1.2 ml of 6% Dextran 
500 (Sigma-Aldrich),    prepared in 0.9% NaCl saline solution, was added. After mixing, 
the sample was incubated at room temperature for a minimum of 40 minutes to allow for 
plasma separation and erythrocyte sedimentation. The leukocyte-rich plasma was then 
carefully removed and layered over 3 ml of NycoPrepTM 1.068 in a 15 ml centrifuge tube. 
This was then centrifuged for 15 minutes at 1300rpm at room temperature. Following this 
the plasma was removed to within 3–4 mm of the interface and immediately aliquoted for 
storage at –20°C. The remaining plasma and the top half of the NycoPrepTM 1.068 layer 
which contained the enriched monocytes, was then aspirated. The cells were then washed 
twice by being centrifuged at 1300rpm for 7 minutes at room temperature in 0.9% NaCl 
saline solution containing 0.13% EDTA and 1% FBS. Figure 2.4 shows a flow diagram of 
the procedure. 
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 Appendix figure 1. Flow diagram of the NycoPrep 1.068 monocyte isolation protocol.  
1 NycoPrep 1.068 with the leukocyte-rich plasma layered on top.  2. Separation of 
mononuclear cell fractions 3. Removal of the plasma.  4. Collection of monocyte (M) 
cell layer. (Figure reproduced from the Nycomed Density Gradient Media Applications 
and Products catalogue 2000). 
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2. Principles of Transverse Heated-Graphite Furnace Atomic Absorption 
Spectrometry (T H-GFAAS)  
 In atomic absorption (AA) spectrometry, light of a specific wavelength is passed through 
the atomic vapour of an element of interest, and measurement is made of the attenuation of 
the intensity of the light because of absorption. Quantitative analysis by AA depends on: 1, 
accurate measurement of the intensity of the light and 2, the assumption that the radiation 
absorbed is proportional to atomic concentration. 
Samples to be analysed by AA must be vaporised or atomised, typically by using a flame 
or graphite furnace (figure 2.5). The graphite furnace is an electro-thermal atomiser system 
that can produce temperatures as high as 3,000°C. The heated graphite furnace       
provides the thermal energy to break chemical bonds within the sample and produce free 
ground-state atoms. Ground-state atoms then are capable of absorbing energy, in the form 
of light, and are elevated to an excited state. The amount of light energy absorbed increases 
as the concentration of the selected element increases. 
Appendix Figure 2. Diagram showing the basic GFAAS components  
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3 Chemotaxis  
The blood was prepared according the whether using PBMCs, monocytes only, or whole 
blood leukocytes (2.11.1) a sterile 24 well plate (Scientific Laboratory Supplies). The 
chemokine solutions required were made with serum free   DMEM-F12 made up to 800μl 
for each well. 5μm pore filters (Merck Chemicals, Nottingham, UK) were suspended in 
each well and approximately 100,000 leukocytes were added to the well of each filter well 
to give a final volume of 400μl with serum free  DMEM-F12. The plate was then left for 
30 minutes for migration to occur. All of the above was carried out using solutions at 37
o
c. 
Following the migration the medium from the bottom well was removed and a FACS 
analysis was performed. Negative controls were the same as above with the exception of 
omitting the chemokine in the bottom well. Positive controls were as above with the 
chemokine replaced with a suitable chemoattractant.  
 
 
4 Endothelial cell isolation from fresh synovium  
4.1  Separation of endothelial cells from fresh synovium with collagenase and DNaseI.  
The tissue sample was collected by the surgeon after informed consent was gained from 
the patient and stored at 4
o
c for use within 18 hours. The digestion solution was prepared 
by placing 39.5ml DMDM-F12 medium with penicillin and streptomycin, FBS and 
fungizone (as in section 2.5, herein referred to as complete medium) in a 50ml falcon tube   
500μl of DNaseI was added (giving a final concentration of 40μg/ml) and 10ml of 
10mg/ml collagenase XI was added giving a final concentration of 2mg/ml. 
The tissue sample was rinsed in fresh complete medium to eliminate blood clots and was 
then placed in a petri dish and cut up into pieces approximately 3mm
2
. A region of the 
tissue which appeared highly vascularised was cut up where possible to maximise the 
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chance of  isolating ECs. A metallic mesh  was cut to a size which would fit over the petri 
dish, then wetted with complete medium. The diced tissue sample was transferred to the 
mesh which was placed over a clean petri dish where the tissue was rinsed with complete 
medium again. 
The diced tissue was split between 2 x 50ml falcon tubes containing 10ml of the digestion 
solution and incubated at 37
o
c for 15 minutes whilst shaking at 230rpm. The supernatant 
was removed and the pellet resuspended before placing back on the mesh and rinsing with     
complete medium, at which stage the lymphocytes should have been fully eliminated. The 
tissue was split between 2 x 50ml falcon tubes containing 15ml of the digestion solution 
and incubated at 37
o
c for 45 minutes whilst shaking on a roller.  
After this the mesh was rinsed well and placed over a clean petri dish and wetted with 
fresh complete medium. The tissue sample was poured from the falcon tube back onto the 
mesh and the eluate was allowed to pass through the mesh into the petri dish. The eluate 
was then transferred from the petri dish into a clean 50ml falcon tube by passing it through 
a 40μm sterile filter. The exact volume of eluate was recorded and a cell count was 
performed. The cell suspension was then transferred into 2 x 15ml falcon tubes and 
centrifuged at 1600rpm for 5 minutes ready for magnetic labelling. 
 
 
4.2 Magnetic labelling of isolated EC cells 
The supernatant was removed from the pellet resuspended in 80l PBS/BSA/EDTA per 
10
7
 total cells. Following this, mouse anti-human Duffy antigen IgG1 (Dako) was added 
(at 1:200 concentration) and incubated at 8-10C for one hour. 20l rat anti-mouse IgG1 
micro-beads per 10
7
 total cells was then added and once well mixed was incubated at 6-
12C for 15 minutes. 
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PBS/BSA/EDTA labelling buffer was added at 10-20 x the total volume to wash the cells 
and they were centrifuged at 1100RPM for 10 minutes. The supernatant was removed and 
the cells were resuspended in 500l of buffer per 108 total cells. 
 
4.3 Magnetic separation of isolated EC cells 
The column was placed in the magnetic field of the MACs separator and prepared by 
washing with 500l of the buffer. The cell suspension was added to the column for 
selection to occur and the column then rinsed with 500l of the buffer three times. The 
column was removed from the separator and placed in a 15ml falcon tube where 1ml of 
buffer was added to the column and the positive cell fraction was removed using the 
plunger. The positive fraction was transferred to a freshly prepared column and rinsed as 
above. The positive cells were then transferred to a T25 culture flask containing the pre 
warned appropriate amount of EGM-2 complete medium and placed in the incubator at 
37C with 5% CO2. 
 
 
 
 
 
 
 
 
 
Appendix 
 
349 
 
Appendix table A. Patient immunofluorescent data (continued on next page) 
 
Chemokine 
RA Sample  
1  2  3  4   5  6  7   8 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
CCL1 0%* 8%* 31% 3%* 23%* 14%* 9%* na 
CCL2 41% 29%* 43% 50% 45% 71%* 89%* 44% 
CCL3 11%* 31% 60%* 9%* 30% 8%* 61%* 10%* 
CCL4 25%* 6%* 75%* 71%* 71%* 100%* 73%* 78%* 
CCL5 55% 61%* 67%* 57% 45% 50% 9%* 15%* 
CCL7 58% 49% 87%* 48% 91%* 68%* 85%* 68%* 
CCL8 43% 78%* 74%* 69%* 65%* 67%* 89%* 25%* 
CCL10 36% 61%* 89%* 38% 73%* 3%* 76%* 44% 
CCL11 7%* 0%* 13%* 15%* 57% 18%* 13%* 5%* 
CCL12 5%* 3%* 30%* 6%* 2%* 13%* 6%* 12%* 
CCL13 65%* 41% 8%* 76%* 46% 55% 54% 26%* 
CCL14 37% 71%* 98%* 58% 69%* 94%* 82%* 76%* 
CCL15 52% 13%* 56% 44% 63%* 64% 56% 31% 
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synovial ECs.  * indicates chemokines present on 60% of vessels. 
Chemokine 
RA Sample  
1  2  3  4   5  6  7   8 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
% VWF+ 
Ch + 
%VWF +  Ch 
+ 
CCL15 52% 13% 56% 44% 63%* 64% 56% 31% 
CCL16 100%* 47% 83%* 98%* 75%* 71%* 74%* 45%* 
CCL17 4% 7% 86%* 0% 5% 33% 3% 0% 
CCL18 30% 13% 44% 41% 70%* 24% 47% 36% 
CCL19 58% 98%* 80%* 72%* 95%* 81%* 83%* 73%* 
CCL20 10% 19% 11% 28% 16% 18 31% 15% 
CCL21 5% 40% 48% 4% 8%* 34% 76%* 74%* 
CCL22 46% 62%* 73%* 8% 74%* 72%* 74%* 67%* 
CCL23 15% 41% 32% 27% 49% 37% 54% 46% 
CCL24 28% 22% 39% 6% 29% 43% 44% 19% 
CCL25 16% 9% 37% 37% 39% 43% 29% 17% 
CCL26 74%* 56% 86%* 59% 95%* 60%* 50% 29% 
CCL27 4% 5% 6% 11% 12% 13% 10% 6% 
CCL28 43% 35% 70%* 40% 25% 64%* 40% 12% 
